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A laser is a source of light in the visible or infrared region of the light spectrum that 
emits rays with a high spectral density on a very small area. The word laser is an acro-
nym for "Light Amplification by Stimulated Emission of Radiation". Various lasers have 
been used for diverse medical purposes ranging from dermatological to 
ophtalmological indications. For example, Q-switched lasers, like the Ruby laser, de-
liver ultra short high intensity pulses, which are effective for removing tattoos, some 
benign pigmented lesions and hair removal. Vascular lasers, such as the flashlamp 
pumped dye laser, are effective for treating port wine stains, hemangiomas, 
telangiectasia, rosacea and spider naevi. C02 lasers are useful for treating disorders 
of the skin surface texture and topography such as wrinkles, scars, sun damage, 
benign skin appendages and rhinophyma (Table I and II). 
Flash lamps 
Although not a true laser, Intense Pulsed Light Sources (IPLS) is currently used for the 
same indications in dermatology as lasers. IPLS, also called flashlamp, is a device in 
which the full spectrum of non-coherent light and near infrared radiation are filtered to 
select a specified range of wavelengths. The cost of flashlamp devices and of the ap-
plying procedures is similar to that of comparable lasers. These devices are capable 
of effectively treating pigmented skin lesions, birthmarks, facial spider veins, leg 
veins, as well as performing hair removal. For example, the IPL EllipseFiex® DDD (Dan-
ish Dermatologic Development, Hoersholm, Denmark) has been used in the treatment 
of pigmented lesions like epidermal lentigo solaris, macular melanocytic nevi, 
Becker's nevi and nevus spilus. The PhotoDerm~L (ESC Medical Systems Ltd. , 
Yokneam, Israel) has been used in the treatment of vascular lesions (telangiectasia, 
spider nevi , erythrosis interfollicularis colli , senile angioma, port wine stains) and tore-
move hair. Recently a new technology combining IPLS with radio frequency was intro-
duced. An example of this is the Aurora DS/SR® from Syneron. This new ELOS™ 
(electro-optical synergy) can be used to treat a broad range of skin, vascular and 
pigmented abnormalities, as well as to remove hair (Table Ill and IV). 
Historical developments 
Albert Einstein postulated the occurrence of stimulated emission of radiation in 1917. 
Four decades passed before his theory was applied in the construction of the first la-
ser instrument. In 1958, Townes and Schawlow succeeded in developing maser tech-
nology incorporating microwaves of the electromagnetic spectrum that could be used 
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for infrared and visible light. In 1960, Theodor Maiman of Hughes Aircraft excelled in 
constructing the first working laser that used a ruby crystal. Javan, Bennet and Harriot 
are considered to be pioneers in the area of helium neon lasers from which the C02 
laser followed in 1966 and the Argon laser in 1968. 
Components of a laser 
There are three essential components of a laser system. The first is a lasing medium, 
wh ich may be a gas, crystal, liquid, or semiconductor. The second is a source of exci-
tation for the lasing medium, such as flash lamps or continuous light, radio frequency, 
high voltage discharge, diodes, and in some cases, another laser. The third compo-
nent are mirrors used to reflect the excited photons back into the resonant cavity 
containing the lasing medium. 
Generation of laser radiation 
As the lasing medium is excited, molecules are elevated to a higher energy level. 
Some of the excited molecules spontaneously decay back to the original lower en-
ergy, or ground state, releasing a photon. If the photon is emitted in the right direction, 
then it will hit one of the mirrors at the end of the resonant cavity and be reflected back 
into the excited lasing medium. This excited photon can "stimulate" another excited 
molecule to decay back to the ground state, releasing another photon that travels in 
the same direction, and in turn is reflected back into the resonant cavity stimulating 
emission of even more photons. If most of the molecules in the lasing medium are in 
the excited state, termed a "population inversion", there is a net amplification of light 
energy. 
The Q-switched laser is one in which a device introducing important losses in the res-
onant cavity and preventing lasing operation is suddenly switched to a state where the 
device introduces very low losses. This rapidly increases the quality factor (Q) of the 
cavity, thereby allowing the build-up of a short and very intense laser pulse. Typical 
pulse durations are in the nanosecond range. 
Properties of laser light 
Unlike ordinary light, laser light is coherent, collimated, and monochromatic. Coherent 
refers to the synchronized phase of the light waves, collimated refers to the parallel 
nature of the laser beam (laser light is emitted in a very narrow beam with all the light 
rays parallel) and monochromatic refers to the single color or wavelength of the laser 
beam. 
Some important parameters of lasers 
Absolute Energy: The total energy in a laser pulse or system, the unit is Joule (J) , and a 
typical value for a single laser pulse is 100 mJ. 
Fluence: The amount of energy per surface or fluence, also called dose, is usually 
stated in J/cm2 • 
Laser Power: Refers to the laser optical power output. If the selected laser power is 
low, the processing time must be increased. However, if the selected laser has more 
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power than necessary, the operation expense will be higher. So choosing the laser 
power properly is very important. 
Intensity: The laser power per unit area, measured in W/cm2 • Intensity is closely re-
lated to the laser focus spot size and the pulse lasting time. 
Wavelength (1): The wavelength of a laser is related to stimulated energy transition. The 
shorter the wavelength, the higher is the energy ofthe photon. The wavelength also af-
fects the maximum resolution and focalization: the shorter the wavelength, the higher 
is the resolution and the better is the focal property. 
Focal Spot Size: Focal spot size determines the maximum energy density that can be 
achieved when the laser beam power is set. This parameter is very important for mate-
rials processing. 
Depth of Focus: The laser light is first converged at the lens focal plane, then it di-
verges to a wider beam diameter again. Depth of focus is the distance over which the 
focused beam has about the same intensity. It is defined as the distance over which 
the focal spot size changes from -5% to +5%. Usually the longer depth of focus is 
preferred. 
Light-tissue interactions 
Laser light's monochromaticity is responsible for its selective effect on biological tis-
sue. Whenever light encounters tissue, it can be transmitted, scattered , reflected, or 
absorbed, depending on the type of tissue and the wavelength (color) of the light. 
However, light absorption must take place for there to be a biological effect. Any given 
wavelength of light may be strongly absorbed by one type of tissue, and be transmit-
ted or scattered by another. Each type of tissue has its specific absorption character-
istics depending on its specific components (i.e., skin is composed of cells , hair 
follicles, pigment, blood vessels, sweat glands, etc.). The main absorbing compo-
nents, or chromophores, of tissue are: 
Hemoglobin in blood 
- Melanin in skin, hair, moles, etc. 
- Water (present in all biological tissues) 
When light is absorbed, it delivers energy to the tissue, and the tissue's reaction de-
pends upon the intensity and exposure time of the light. An extremely intense, but very 
short pulse of laser light will usually cause an explosive expansion of tissue, called a 
photomechanical (photodisruptive, photoacoustic) reaction. A less intense, longer 
pulse causes a rapid heating, or photothermal effect. Lower intensities applied for lon-
ger times will cause a photochemical change, either by a slow transfer of energy as 
heat, or by a specific chemical reaction as made use of in photodynamic therapy. In 
actual practice, all of these interactions coexist. By selecting the proper wavelength, 
intensity, and pulse duration, the desired effect can be maximized. 
Selective Photothermolysis' is the process in which the transfer of laser energy is re-
stricted to a particular site because of the selective absorption of a chromophore at 
that site. In other words, proper selection of the wavelength and of the exposure time 
results in specific damage of the desired target tissue. For selective photothermolysis 
to occur, the following must be chosen accordingly: 
- The appropriate wavelength selectively absorbed by the target tissue 
- The appropriate exposure time which should be less than the thermal relaxation 
time of the target tissue 
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- The appropriate energy density, or fluence to produce the desired effect, such as 
vaporization, coagulation, or photo disruption 
Extended Theory of Selective Photothermolysis2 is a relatively new theory that postu-
lates the selective thermal damage of non-uniformly pigmented structures in biologi-
cal tissues. The following conditions should be met: 
Just as is the case with the classical selective photothermolysis, here too the elec-
tromagnetic radiation (EMR) wavelength should be chosen to maximize contrast 
between the absorption coefficient of the pigmented area and that of the tissue 
surrounding the target 
- The EMR power should be limited to prevent absorption loss in the pigmented 
area, but it must be sufficient to achieve a heating temperature higher than the tar-
get damage temperature 
- The pulse width should be made shorter than or equal to the thermal damage time, 
which can be significantly longer than the thermal relaxation time 
There are many medical laser systems available today, and most of them use the prin-
cipal of selective photothermolysis, which means getting the right amount of the right 
wavelength of laser energy to the tissue to be treated in order to damage or destroy 
only that tissue and nothing else (for example chromophores). 
Taking all these points into consideration it also is important to evaluate the skin type 
(Table V) before treatment. With increasing skin type, the risk of postinflammatory 
hyperpigmentation is greater. 
The following lasers are widely used in medical practice: 
Argon Laser 
As one of the first lasers in clinical use, the Argon laser is a continuous wave gas laser 
that emits blue-green light at 488 and 514 nm which is strongly absorbed by hemoglo-
bin and melanin. Although the beam may be mechanically pulsed, there is significant, 
non-selective heating in surrounding tissues, thus increasing the chance of scar 
formation. It uses include: 
- Retinal and inner ear surgery 
- Treatment of thick or nodular port wine birthmarks 
- Treatment of facial spider veins, small dark moles, cherry hemangioma 
Pulsed Dye Laser (POL) 
In this laser, a lasing medium of Rhodamine dye is excited by a flash lamp. The Pulsed 
Dye Laser is effective in treating vascular lesions such as cutaneous hemangiomas, 
port wine stains, cutaneous lupus erythematosus, oral granulation tissue and some 
vascular birthmarks. 
Ruby Laser 
The Ruby laser emits red light at a wavelength of 694 nm. The lasing medium is a syn-
thetic ruby crystal of aluminum oxide and chromium atoms, which is excited by 
flashlamps. Ruby laser light is strongly absorbed by blue and black pigments, and by 
the melanin in skin and hair. Current uses include: 
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Treatment of tattoos (Q-Switched mode) 
Treatment of pigmented lesions including freckles, liver spots, Nevus of Ota, 
cafe-au-lait spots (Q-Switched mode) 
(free-running mode) 
VAG Lasers 
YAG lasers use an Yttrium-Aluminum-Garnet crystal rod as their lasing medium. Dis-
persed in the YAG rod are atoms of rare earth elements, such as Neodymium (Nd), Er-
bium (Er) or Holmium (Ho), which are responsible for the different properties of each 
laser. All YAG lasers may be operated in continuous or pulsed mode, although a par-
ticular medical device is usually only capable of one or the other. The Q-Switched 
Nd:YAG is effective for black tattoo ink and has been used with fair results to remove 
hair. The millisecond-range Nd:YAG laser light is very effective for long-term hair 
removal. 
C02 Laser 
Often referred to as the "Surgical Laser", it is unlike any other medical laser, because 
its action on tissue is directly visible when used. Strongly absorbed by water, which 
constitutes more than 80% of soft tissue, the C02 laser emits continuous wave or 
pulsed far infrared light at 1 0,600 nm, which can be focused into a thin beam and used 
to cut like a scalpel, or defocused to vaporize, ablate, or shave soft tissue. Its uses in-
clude: 
Removal of benign skin lesions, such as moles, warts, keratoses 
As a "laser scalpel" in patients or body areas prone to bleeding 
"No-Touch" removal of tumors, especially of the brain and spinal cord 
Laser surgery for snoring 
Shaving, dermabrading, and resurfacing scars, rhinophyma, skin irregularities 
Cosmetic laser resurfacing to remove wrinkles 
Table 1: The use of lasers in treating different skin conditions 
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Table II: New laser systems for hair removal and skin renewal 
Sr Name Company Indication '!..I ss 
no. 
nm/ mm 
1) CooiGiide® Altus Medical, hair removal '!.. = 1064 nm 
Vantage, 
CooiGiide® Excel , 
Burlingame, CA. vascular lesions ss = 3,5,7 or 10 
Laser Genesis. 
2) Palomar SLP®1 000 Palomar Medical hair removal '!.. = 810 nm 
Diode Laser, Tech. vascular lesions 532 nm, 1064 nm 
Palomar Q-Y AG tattoos and ss = 4-12 
5TM Nd:YAG laser, pigmented lesions ss = 2,4,6 
3) Dornier Medilas D Dornier Medizin- vascular lesions '!.. =940 nm 
Skinpulse Laser. hair removal ss = 0.5-5 
Medilas D 
Skinpulse S 
4) CooiTouch II laser ICN Pharmaceutic wrinkle treatment 1320 nm 
CooiTouch VARIA Als, Inc. CA. hair removal 1064 nm 
5) IRIDERM 810 
Diolite 532 
vascular treatment ss = 6-10 











The flashlamp, also known as intense pulsed light source (IPLS), is the perfect com-
plement to lasers. Employing a broad spectrum of light energy in a range of wave-
lengths, IPL supplies high levels of light power in millisecond bursts. IPLS devices also 
offer sophisticated , computer-driven precision and tremendous versatility. Due to the 
nature of the treatment, Intense Pulsed Light energy can be applied to the sub-surface 
skin layers for gentle and gradual results with almost no side effects and patient 
downtime. For certain aesthetic challenges, IPLS technology provides a refining touch 
to laser procedures in general. 
Developed in the 1930's by Harold E. Edgerton, a flashlamp is an arc lamp that oper-
ates in the pulsed mode and is capable of converting stored electrical energy into in-
tense bursts of radiant energy covering the ultraviolet, visible and infrared regions of 
the spectrum. 
As is the case with lasers, flash lamps began to be used for medical purposes in the 
1960's. By the mid-1990's, researchers were exploring the use of flashlamps to treat 
vascular lesions such as port-wine birthmarks. Today the flashlamp pulsed dye laser 
is also designed to permanently remove or greatly reduce the appearance of 
blemishes. 
Flash lamps are similar to all other arc lamps in that an electrical current gets passed 
through a gas, producing optical radiation. Xenon is used in most flashlamps, since it 
is the most efficient of the inert gases at converting electrical energy into optical en-
ergy. Krypton is sometimes used because of its high efficiency in the near-infrared 
region. 
Although there are many shapes and sizes of flashlamps, there are only two distinct 
types- linear, or wall-stabilized; and bulb, or probe-stabilized. One such well-known 
type is the linear xenon flashlamp. It consists of a quartz tube with two sealed elec-
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trades - cathode and anode, made from tungsten or from special low-sputtering ma-
terials . The device is usually filled with the xenon gas at ca. 200 to 400 Torr pressure. 
However, krypton or a mixture of noble gases at various pressures could also be used. 
A flashlamp can also have a spherical or a spiral envelope. The distance between the 
electrodes varies from a few milimeters (in photo cameras) to almost 1 00 em for spe-
cial high power lamps. A typical linear xenon flashlamp has a distance rang ing form 
about 100-300 mm between electrodes and a bore diameter of about 4-9 mm. 
Flashlamp operation 
To operate a flashlamp, first the electrical energy is loaded into a capacitor. A high 
voltage switch provides the means to unload this stored energy quickly into a 
flash lamp tube and to generate a light emitting plasma. Its parameters are defined by 
lamp impedance and by electrical parameters of a driving circuit - the lamp's Pulse 
Forming Network. 
The electrical scheme is far more complicated and costly if heat for a flash lamp cath-
ode is required continuously between pulses. It can be accomplished with a so-called 
simmer- a steady DC discharge (or long-pulsed discharge) that keeps the cathode at 
a desired temperature (e.g. at 800°C}. This is done to sustain a special porous matrix 
structure of a cathode that in turn dramatically reduces the cathode sputtering by 
trapping discharged ions. Failing to do so especially at high loads, causes an exten-
sive sputtering that will darken a quartz envelope around the cathode area. As a result, 
respective parts of the quartz envelope will absorb more light and the quartz will 
overheat to the point of breaking. 
A typical energy load onto a flash lamp ranges from a few Joules to hundreds of Joules 
or even thousands of Joules for high-power applications. The respective peak cur-
rents can be up to a few thousand amperes. 
The temperature of the plasma and its light output strongly depend on the parameter 
called the Current Density J (A/cm2) which is often defined as the ratio of the lamp 
peak current to the surface area of the lamp bore. 
Current densities from hundreds to thousands A/cm2 produce a discharge plasma 
with respective electron temperatures ranging from ca. 9.000 °K to ca. 25.000 °K. A 
flashlamp can be considered somewhat similar to the solar spectra because of its 
dense spectrum. 
Any repeatedly pulsing device, including a flashlamp, has three powers: 
Average power, which is the total electrical power consumed by a lamp 
- Pulse power which is a ratio of pulse energy to pulse duration 
- Root-mean-square power, a function of pulse parameters and their repetition rate 
A flashlamp bombards a media with UV photons at extreme densities a thousand 
times more often than a continuous wave lamp does. It eliminates toxic chemical sub-
stances, bacteria, etc. that are present in or on a treated medium. 
It also provides unique conditions for pulsed curing and for cold vapour deposition; 
and it provides a lot of light for photographic devices, for pumping lasers, etc. Recent 
advances in high voltage/high current components and the improvement of the life-
time of flashlamps made it possible to design cost-effective pulsed UV systems for 
many applications. 
Full spectrum (non-coherent) light and near infrared radiation are filtered to select a 
specific range of wavelengths. This filtered light is delivered from a handpiece into the 
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Table Ill: Use of flash lamps in treating different skin conditions 
N. Flash lamp Indication )../ ss Reference 
1) IPL (Ellipse Flex; DOD) naevi, lentigines solaris, 600 950 Bjerring P25 
[Danish Dermatologic macular melanocytic nevi SS=48x10 
Development, Hoersholm, venous-lake angioma Jay H26 
Denmark]. nevus spilus Gold MH27 
IPL (Ellipse Relax Light 1 000; ODD) facial rhytids Goldberg DJ28 
hair removal Bjerring P29 
2) PhotoDerm®vL vasculair lesions "!.. = 500-1200 nm Schroeter CA30 
(ESC Medical Systems Ltd., port-wine stains SS=8x35 Raulin C31 
Yokneam, Israel) cavernous hemangioma ss=8 x 15 Cliff s32 
FosterTD33 





3) SkinStation®, acne therapy ).. = 400-1200 
SpaTouchTM, SPRTM. Radiancy, hair removal SS = 22 X 55 
Orangeburg, NY. skin rejuvenation SS=12x35 
hair removal 
skin rejuvenation 
4) Palomar EsteluxTM Pulsed- Light hair removal ).. = 500-1400 
System vascular lesions SS=16x46 
(LuxY, LuxG, LuxR, LuxRs from sun-induced pigmented SS=12x12 
Palomar Medical Technologies) lesions ss=16x46 
acne treatment SS = 12 X 28 
5) Aurora DSTM, Aurora SR System hair removal A. = 680-980 Sadick NS40-42 
(with radio frequency from treatment of pigmented & I= 580-980 
Syneron Corporation) vascular lesions SS = 12 X 25 
wrinkle reduction 
A. - wavelength in nm, ss- spot size in mm 
Table IV: Comparing the use of intense pulse light during hair removal 
Advantages of using IPL Disadvantages of using IPL 
Some patients have experienced long-lasting hair 
removal or permanent hair reduction. 
Long-term data on safety and effectiveness have not 
been established. 
Light-skinned patients with dark hair have the best 
results . 
It is useful for large areas such as backs or legs. 
It is considered to be safe if performed properly. 
It is not as effective on unpigmented hairs and red or 
blonde hair. 
It must be used very cautiously on darker skin tones 
or on consumers who like to tan themselves. 
Improper treatment can cause burns, skin 
discoloration lasting for several months, or patchy or 
grid-like regrowth. 
skin, where it targets dark material such as the pigment in the hair. This is intended to 
cause thermal and/or mechanical damage to a hair follicle while sparing its surround-
ing tissues. The filters can be adjusted to match the patient's skin type and the target 
lesion. 
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Table V. Fitzpatrick classification for sun-react ive skin types 
Skin type Colour Reaction to uva Reaction to sun 
Type I Caucasian; Very Sensit ive Always burns easily, never tans; very fair 
blond or red hair, freckles, skin tone 
fair skin, blue eyes 
Type II Caucasian; Very Sensitive Usually burns easily, tans with difficulty; 
blond or red hai r, freckles, fair skin tone 
fair skin, blue eyes or green 
eyes 
Type Ill Darker Caucasian, Sensitive Burns moderately, tans gradually; fair to 
light Asian medium skin tone 
Type IV Mediterranean, Moderately Sensitive Rarely burns, always tans well; medium 
Asian, Hispanic skin tone 
Type V Middle Eastern, Minimally Sensitive Very rarely burns, tans very easily; olive 
Latin, light-skinned black, or dark skin tone 
Indian 
Type VI Dark-skinned black Least Sensitive Never burns, deeply pigmented; very 
dark skin tone 
Differences between flashlamps and lasers 
Type of light 
As mentioned earlier, flash lamps do not use one wavelength of light the way a laser 
does. Flashlamps emit every wavelength of light in the visible spectrum, and emit par-
tially into the band of infrared radiation (up to about 1200 nm). Practitioners select a 
cutoff filter to block out lower wavelengths. In addition flash lamp light is noncoherent 
while that of lasers is coherent. 
Size and shape of the spot (beam) 
Most flashlamps emit a beam that covers more area than a laser would , and most 
flashlamps also have a rectangular spot, rather than the round type usually standard 
for lasers. 
Examples of IPL sources used for medical purposes {Table Ill and IV) 
1) Plasmalite®: A light source that produces non-coherent broad band of pulsed light, 
with emitted wavelengths ranging from 600-920 nm with a spectral peak at 700 nm. It 
is used in the treatment of wrinkles and both vascular and pigmented skin lesions. 
2) PhotoDerm~L (vascular lesions): The light pulses are directed at the spider and 
varicose veins as well as at vascular birthmarks. The tissue targeted is the haemoglo-
bin in the blood. 
3) PhotoDerm®PL (pigmented lesions): The light pulses are directed at age spots, 
freckles, flat-pigmented birthmarks and other types of discoloration. The tissue tar-
geted is the melanin in the epidermis. 
4) PhotoDerm®HR and Epilight® (hair removal) : This appliance makes it possible to 
eliminate unwanted hair, supposedly permanently. The pulsed light is computer con-
trolled and with the use of special fil ters Selective Photothermo/ysis damages the folli-
cle permanently. The pulses of light target the melanin i_n the hair shaft and travel to the 
foll icle, heating and destroying it. 
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5) Syneron has introduced a new ELOS™ (Electro-optical synergy) technology for the 
treatment of a wide range of skin, vascular and pigmented abnormalities, as well as for 
hair removal. ELOS technology utilises the synergy between electrical (conducted ra-
dio frequency) and optical (light or laser) energies. This promises to be a highly effi-
cient, safe and cost-effective system for the future use. 
Given all of the differences in between laser and IPLS devices and the need for addi-
tional information in IPLS treatment applications, the aim of this study was to evaluate 
new treatment possibilities using Intense Pulsed Light Sources and to address the fol-
lowing questions: 
1. What are the treatment effects on the skin after using IPLS? 
2. Efficiency of IPLS on hair removal ? 
3. Is the hair removal achieved using IPLS long-lasting and can we conclude perma-
nent? 
4. Is there an advantage to using IPLS over needle epilation in hair removal in trans-
sexual patients? 
5. Can IPLS be effectively used in the treatment of facial and leg telangiectasia? 
6. Regarding vascular lesions, is IPLS an effective alternative treatment to for 
Rosacea? 
7. How effective is IPLS in the treatment of pigmented lesions? 
16 
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Introduction 
Transforming growth factor-beta (TGF-P ) is a protein, which plays a principal role in 
the intracellular signalling. ' The most important function is its ability to stimulate syn-
thesis of extracellular matrix (ECM) that is responsible for wound formation and tissue 
reconstruction ! TGF-p acts via autocrine and paracrine mechanisms to regulate the 
interactions between cells and between cells and matrix in wound healing, involving 
inflammation, re-epithelialization, angiogenesis, and the production of extracellular 
matrix. 3 .. It stimulates the synthesis of multiple ECM components, including collagens, 
fibronectin, vitronectin, tenascin, and proteoglycans. 5"6 It suppresses matrix degrada-
tion by down regulating the expression of proteases, such as plasminogen activa-
tors7·6 and stromelysin9 and by inducing protease inhibitors, such as plasminogen acti-
vator inhibitor-1 6"10 and tissue inhibitor of metalloproteases-1.7 The presence of 
extracellular matrix has been found to down regulate the expression of the TGF-P1 
gene. ' ' Thus, TGF-P may act as a feedback for extracellular matrix formation . TGF-P is 
also involved in scar formation as neutralisation of TGF-P1 and TGF-p2 in adult 
wounds reduces scarring in rat dermal wounds. '2 By contrast, exogenous addition of 
TGF-p3 to dermal rat wounds results in reduced scar formation. ' 3 Therefore it is clear 
that different isoforms ofTGF-P can have completely opposite effects in wound repair 
although the mechanisms behind these differences are still under investigation. '• 
Transforming growth factor-p is also found to be involved in lymphopoiesis and is re-
quired for the development of plasma cells secreting all secondary isotypes.' 5 
It has been documented that TGF-p plays important roles in the induction of catagen 
phase of the human hair cycle.16"17 An isoform of TGF-P acts as an inducer of hair folli-
cle morphogenesis and is both required and sufficient to promote this process.'• 
During embryological development, specialized cells of developing multicellular or-
ganisms are surrounded by extracellular matrix, comprising largely of different col-
lagens, proteoglycans, and glycoproteins. This ECM is a substrate for tissue 
morphogenesis, which lends support and flexibil ity to mature tissues and acts as an 
epigenetic informational unit in the sense that it transduces and integrates intracellular 
signals via distinct cell surface receptors. Consequently, ECM-receptor interactions 
have a profound influence on major cellular programs including growth, differentia-
tion, migration, and survival. In contrast to many other ECM proteins, the tenascin (TN) 
family of glycoproteins (TN-C, TN-R, TN-W, and TN-Y) displays highly restricted and 
dynamic patterns of expression in the embryo, particularly during neural develop-
ment, skeletogenesis, and vasculogenesis. These molecules are reexpressed in the 
adult during normal processes such as wound healing, nerve regeneration, and tissue 
involution, and in the pathological states including vascular disease, tumour genesis, 
and metastasis. Expression of tenascins is known to be regulated by a variety of 
growth factors, cytokines, vasoactive peptides, ECM proteins, and biomechanical 
factors.'• 
Different research studies have been undertaken to examine the role of tenascin and 
transforming growth factors in the diagnosis and prognosis of various diseases and 
pathological conditions. Kava et al in a series of ductal carcinomas of the breast ob-
served that tenascin limits tumour spread .20 
Immunohistochemical detection of molecules involved in inflammatory reaction can 
be useful for the diagnosis of vitality in skin wounds. Ortiz-Rey et al studied the ex-
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pression of fibronectin (FN) and TN in 58 human skin wounds. Both vital and postmor-
tem hemorrhages showed an enhanced positivity for FN and TN, thus impeding the 
diagnosis.2' The presence and distribution of tenascin in the human intervertebral disc 
has been studied. It was found that in young, healthy disc, tenascin was abundant 
throughout the annulus, while degenerating discs in adults showed localization re-
stricted to the pericellular, and rarely, more restricted intra territorial matriX.20 These 
observations indicated that changes in the amount and distribution of tenascin might 
have a role in disc aging and degeneration ! 2 
The role of transforming growth factor- f3 in the pathogenesis of liver diseases and its 
possible use as an indicator of disease progression has been suggested ! 3 The effect 
of tropically applied TGF-[31 on the rat gingival wound healing process after flap sur-
gery was evaluated by immuno-histochemistry for extracellular matrix molecules, 
such as tenascin, heparan sulfate proteoglycan and type IV collagen, and for prolifer-
ating cell nuclear antigen in fibroblasts. It was found that TGF-[31 application ap-
peared to promote granulation tissue formation in periodontal wound healing!• A 
study on wound healing proposed that the frozen cultures of human keratinocytes 
promote faster reepitheliazation through the release of growth factors such as TGF-al-
pha and through the stimulation of murine sub epithelial cells, by TGF-[3, to secrete 
basement membrane proteins such as collagen IV, laminin, and tenascin, which pro-
vide a provisional substrate that improves migration of the murine epidermal cells!• 
There have been very few studies probing into the changes brought about by radiation 
on TN and TGF. An early response to radiation exposure was the induction of TGF-[3, 
which mediated numerous events during tissue repair, growth, and extracellular ma-
trix production. 25 Radiation induced activation of TGF-f3 may have profound implica-
tions for understanding tissue effects caused by radiation therapy! 6 Transforming 
growth factor-f3 was recently shown to be rapidly activated after in vivo radiation ex-
posure, which also generates reactive oxygen species. It was postulated that oxida-
tion of specific amino acids in the latency-conferring peptides leads to a conformation 
change in the latent complex that allows release of TGF-[3.27 
The aim of our study was to investigate the stimulation of growth factor e.g. TGF-13 and 
release of ECM proteins such as tenascin after radiation with intense pulsed light 
sources. 
Materials and methods 
Animal Model 
The protocol was approved by the Veterinary Ethical Commission (DEC), Maastricht, 
the Netherlands. Two male dark-haired pigs were chosen randomly from the Experi-
mental Surgical Department of the University Hospital Maastricht, the Netherlands. An 
intra muscular injection of Azopyrone (0.5 mg/ kg) was given to initiate anaesthesia in 
them. The anaesthesia was maintained with halothane (3-4%) and nitrous oxide. The 
back region of the pigs- between their forelegs and hind legs, and the abdomen was 
shaved to achieve a maximum penetration depth. The area was washed with hibiscub. 
Treatment sites were outlined by West Indian ink applied to the skin with hypodermic 
needles. Four marks outlined a 40x20cm2 treatment area. No ointment was applied 
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pre- and postoperatively in the treatment area. No chemical or mechanical 
debridement was performed during follow up examinations. To be certain that the 
pigs did not experience any pain, Buprenorphine 0.05-0.1 mg/kg i.p. was given soon 
after the treatment. The animals were euthanized after 120-360 days after treatment 
using intravenous nembutal (100-150 mg/kg) (Table 1). 













The pigs were treated according to the protocol (Table II). A stencil was placed on the 
back of the pigs, in order to treat the same surface every time. The pigs underwent 
general anaesthesia for 15-30 min (5 times for the treatment and 5 times for the biop-
sies). In total there were 40 flashes per pig per treatment. Using Vasculight® 590 and 
695 nm and using Quantum®, 565 and 640 nm filters were used. The pulse times used 
were 6.5-21 ms and the fluence was 35-60 J/cm2 • 
An entire surface of 40 x 2.8 cm2 was treated per pig. The treatment took 4-5 min. 
There was an interval of 4 weeks between the treatments. 
Biopsies were performed immediately following light treatment and then on the 2nd, 
7th, 14th and 28th days postoperatively. In the second month, one week after the last 
biopsy, the pigs were reradiated and after 3 weeks biopsies were performed again. 
This was continued for four months. A total amount of 240 biopsies were thus taken. 
Full thickness 3-mm punch biopsies were obtained from each treated site. Tissue 
specimens were fixed in formalin, embedded in paraffin, sectioned and stained with 
hematoxylin and eosin for light microscopic examination. 
Table II: Parameters used for the treatment of the pigs 
Wavelength Pulse time En erg!, 
(nm) (ms) (J/cm ) 
550 5-3 40 
590 7-7 40 
645 4-2.5 35 
695 7-7-7 60 
565 4.2-5-4 40 
640 4.2-4.8 35 
Follow-up 















The pigs were followed daily during the first week. After that they were seen and evalu-
ated after 1, 2, 3, 6, 12, and 30 weeks. They were examined for among other things; 
presence of crust formation, swelling , bleeding , erythema, wound healing, scar for-
mation, depigmentation and loss of hair. Photographs were taken before and after the 
treatment. 
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Intense pulsed light 
The Vasculight® (ESC Medical Systems Ltd., Yokneam, Israel) and Quantum® (ESC 
Sharplan) are based on the principal of selective photothermolysis. In contrast to laser 
systems, these flashlamps use non-coherent light of a broad band spectrum in the 
range of 500-1200nm. By applying different cut-off filters (550, 570, 590 nm), a spe-
cific part of the shorter wavelengths can be cut off. 
The pulse duration ranges between 2-5 ms (Vasculightj and 6-26 ms (Quantumj . The 
fluence ranges between 3-90 J/cm2 (Vasculightj and 5-45 J/cm2 (Quantumj . The size 
of the treatment head (8X35mm and 8X34mm) plays an important role in improving 
light penetration into the tissue since a large spot size diminishes the scattering of the 
light beam. 
A water-containing gel is used between the skin and the probe during treatment, 
which allows a good optical coupling of the light and also a better heat transfer from 
the epidermis to the gel. 
By changing the different parameters of the flashlamps; namely energy, wavelength, 
pulse duration etc., one can achieve efficient treatment for a variety of lesions with a 
high degree of selectivity and safety. 
Method 
Tissue preparation for immunohistochemistry 
Tissue blocks of pig skin biopsy were fixed in 4% neutral buffered paraformaldehyde 
at 4°C for 4-12 hours. The specimens were then routinely processed for paraffin em-
bedding at 56°C as previously described. Paraffin sections measuring 4 ~--tm were used 
for light microscopy and immunohistochemistry. 
Immunohistochemistry 
Paraffin sections were deparaffinized and rehydrated. Immunohistochemical demon-
stration of tenascin and TGF-P antigens was performed on these sections with the 
avidin-biotin peroxidase (ABC) method. Briefly, these sections were processed 
through the following incubation steps: 1) hydrogen peroxide 3% in methanol for 30 
min to block endogenous peroxidase; 2) normal goat serum for TGF-P1 and normal 
horse serum for tenascin, diluted 1:75 v/v, for 30 min to 1 h to reduce non-specific 
background staining; 3) incubation with primary antibody anti TGF-P1 (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) and with primary antibody anti tenascin (Sigma, 
St Louis, MO) overnight at 4°C; 4) biotinylated secondary antibody: goat anti-rabbit 
lgG (forTGF-P1), and horse anti-mouse lgG (fortenascin), diluted 1:200 v/v, for 30 min 
to 1 h (Vector Labs, Burlingame, CA); 5) ABC complex for 1 h (Vectastain ABC kit, Vec-
tor Labs), 6) histochemical visualisation of peroxidase using 3',3'diaminobenzidine 
hydrochloride as chromogen (Sigma) for 5 min in a dark room. Sections were then 
rinsed in tap water, counterstained with haematoxylin, dehydrated and mounted with 
Eukitt (Kindler GmbH & Co., Freiburg, Germany). 
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For the above immunohistochemical procedures controls were performed: a) by omit-
ting the primary or secondary antibody; these controls showed negative results; b) by 
using human placenta as positive control for tenascin and TGF-P1 antibodies. 
Statistical data 
The statistical analysis of the data was descriptive. The data is presented as contin-
gency tables in order to detect association between technical and clinical parameters. 
Exact Fisher tests were used to evaluate the homogeneity of the tables, p- values be-
low 0.05 are considered significant. 
Results 
Clinical Observations 
After every treatment erythema was observed. It was noted that after using the follow-
ing parameters: wavelength 640 nm, pulse time between 4.2-4.8 ms and energy of 35 
J/cm2 the erythema seen was negligible. In some cases the upper epidermis was 
sealed off but it later recovered. Transient depigmentation was noticed, which disap-
peared after some time. Hair was burnt. There were no blisters seen. 
Histological Findings 
In the biopsy samples, after the first day, TGF-P immunohisto-reaction was localised 
in the epidermal layer, the hair follicle, endothelial vessels, fibroblasts and the plasma 
cells. After 1 week a subsistent increase was recorded. On the 14th day, there was a 
sharp decrease, similar to that on the first day of the treatment and at some places 
even lower to those levels. After one month, TGF-p rose to achieve a peak value and 
began to slowly fall to day 60 and continued to do so till the 90th day. After that its 
presence began to pick up and on day 120 we again saw a high occurrence. 
Tenascin was visible below the epidermal germ layer and around the hair follicles im-
mediately after treatment. After one week, its presence increased in the germinative 
epidermis, papillar dermis and the plasma cells, while in the endothelial vessels and 
the follicular bulb there was a sharp decrease. On day 14, tenascin continued to rise in 
the germinative epidermis, papillar dermis, in the endothelial vessels and follicular 
bulb a subsistent amount was recorded, while in the plasma cells a sharp fall was 
seen. After a month there was a sharp decrease, but this gradually recovered in the 
germinative epidermis, papillar dermis and the follicular bulb on day 60. In the endo-
thelial vessels and plasma cells it was absent. After three months a gradual increase in 
its presence was seen (Figure 1-3). 
Discussion 
The results of this study indicate that there is an increase in the immunoreactivity of 
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by irradiation with an intense pulsed light source. Moreover we observed that TGF-p 
stimulates the increase in the concentration of fibroblasts and plasma cells. 
One day after radiation, the appearance of TGF-p in the basal epidermal layer and the 
follicular bulb was detected. Fibroblasts and plasma cells were also strongly positive. 
After 1 week the outermost epidermis, endothelial vessels, follicular bulb, fibroblasts 
and plasma cells were intensely stained. TGF-P immunoreactivity decreased after 2 
weeks, similar to that as on the first day of the treatment. After one month, the expres-
sion of TGF-P reached a peak value. This began to slowly fall to the second month and 
continued to do so till the third month. Subsequent to that its presence started to in-
crease and on day 120 we again saw a high occurrence. 
Tenascin was visible below the epidermal germ layer and around the hair follicles. At 
about 7-10 days after radiation, the biopsies showed a strong increase in tenascin ex-
pression. It was localised in the papillar dermis, the epidermal layer and also in the 
depths of the dermis, while in the endothelial vessels and the follicular bulb there was 
a sharp decrease. Biopsies showed a sharp decrease in tenascin immunoreactivity af-
ter one month, but this gradually recovered in the germinative epidermis, papillar 
dermis and the follicular bulb in the second month, but not in the endothelial vessels 
and plasma cells, where it was absent. In the third month a gradual increase in its 
presence was seen. 
The results from the present clinical trial are consistent with the general clinical experi-
ence of the principal investigators in other trials. Radiation has already been discov-
ered to be the first exogenous stimulus known to cause latent TGF-p activation in 
situ! 7 In animal models, the TGF-P1 and matrix metalloproteinase content of the me-
dium of cultured cells was significantly elevated after near-infrared irradiation, and it 
was found that the rate of wound closure was significantly accelerated by repeated 
exposures!" Preliminary human studies have shown that exposure to short wave ul-
traviolet light significantly decreased the time to healing of superficial pressure u~ 
cers. 29"30 Application of exogenous TGF-p either locally or systemically has been found 
to accelerate healing, particularly in chronic or impaired wounds. 31 "32 In one study 
extracellular and intracellular TGF-P increased in the periepithelial stromal sheath at 1 
h post radiation and it was also expressed in the previously negative adipose stroma:• 
This elevated expression persisted for 7 days after irradiation:• Immunoreactive 
tenascin was induced in the epithelium by day 1 after radiation, was manifested at the 
epithelial-stromal interface by day 5-9 and persisted as a condensed layer beneath 
the basement membrane through day 14.33 Dissanayake and Mason detected in-
creased TGF-P1 in the culture media of irradiated keratinocytes after 24 hours. 34 
In analysing radiation-induced connective tissue, TN expression was found to be in-
creased in irradiated human skin, which was considered to be due to activation of 
cytokines as a result of irradiation. 35 ln an animal study, within 24 hours after wound-
ing, tenascin appeared in the basement membranes beneath epidermis and hair folli-
cles adjacent to the wound edges and in the wounded edges of cutaneous muscle 
layer.36 At about 5-7 days, all of the granulation tissue was intensely stained with 
anti-tenascin serum. Tenascin immunoreactivity decreased as granulation tissue was 
replaced with reconstructed dermal tissue at 7-14 days, after which it disappeared.36 
Betz et al reported that tenascin appeared first in the wound area pericellularly around 
fibroblastic cells approximately 2 days after wounding. In all wounds with an age of 5 
days or more, intensive reactivity for tenascin could be observed in the lesional area 
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(dermal-epidermal junction, wound edge, areas of bleeding). In wounds with an age of 
more than approximately 1.5 months no positive staining occurred in the scar tissue. 37 
Inflammation is the normal acute reaction of the tissues after any wound or injury. 
Macrophages and neutrophils enter the wounded area and start to clean up foreign 
material, bacteria and dead cells.'" When inflammation has subsided proliferation of 
fibroblasts begins, which also stimulates the synthesis of ECM.'9 Eventually fibroblast 
proliferation stops and ECM matures to provide a connective tissue structure.'9 Sev-
eral growth factors including TGF-~ are responsible for this wound healing process. 
The most common cause of laser-induced tissue damage is thermal in nature, where 
the tissue proteins are denatured due to the temperature rise following absorption of 
laser energy. The thermal effect of lasers on biological tissue is a complex process re-
sulting from three distinct phenomena: conversion of light to heat, transfer of heat and 
the tissue reaction. The thermal injury is known to induce a pronounced activation of 
leukocytes in the connective tissue matrix of the burned skin along with migration and 
activation of white blood cells from the circulation.'0 This phase is followed by release 
of numerous vasoactive agents known to play an important part in the patho-
physiological changes ensuing a burn injury and resulting in increased capillary per-
meability and impaired circulation."·42 
Resurfacing techniques such as dermabrasion, chemical peeling, and laser and 
flashlamp skin resurfacing have been established to attain their therapeutic effects by 
stimulating a wound-healing response that leads to an increase in dermal collagen. 43•48 
For example: the nonablative laser is able to generate dermal temperature increase of 
30-40 degrees C while limiting thermal injury to the epidermis.'9 The dermal heat may 
eventually result in activation of fibroblasts to produce a long term healing response 
and subsequent collagen remodeling .'9'50 Shorter wavelength technologies have been 
hypothesised to induce a heat-mediated cytokine activation." 
The biological activity of transforming growth factor ~1 is controlled by its secretion as 
a latent complex in which it is non-covalently associated with latency-associated pep-
tide (LAP).52 Barcellos-Hoff et al postulated that oxidation of specific amino acids in 
the LAP leads to a conformation change in the latent complex that allows release of 
active TGF-~.53 
Synthesis of TGF-~ increase was registered 1-2 days after activation with BCG vac-
cine, lipopolysacharide and gamma radiation." One study demonstrated activation of 
latent TGF-~ after wounding and noticed that introduction of the latent TGF-~1 gene 
into keratinocytes markedly increased the release and activation of TGF-~ after burn 
injury. 55 
From our findings too we demonstrate that the use of high-intensity flashlamp pro-
duces an artificial wound, which in turn stimulates the induction of transforming 
growth factor-~ and tenascin, as shown by immunohistochemistry. 
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Abstract 
Until recently, previously applied methods to remove hair have ultimately proven inef-
fective or resulted in the formation of scars and small wounds. Different methods for 
removing hair in a more or less permanent way have been used: electrolysis, 
thermolysis and the blend method. In this study we describe the removal of hair with-
out side effects by means of non-laser incoherent emitted light, produced by the ILS 
flashlamp. In a multicentre study we treated 40 women with a median age of 38.6 
years with hirsute hair growth of different hair colours on the upper lip and chin. In gen-
eral 76.7% of the hair was removed within 6 treatments, with an average fluence of 
38.7 J/cm2 and a mean wavelength of 585 nm per patient. 
A correlation was found between the percentage reduction of hairs and the number of 
treatments and between hair removal and needle epilation before treatment. Further-
more, a correlation was seen between hair reduction and wavelengths of 570 nm and 
550 nm. No association was found between hair removal and clinical data of the pa-
tients, nor between hair reduction and technical data of the device. This study pres-
ents a new alternative for hair removal. 
Key words: hair removal , hirsute, light-source, pulse mode, laser therapy. 
Introduction 
Women with unwanted hair growth on the face, neck and body have social and physi-
cal problems, which are encountered daily in dermatological and cosmetic practices. 
Female patients are devided into three groups: a group of hirsute patients, who show 
a male pattern of hair growth due to the increased influence of androgenes on hair fol-
licles; a group of patients with hypertrichosis, which is in general a density of hair 
growth; and a group of patients with cosmetic concerns. The patient should be asked 
which type of hair removal she prefers. There are several physical methods of tempo-
rary hair removal: shaving , which does not change the quality, quantity or texture of 
the hair, but whichgives many side-effects such as skin irritation, crusts and beard 
stubbles; '· 2 hair removing gloves, which can be used several times a day, which are 
made of dermabrative paper; 3 bleaching hair with 6% H2 0 2 which does not remove 
hairs but makes it invisible as there is no shadow of the beard on the upperlip and chin 
anymore; plucking, which is generally used for small areas and may give 
postinflammatory hyperpigmentation; and waxing, which lasts longer than shaving or 
depilatory agents.' Side-effects are among others, thermal burns, folliculitis and ery-
thema of the skin . Chemical depilatory agents include thioglycol acid, barium, sulphur 
compounds and antimony, which hydrolise bonds through which hairshafts are bro-
ken down. 2 '3'5 
Electrical epilation methods for hair removal are: electrolysis, thermolysis and the 
blend method.6 '7 Electrical epilation has several disadvantages, such as pain, even if 
local anaesthetics are applied. Furthermore, this method is more time consuming and 
side effects are seen , such as scars, irritation of the skin, hyper and hypopig-
mentation. 
Surgical depilation was introduced by Bouwman in 1978, who performed a submental 
incision, where the subcutaneous fat is trimmed until the follicles were visible, and the 
hair roots were cut with serrated scissors. " 
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Different lasers are used for removing hair. The concept of using selective 
photothermolysis with laser light for hair removal was first described by Kuriloff in 
1988 for pharyngo-oesophageal hair growth ." The Argon Laser was used for 
photo-epilation in the treatment of trachomatous trichiasis1 0,11 and the Neodynium 
Yag Laser for epilation of hair-bearing urethral grafts.12 Dover was one of the first to 
succeed in showing that the Ruby laser caused selective injury to pigmented hair folli-
cles.13 Zaias proposed the concept of a pulsed laser for hair removal in 1991.'4 
Grossman performed another study in which he showed that the normal mode Ruby 
laser pulses damage the hair follicles.'5 
The other mode methods are: Alexandrit laser: 755 nm wavelength; one pulse mode; 
20 ms pulse duration, the Diodenlaser (LightSheer): 800 nm wavelength; 1 pulse 
mode; 5-30 ms pulse duration, the Lichtblitzgerat (Ellipse R): 600-950 nm wavelength; 
1-5 pulse modes; 0.2-50 ms/pulse for pulse duration, the Nd: VAG-laser: 1,064 nm 
wavelength; 1 pulse mode; 20-40 ns (q-sw.) pulse duration, and lastly the Ruby laser: 
694 nm wavelength; 1 pulse mode; 0.8-3.0 ms (frm) pulse duration. 
It is necessary that the laser beam penetrates deep into the dermis in order to reach 
the hair follicles and to be selectively absorbed by melanine. 
A new laser-like device, the PhotoDerm~L was developed by Energy Systems Cor-
poration (ESC), Israel , mainly for the treatment of vascular lesions located deep in the 
skin, such as therapy resistent portwine stains, essential telangiectasia, erythrosis 
interfollicularis, red keloids and small varicose veins.' 6·23 
This treatment consists of an intense light source which emits non-coherent light with 
a constant spectrum between 515 and 590 nm, variable pulse times, energy ranges 
between 20 and 60 J/cm2 and different operating modes. 
Although the PhotoDerm~L is not a coherent light source, the operation principle is 
the same as that of lasers. The energy produced works on a specific structure in the 
skin without inducing much heat in the surrounding tissues. This process is called se-
lective photothermolysis.24 The risks for side-effects such as scar formation or 
hyperpigmentation are negligible as long as the right parameter settings for each indi-
vidual patient are respected. It was noticed that during the treatment of vascular le-
sions on the face permanent hair loss in the face occurred as side-effect of this 
treatment with the PhotoDerm~L. Case reports have been described for definitive 
hair removal. 25 
A new device introduced after the PhotoDerm~L flash lamp was the Epilight.® This device 
works with different wavelengths (e.g. 590, 615, 645, and 695 nm), is expected to pene-
trate deeper into the skin and works with higher energy and as many as five pulse modes. 
This study was carried out due to our interest in treating patients with hypertrichosis 
and hirsutism, and because research into the use of selective photothermolysis for 
hair removal is nonexistent. 
Materials and methods 
Patients 
Forty female patients were randomly chosen in the Medical Centre Maastricht, the 
Netherlands, the Karsruhe Lasercentre, Germany, and the Zurich Lasercentre, Swit-
zerland. 
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A careful history of abnormal hair growth was taken for each patient. When necessary, 
patients were sent for further investigations by an endrocrinologist or gynaecologist. 
The median age of the patients was 38.1 years with a minimum of 20 and a maximum 
of 58 years. Patients were being divided into 4 different age-groups: group 1: < 30 
years (8 patients); group 2: < 40 years (13 patients); group 3: <50 years (16 patients) 
and group 4: > 50 years (3 patients). Patients were scored in relation to their skin 
types, according to Fitzpatrick's classification: there was one patient with skin type 1, 
24 patients with skin type 2, 13 patients with skin type 3 and 2 patients with skin type 
4. Out of 40 patients, 8 had black hair, 26 brown hair, 5 blond hair and 1 mixed hair. In 
the group of forty patients, 8 (20%} women had a positive family history of hirsutism, 
34 (87.5%) patients had normal periods, 4 (1 0%) patients had irregular periods and 1 
(2.5%) patient was menopauzal. Fourteen (35.1 %) women were using contraceptive 
drugs, 3 (7.5%) were being hormonally treated, 2 (5%) patients were shaving daily, 
and 36 (90%) were plucking daily (of which 23 (63.8%} were plucking hair for up to 5 
min and 13 (36.1 %) for longer than 5 min). Patients were seen and scored by two dif-
ferent physicians. They were asked to shave 3-4 days before treatment. They were 
advised to shave rather than pluck the hair or dewax and to use a sun blocker during 
the time of treatment. The treated area was cooled with an icepack and, if necessary, 
Zilversulfadiazine creme, Flammazine" , (Solvay Pharma), Weesp, the Netherlands 
was applied. A test spot was marked beneath the left chin (with a right side as control}. 
After one week, a month and three months, hair counts of the test spots beneath the 
chin were estimated in the same patients at the Medical Centre Maastricht. An estima-
tion was used, without counting. The percentage of hair before treatment was com-
pared to the percentage present at evaluation . 
PhotoDerm"'VL 
The principle of the operation of the PhotoDerm"VL (ESC Medical Systems Ltd, 
Yokneam, Israel} is based on the principle of selective photothermolysis, where the 
light, absorbed by the specific lesion, leads to its heating to a temperature, high 
enough to cause thermal damage (T>80°C}, sparing the epidermis and the surround-
ing healthy dermis. In contrast to laser systems, the PhotoDerm"VL uses incoherent 
light of a broad band spectrum in the range of 500-1 ,200 nm. By applying different 
cut-off filters (515, 550, 570, 590 nm), a specific part of the shorter wavelengths (below 
the indicated filter) can be filtered off. 
The tissue penetration depth of visible light depends on the wavelength; longer wave-
lengths are less absorbed by the skin. Alteration of the spectral range used during 
PhotoDerm"VL treatment (which is done by selecting different cut-off filters) allows for 
modification of the light penetration depths to match the specific target structure, i.e. 
vessels of different sizes and depths, hair follicles etc.' 9 The use of different cut-off fil-
ters also allows for adjustment of the treatment parameters to the patient's skin type. 
Using longer filters, which control the spectrum to higher wavelengths, results in less 
overlap with the higher absorption coefficient of melanin, the concentration of which 
depends on the skin type. 
The pulse duration can be varied, ranging between 2 and 25 msec and should be 
lower than the thermal relaxation time of the target tissue, so as to avoid cooling of the 
lesion during application of light energy. In order to improve the selectivity of the light 
to the target tissue only, the PhotoDerm"VL also provides- besides a single pulse- se-
34 
ries of two and three pulses, with controlled intervals between the pulses in the range 
of 1 0-500 msec. This delay allows for cooling of the epidermis. 
Fluences applied by the PhotoDerm~L range between 3 and 90 J/cm2 • 
The size of the PhotoDerm®VL treatment head (8 x 35 mm) plays an important role in 
improving light penetration into the tissue, since the large spot size diminishes the 
scattering. 
A cooling gel is used over the skin during PhotoDerm~L treatment, which allows 
good optical coupling of the light to the patient's skin and also allows better heat 
transfer from the epidermis to the cold gel. 
Statistical analysis 
The statistical analysis of the data was performed in a descriptive way. The data are 
presented as contingency tables in order to detect association between technical and 
clinical parameters. Exact Fisher tests were used to evaluate the homogeneity of the 
tables; p-values below 0.05 are considered significant. The Pearson Coefficient inter-
val tested the relation between hair removal and mean treatment intervals per patient. 
Results 
Histology 
Hair shafts showed fragmentation . No focal ruptures of the follicles and no 
hemorrhage was found (Fig. 1 ). No coagulation of the surrounding 
dermalcollagen was seen. The replace follicle showed new collagen formation 
without any sign of scarring, and capillaries were present in the new collagen 
formation (Fig. 2a and 2b). The control biopsies showed no changes in follicles 
of the surrounding area. 
Clinical observations 
In the beginning of the study there was a tendancy in all centres to use a single pulse 
as a pulse mode, a pulse duration of approx. 5-6 msec, a wavelength of 590 nm for 
dark hairs, 550 nm for blond hair, and a fluence between 35-40 J/m2 • Later on, the 
treatment was changed to double pulses as pulse modes, with 5 msec per pulse dura-
tion and fluences between 35-40 Jf m2 • 
At the Medical Centre Maastricht the treatment intervals were as follows: 
6 weeks after the first treatment, 8 weeks after the second treatment, 3 months after 
the third treatment, and 3-4 months after the fourth treatment. 
Depending on the skin type, delays were chosen to cool the epidermis in between the 
pulses, e.g. for skin type 1 and 2 a delay" of 10-20 msec was chosen , with a double 
pulse as pulse mode, for skin type 3 a delay of 30 msec was chosen, and if treating 
skin type 4, a delay of > 50 msec was used. 
The patients experienced the treatment as the stinging of a needle, but less painful 
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Figure 1. The epithelial cells of the folli-
cle have partially disappeared and are 
replaced by macrophages containing 
melanin pigment. HE, magnification 
40x. 
Figure 2a. Replacement of the hair 
follic le by new formation of fibrous 
tissue and collagen. The capillaries 
are enclosed. Trichome stain, magni-
fication 1 Ox. 
Figure 3a. Patient with hirsute hair grow1h on the chin. 
Figure 3b . The same patient treated after Qne year. 
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Figure 2b. The newly formed collagen 
bud, trichome stain, magnification 40x 
to the fluences, pulse times and pulse modes. The shorter the pulse times(< 3 msec) 
were, the more edema and erythema was observed. Fitzpatrick skin types 1 and 2 
with dark hairs showed less side- effects than skin type 3. Only two patients with skin 
type 4 were treated. As epidermal side- effects in skin type 3 and 4 we first noticed er-
ythema. Imprints, which turned into crusts, were observed after 24 hrs and sealed off 
after 4-7 days. Hyperpigmentation was seen in 20% of patients; hypopigmentation 
was not seen at all. The skin of the neck and the upper lip was much more sensitive. 
Fluences were reduced about 2-3 J/cm2 in the neck compared to the cheeks and chin. 
Most of the time about 20% of hair disappeared after the first treatment in dark- haired 
individuals. Depending on the hair cycles, growth of new hair was observed . Dark hair 
was removed in fewer treatment sessions, compared to blond hair (Fig. 3a and 3b). 
According to our experience, hair loss is proportional to wavelength (the higher the 
wavelength the more delayed the hair loss), and therefore it was mostly longer than 
one week. 
In the Medical Centre Maastricht, treated hairs which were long enough were plucked 
out beneath the chin, as was untreated hair from the opposite side of the chin. These 
were subsequently compared under the microscope. The treated hair was shrunk and 
broken at the epidermal border and the follicle was partly damaged. The untreated 
hair showed normal outer and inner root cell sheet and a normal follicle. 
Clinical data 
The median age of the 40 hirsute women was 38.6 years with a minimum age of 20 
years and a maximum of 58 years. The median percentage of hair loss was 76.6% with 
a minimum of 50% and a maximum of 95% with an average of 6 treatments. The treat-
ment data of the patients, such as hair color, energy, wavelength, percentage of hair 
reduction and number of treatments, are found in Table I. 
The treatment interval was 57.6 days per patient, but only data from 30 patients was 
available. The Pearson Coefficient interval tested the relation between the hair re-
moval and mean treatment intervals per patient. The Pearson Coefficient interval was 
-0.55, which means the shorter the treatment interval, the greater the hair removal re-
duction. 
In this study we found a significant correlation between the percentage of hair loss 
and the number of treatments ( p = 0.04) (Table II). Two out of 39 patients showed are-
duction of 50% within two treatments. Five out of 39 women had lost 89% of hair after 
7 treatments (Table II). 
Furthermore a correlation was found between hair removal and needle epilation be-
fore treatment (p = 0.002) (Table lilA). Twenty- six out of 40 (65%) patients had under-
gone no previous needle epilation. This group reacted much better to hair removal 
than the group which had experienced prior needle epilation. Moreover, a correlation 
was seen between the reduction of hair and the wavelength of 570 nm (p = 0.0001) 
and a trend was observed with wavelength of 550 nm (p = 0.08). Further association 
was observed between hair removal and the different energy groups. Energies were 
separated into 5 groups (Table Ill B). A correlation was seen between hair removal and 
energy groups 1 ( < 30 J/cm2) and 5 (46-50 J/cm2) (p = 0.04), as well as between hair re-
moval and energy groups 2 ( 31-35 J/cm2) and 5 (46-50 J/cm2) (p =0.008). This indi-
cates that a fluence below 30 J/cm2 and the fluence between 31-35 J/cm2 had more 
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Table I. Clinical and technical data of patients 
No. of Patients Hair colour Energy J/cm2 Wave length nm Haire Reduction No. of Treatment 
fair 35.0 560.0 90 4 
2 fair 31 .6 558.0 90 7 
3 dark 41.0 560.0 50 2 
4 dark 33.5 590.0 90 6 
5 dark 38.3 590.0 80 4 
6 fair 28.8 572.0 95 5 
7 dark 44.6 570.0 90 7 
8 dark 34.3 567.5 90 13 
9 dark 28.0 560.0 95 7 
10 dark 30.0 570.0 90 7 
11 dark 34.3 587.0 90 6 
12 dark 28.0 580.0 90 6 
13 dark 30.0 570.0 90 6 
14 dark 29.4 586.0 80 8 
15 dark 29.5 585.0 60 5 
16 dark 32.3 590.0 60 5 
17 dark 37.3 580.0 80 5 
18 fair 36.0 617.5 80 4 
19 dark 38.5 602.5 75 11 
20 fair 35.0 586.3 75 8 
21 dark 40.0 602.5 50 4 
22 dark 44.0 585.0 95 11 
23 dark ND 615.0 75 6 
24 dark 44.4 586.0 90 5 
25 dark 50.0 590.0 80 9 
26 dark 46.0 590.0 50 4 
27 dark 45.0 590.0 70 5 
28 dark 40.5 590.0 80 11 
29 dark 48.0 590.0 66 4 
30 dark 51 .0 590.0 85 9 
31 dark 43.5 590.0 90 9 
32 dark 37.4 590.0 60 5 
33 dark 49.0 590.0 50 4 
34 dark 43.7 590.0 90 12 
35 dark 47.3 590.0 66 6 
36 fair 41 .0 565.0 50 3 
37 dark 43.8 590.0 80 7 
38 dark 39.3 590.0 50 3 
39 dark 50.0 615.0 50 2 
ND : not done. 
Table II. Specification of number of treatments 
No.of treatments N Mean Std Dev Min Max 
reduction 
2 2 50.0 0.0 50 50 
3 2 50.0 0.0 50 50 
4 7 66.6 17.0 50 90 
5 7 73.6 14.9 60 95 
6 6 83.5 10.5 66 90 
7 5 89.0 5.5 80 95 
8 2 77.5 3.5 75 80 
9 3 85.0 5.0 80 90 
10 3 83.3 10.4 75 95 
11 90.0 90 90 
12 90.0 90 90 
p = 0.04 
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Table lila. Clinical data of the patients 
Variable N Mean St Dev p 
Needle epilation No 26 81 .3 13.1 
Yes 15 68.8 16.7 0.02 
Age group 1 8 68.3 17.0 
2 13 73.2 16.1 0.52 
1 8 68.3 17 
3 16 80.3 13.6 0.10 
2 13 73.2 16.1 
3 16 80.3 13.6 0.2 
Skin type 2 24 77.7 16.4 
3 13 78.2 13.7 0.93 
Family history No 32 78.5 14.4 
Yes 8 68.3 18.9 0.18 
Pi I No 26 77.1 15.4 
Yes 14 75.1 16.7 0.71 
Medication No 37 76.9 15.3 
Yes 3 70.3 22.8 0.66 
Hair colour Blond 6 80.0 16.4 
Brown 34 75.8 15.7 0.57 
No plucking 0 4 81.5 11.4 
Daily 5 min 23 74.6 16.9 0.34 
No plucking 0 4 81.5 11.4 
Daily 15 min II 13 78 14.9 0.64 
Daily5 min I 23 74.6 16.9 
Daily 15 min II 13 78 14.9 0.52 
Table lllb. Technical data 
Variable N Mean St Dev p 
Wave lengths 
550 7 83.6 16.3 
590 23 70.5 14.3 0.08 
570 8 90.6 1.7 
590 23 70.5 14.3 0.0001 
Energy groups 
1 < 30 J/cm2 5 84 14.7 
5 46-50 J/cm2 7 63.8 14.6 0.04 
2 31-35 J/cm2 9 85 10.6 
5 46-50 J/cm2 7 63.8 14.6 0.005 
effect on hair loss than higher energies, but the number of patients (three) was too 
small to formulate a conclusion. 
There was no statistically significant correlation found between the percentage of hair 
reduction and the different hair colours (black, brown, blond or mixed). Furthermore 
no correlation was seen between hair removal and the four age groups, nor among 
patients with a positive family history, contraception use or hormonal treatment ( Ta-
ble lilA). No relationship was found in hair removal between skintype 2 and 3, nor was 
there an association between hair removal and the different times of plucking (Table 
lilA) and technical data, such as pulse modes and pulse times (Table 1118). 
Discussion 
In our multicentre study, in which we investigated the use of the ILS flash lamp, for hair 
removal in hirsute women, we found a correlation between hair removal and number 
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of treatments and needle epilation prior to treatment. Moreover a relationship was 
observed between hair loss and wavelength, of 570 nm and 550 nm. Further associa-
tion was seen in hair removal and two different energy groups. There was no stati-
stically significant correlation found between the percentage of hair reduction, the 
number of treatments and the different hair colours (black, brown, blond or mixed). 
There was no relation between hair removal and the four age groups, nor among pa-
t ients with a positive family history, contraception use or hormonal treatment. No cor-
relation was found in hair removal between skintypes 2 and 3, neither was there any 
association between haie removal and the different times of plucking and technical 
data, such as pulse modes and pulse times. 
Previous methods such as epilation (using a needle inserted into the follicle to destroy 
the germinative bulb), can cause many side- effects, such as superficial crusting, ery-
thema and scar formation with pitholes in the skin resulting in an irregular surface, es-
pecially on the upper lip and chin. If left untreated, these side-effects persist 
throughout the years, but they can be avoided by reducing the current!• In patients 
who experienced prior needle epilation, scar tissue is regularly found around the folli-
cles. This would explain our finding that patients who did not have needle epilation be-
fore treatment with the flashlamp show much better results. Scar tissue limits the 
scattering of light, therefore less absorption of melanin in hair shafts and follicles is ob-
served. This effect explains our finding that patient who had undergone needle 
epilation previously need more treatment sessions. 
New methods which cause less side effects and which are at least as efficient need to 
be developed. The ILS removal of hair fulfills these requirements. As shown in the 
study, this device causes no scars or skin infections. 
Using the ILS, the pigment of the hair is absorbed from the light beam, transformed 
into energy, then into heat. As the hair shaft is 1-2 mm long coming out of the epider-
mis, it may enhance the absorption of melanine and scattering throughout the dermis 
up to the follicle. The heat coagulates the hair follicle in the deep dermal tissue. In the 
early post-treatment period partial or complete coagulation necrosis takes place. This 
necrosis does not extend into the surrounding dermal fibrous tissue. In our study the 
feeding vessels and the hair erector muscles remained intact. If the dermal papil cells 
are completely destroyed, this will result in a complete loss of hair. Hair can come out 
of the same follicle if the dermal papil cells are not completely destroyed. Hair can 
regrow from the bulging area which is not destroyed by light and which is localised in 
the opposite side of the sebaceous glands. 
Depending on the structure of the hair and the content of pigment, a choice of variable 
energy has to be made to destroy the follicle. The different pulse modes of ILS make it 
possible to apply higher energies, cooling the skin between each pulse, yet still 
generating enough heat to destroy the hair follicle. The setting has to be changed in 
relation to the thickness and the colour of the hair. 
One of the advantages of the treatment with ILS flashlamp is the extremely selective 
thermolysis leading to an intact epidermis, in contrast to the Blend method. Only in 
rare cases, about 15%, were lesions of the epidermis imprints observed at a treatment 
protocol of short-pulse times. Most of the times the epidermis remained intact. 
Folliculitis, which is sometimes seen with the Blend method or home epilating de-
vices, 26•28 can be avoided by using the flashlamp. No cases of folliculitis were observed 
in this study. One advantage of this treatment is reduced pain, as compared to needle 
epilation. Most patients experienced this treatment as a mild sunburn sensation last-
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ing for several hours. Having the choice of different fluences makes it possible to treat 
skin appendages without damaging the epidermis. Our group of patients, divided into 
different energy groups, was too small to allow for the formulation of any conclusions. 
Another advantage of the ILS flashlamp is its broad spectrum of wavelengths. De-
pending on the skin type and hair colour, a choice can be made between the range of 
515 nm and 590 nm. 
In our study, a correlation was found between hair reduction and the wavelengths of 
570 nm. With this device, there are many technical factors which have an effect on hair 
removal , such as pulse times and pulse modes. The number of patients was too small 
in our study to conclude that the wavelengths of 570 nm may be the best wavelength. 
All other technical data have to be taken into consideration as well. Depending on the 
colour and the thickness of the hair, different energy ranges can be used. Compared 
with the Blend method, the ILS flashlamp has a spot size of 1 mm and can treat skin-
surfaces of 2.8 cm2 per impulse. ILS is much more time- efficient and financially bene-
ficial than the former methods, because this device offers many varieties of possible 
settings. 
With a choice of using individual parameters for each type of hair and skin , hair can be 
removed in an easier manner in the near future. The ILS therapy will be more success-
ful than the classical methods described above. A larger area can be treated and due 
to a good application of energy to the hair, scar formation as a result of overheating 
can be avoided. To adjust the exact parameters for each type of hair and skin, more 
investigation, including pathological examination of the skin up to 5 years, has to be 
carried out. One such follow-up study is currently being carried out in our clinic. 
Our multicentre study was the first of its kind in Europe, carried out on a long-time ba-
sis. The number of forty patients is too small to confirm our clinical observations. To 
confirm long-term results, further studies should be performed, including patients of 
skin type 6. 
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Summary 
Transsexualism as a condition requires hair removal. Twenty-five male-to-female 
transsexual patients were included in this study on epilation using the Intense Pulsed 
Light Source (IPLS). Patients received a varying number of treatments, depending on 
their response. A mean hair clearance rate of 90% was achieved in the studied pa-
tients. The average number of treatments per patient was nine. A negative correlation 
was found between hair removal and the age of the patient. Hair removal was also 
found to be more effective when the patients had not used any needle epilation. No 
difference in hair removal was found between transsexual patients, who were hor-
monal, and these who were not. Follow-up lasted an average of 44 months. This study 
proved that the IPLS has the potential to be effective, permanent, and painless espe-
cially in younger patients who have not used any mechanical methods for epilation be-
fore photoepilation. 
Transsexualism can be defined as a syndrome characterized by an incongruency of 
gender identity and biological sex.' According to the American Psychiatrists Associa-
tion's Diagnostic and Statistical Manual of Mental Disorders, 4th edition, 
transsexual ism is classified as a gender identity disorder and can be diagnosed in the 
presence of the following criteria2 : a strong, persisting cross-gender identification; 
persisting discomfort with one's assigned natal sex and its associated gender role; 
and absence of any physical intersexual condition. 
Although it is not the aim of this article to refer to the essentials of diagnosis for 
transsexual ism, it is important to know that there are more than one set of criteria for 
the same in use. This depends on the geographical region.2·• In general transsexuals 
are put on hormonal therapy to accomplish some degree of feminization. 5 Feminizing 
hormones given together with antiandrogenic hormones inhibit the effects of endoge-
nous male hormones. This has a varying consequence on the distribution of body hair 
in these individuals. Some of the effects of feminizing hormones include reduction of 
the growth of body hair and lightening of the hair texture and the color. These effects 
are, however, slow in onset and have unpredictable results! Furthermore, a reduction 
in facial hair is seldom achieved. An effective, permanent method of hair removal is 
therefore ideal for transsexuals as part of the supportive management in gender reas-
signment. Several methods, including the different types of electrolysis and laser 
epilation, are used with varying effectiveness."·7 These are the more permanent meth-
ods of hair removal available in contrast to shaving, plucking, and waxing, which are 
temporary. s.,o During electrolysis, patients regularly require repeated treatments over 
several years. Many patients find this procedure very painful , and anesthesia as well 
as sedation is aften required preoperatively. 
It is believed that lasers and other light sources effect hair removal selectively by act-
ing on melanosomes. These tend to be concentrated around the hair bulb, precisely 
the area responsible for hair growth. Laser light and intense pulsed light, at a wave-
length that is absorbed preferentially by the melanin in the hair follicle, heat the hair 
and its root selectively, causing destruction of the hair follicle yet sparing the sur-
rounding tissue. This is the principle of selective photothermolysis first described by 
Anderson and Parrish. " 
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Photoepilation has the advantage that many hairs can be treated at the same time 
and , unlike electrolysis, there is no need to use a needie or anesthesia. Clinical experi-
ments will have to prove its permanency. 
When light energy interacts with tissue (in this case, skin) it is converted into other 
forms of energy, including heat energy. As a result there are three major methods" by 
which lasers in particular bring about the removal of hair: mechanical destruction, 
thermal destruction, and photochemical destruction of hair follicles. It is easier to treat 
light-skinned individuals with dark hair than dark-skinned individuals, because in 
dark-skinned individuals melanin-absorbing laser light causes dangerous heating of 
the skin itself. However, there are reports on the effectiveness and safety of the In-
tense Pulsed Light Source (IPLS} in removing hair in individuals with Fitzpatrick types 
V and VI skin. 13 This study, though, did not encounter skin types V and VI. 
In the past, studies were carried out on hair removal in hirsute women using the IPLS. 14 
To our knowledge this is the first study dealing with hair removal exclusively in 
male-to-female transsexual patients. This population, with unique characteristics, 
lends itself well to our study. To assess further the technique of selective photo-
thermolysis, this study was carried out in a group of individuals in whom an effective, 
permanent method of hair removal is of great importance. 
Patients and methods 
Twenty-five patients between the age of 22 and 67 years (average, 36.5 years) were 
selected in the Medical Center Maastricht, the Netherlands; the Lasercentre 
Karlsruhe, Germany; and the Lasercentre Zurich, Switzerland. 
These were patients diagnosed by a psychiatrist to be candidates of transsexual ism 
who were undergoing the Real Life Test to confirm the diagnosis before allowing gen-
der reassignment surgery. A careful history of hair growth was ascertained from each 
patient. If necessary the patients were sent for further investigations to an endocrinol-
ogist or gynecologist. 
Skin types II, Ill , and IV were encountered in the study. Seventeen patients (68%) had 
skin type II, 6 patients (24%) had skin type Ill, and the remaining 2 patients (8%) had 
skin type IV. The 244 majority of the patients (N = 22, 88%) had dark hair; the rest were 
blond. 
Patients were advised to shave 1 to 2 days before the treatment (instead of plucking 
and waxing) and to use a sunblock during the time of treatment. 
An IPLS (Photoderm"VL; ESC Medical Systems Ltd., Yokneam, Israel} was used. Gel 
was applied to the skin to act as a coupling agent between the treatment head and the 
skin. The settings on the machine were adjusted according to the patient characteris-
tics of skin type and hair color. Irradiation with intense light was first carried out on a 
test spot. This was viewed 10 minutes later to assess the surrounding skin for adverse 
side effects such as perifollicular ederna. If there were no side effects then the therapy 
with IPLS was continued over a larger surface area. Twenty of the 25 patients had hair 
removed from the face and the neck, and the remaining 5 patients had hair removed 
from the face only. The area of treatment was a spot 2.8 cm2 • Depending on whether 
the hair was removed from the face and neck (approximately 80 spots) or only from 
the face (approximately 60 spots) , time taken for the treatment sessions varied. It 
ranged from 30 to 90 minutes. 
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The condition of the hair under the test spot was also assessed. Two parameters in 
particular were examined: breakage of the hair and retraction of the hair into the 
sheath. 
The face and neck were cooled with an ice pack afterward, and Flammazine cream 
(silver sulfadiazine from Solvay Pharma, Netherlands) was applied. 
After the first treatment the patients were again examined at intervals of 4 to 6 weeks. 
Thereafter, patients were seen at varying intervals depending on their response to 
therapy with the IPLS. 
Treatment modalities 
The IPLS Photoderm~L uses incoherent light of a broadband spectrum in the range 
of 500 to 1 ,200 nm. The wavelength is filtered by cutoff filters (515, 550, 570, 590, 615, 
645, 695, and 755 nm). The longer the wavelength, the deeper the penetration of the 
light into the epidermal tissue. 
The pulse duration, varying between 2 to 25 msec, has to be lower than the thermal re-
laxation time of the target tissue, so that the tissue does not cool down during the ap-
plication of the light energy. By providing trains of two and three pulses, the 
Photoderm~L improves the selectivity of the light only to the target tissue and en-
ables the surrounding tissue to cool down by causing delay in between the pulses, us-
ing intervals of 1 0 to 500 msec. A cooling gel is applied during treatment to allow good 
optical coupling of the light to the patient's skin for better heat transfer from the epi-
dermis to the cold gel. 
Fluences applied by the IPLS range between 3 and 90 J per square centimeter. The 
size of the IPLS treatment head (8 X 35 mm) plays an important role in improving light 
penetration into the tissue because the large spot size diminishes the scattering. 
Statistical analysis 
A descriptive study was carried out to collect data on patient characteristics and tech-
nical data related to treatments. Hair removal results were then examined for possible 
correlations with various technical variables and the age of the patients using 
Pearson's correlation coefficient. Other patient characteristics were compared with 
the hair removal for possible association using Wilcoxan's two-sample test. These pa-
tient characteristics included skin type, mechanical pretreatments, and hormonal 
pretreatments. 
Results 
In this study, 25 male-to-female transsexual patients were treated for a mean duration 
of 691 days (range, 57-1,485 days). During this time an average of nine treatments per 
patient (range, 2-18 treatments) were performed. The mean success rate in hair clear-
ance was 90% (range, 70-1 00%). Patients were observed for an average of 44 
months. 
Table 1 shows that 16 of 25 patients (64%) had used mechanical methods of epilation 
before photoepilation. Of these patients, only one had used a combination of mechan-
ical methods to achieve hair removal (shaving and needle epilation). Twelve of the 25 
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Table 1: Mechanical pre-treatments 
Mode of Treatment Yes Percent No Percentage 
Needle epilation 12/25 48% 13/25 52% 
Shaving 5/25 20% 20/25 80% 
Plucking 0/25 0 25/25 100% 
Other methods 0/25 0 25/25 100% 
Table 2: Technical data 
Variable Mean Std. Deviation Minimum Maximum 
Duration of treatment (days) 691.8 426.7 57 1485 
Number of treatments 9.1 4.4 2 18 
Mean energy used (J/cm2) 37.2 4.1 28.1 46.5 
Mean pulse duration (msec) 4.1 1.1 2.5 7.3 
patients (48%) had used needle epilation, and 5 of the 25 patients (20%) had used 
shaving. None of the patients in the study had used plucking or waxing as a method of 
hair removal. Twenty of the 25 patients (80%) were on hormonal treatment before 
starting photoepilation treatments using the IPLS. Of the remaining patients, 4 (16%) 
were not treated hormonally and in 1 patient this status was unknown at the time of 
treatment. Of the patients who were on hormonal pretreatment, 6 patients were on 
combination therapy (24% of the total study population). 
During the treatment, the mean energy (fluence) to which each patient was exposed 
per treatment was 37.2 J per square centimeter, as shown in Table 2. The most com-
monly used filter was 590 nm, accounting for 35% of the treatments. 
A significantly better result was obtained in patients who did not use any mode of me-
chanical epilation before hair removal with the IPLS system (p = 0.047). Hormonal pre-
treatment did not make any significant difference in. terms of hair removal. A negative 
correlation was found between hair removal and the age of the patients, indicating a 
more favorable outcome in younger patients (p = 0.052). Finally, no correlations were 
found between hair removal and any of the technical variables such as fluence, pulse 
time, number of treatments, or total duration of treatment. 
Discussion 
Using the IPLS, it is possible to achieve long-term hair reduction. Long-term hair re-
duction is defined as a substantial decrease in the number of terminal hairs at any 
given body site that is stable for a period of time longer than the follicle's complete 
growth cycle. ' 5 Both lasers and the IPLS system use the principle of selective 
photothermolysis for epilation. The ideal method of epilation would be the one that 
achieves longterm/ permanent hair removal in a single treatment without having any 
adverse effects. This would be especially desirable for the current study group of 
male-to-female transsexual patients. 
In our study approximately 90% hair removal was attained in 25 patients over a mean 
total treatment duration of 691 days. These patients were observed for an average of 
44 months after the last treatment. At the end of this follow-up period, all patients were 
still satisfied by the results obtained, and the level of depilation was generally 
maintained. 
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Markedly better results of hair removal in the transsexual patients were found if they 
had not used any mechanical method to remove hair before the treatment with the 
IPLS (the mechanical methods used in this study were needle epilation/electrolysis 
and shaving). These findings are in agreement with former studies showing that elec-
trolysis before photoepilation worsened the results of hair removal. This is believed to 
be the result of scarring produced by electrolysis. The epidermal tissues are de-
stroyed by the nonselectivity of the electrolysis methods including needle epilation. 
A significant negative correlation was found in this study between hair removal and 
the age of the patients (p = 0.052), indicating that hair removal was more effective in 
younger transsexual patients. This is the first time that age has been found to influ-
ence depilation. It is not known whether this is the result of local factors, such as 
changing skin structure with age, or whether hair removal is influenced by the hor-
monal constitution of transsexual patients. Because previous studies on hair removal 
did not find age to be a factor affecting the effectiveness, it is reasonable to assume 
that this is a factor peculiar to hair removal in transsexual patients. Previous research 
already demonstrated that gender reassignment is more successful if the individual 
starts treatment at an earlier age. In studies carried out in male-to-female transsexual 
inmates, loss of androgenization was most dramatic in those who had started estro-
gen and progesterone therapy early in life, whereas feminization was a function of the 
duration of the treatment with the same hormones. 6 The age of the initial diagnosis of 
transsexual ism and the age at which hormonal therapy started was not taken info ac-
count in our patients. These could also be confounding factors influencing our results. 
It is an area to be investigated in future studies. 
Considering that hair is most susceptible to laser light during the late anagen phase 
and that the hair in different parts of the body is in various stages of the hair cycle (mo-
saic pattern of human hair growth), it is necessary to give several treatments before 
achieving satisfactory epilation . This explains the need for multiple treatments used in 
this study (also dependent on the individual response to photoepilation). Several stud-
ies have been undertaken, recounting hair removal using the IPLS system. Some of 
them described the effectiveness of hair removal after a fixed number of treat-
ments. '6.17 This study bas been carried out in the setting of daily practice and the 
course of treatment was tailored to individual needs, which accounts for the rather 
high number of treatments. Clinically, the photothermolytic effect occurs in stages of 
immediate and delayed effects. After a treatment session, depilation (seen as break-
age of hair) takes place but this is usually not complete. The heat coagulates the hair 
follicle in the deep dermal tissue. During the early posttreatment period, partial or 
complete coagulation necrosis takes place. This necrosis does not extend into the 
surrounding dermal fibrous tissue. Macrophages phagocytose the necrotic hair cells, 
which are limited to the hair follicle. These are replaced gradually by fibrous tissue, 
leaving behind only some scattered groups of pigment containing macrophages. 
These disappear after several weeks. '8 The epilatory effect therefore continues over a 
period of a few weeks as the local physiological processes adapt to the selective 
damage. If the dermal papillary cells are destroyed completely, complete hair loss re-
sults. Hair can regrow from the bulging area that is not destroyed by light and that is 
localized on the opposite side of the hair follicle from the sebaceous glands. This is an 
area actively under research by molecular geneticists, particularly to elucidate the na-
ture of molecules responsible for the coding of messages between epidermal and der-
mal (mesenchymal) cells. Studies performed in mice show that these messages occur 
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at particular points in the hair cycle and that they could be responsible for the activa-
tion of hair "germ" cells in the bulge area. '" This variation in the hair growth cycle and 
the bulge area as a source of hair growth could account for the failure of lasers to pro-
duce "permanent" hair removal after only one treatment. 20"21 Furthermore, some lasers 
failed to remove hair even for the length of one complete hair growth cycle. 21 There are 
many technical factors that affect hair removal , such as wavelength, pulse duration, 
and pulse mode. All these technical factors have to be considered while managing pa-
tients. Depending on the color of the hair, the thickness, and the skin type (Fitzpatrick), 
different settings can be used. In this study, no correlations were found between hair 
removal and any of the technical data. Different cutoff filters, pulse durations, and 
fluences were used for patients with different characteristics to achieve optimal 
epilation while minimizing side effects. Prospective studies with a large number of 
standardized patients (e.g. only patients with skin type II) are lacking. The IPLS has al-
ready been shown to be an effective method in the removal of hair in various groups of 
patients including hirsute women. 22 Within the scope of management for transsexual 
patients, the IPLS will certainly create its own niche. For these patients (male-to-fe-
male transsexuals) , IPLS is added to the list of options for epilation. This technique 
has demonstrated clear advantages in comparison with other methods designed spe-
cifically to remove hair. Most of the patients had been exposed to needle epilation 
(electrolysis) , a method that has disadvantages over IPLS in that it frequently causes 
scarring and pain. 22 In the case of male-to-female transsexual patients, not only male 
facial hair has to be removed but frequently hair from the much more sensitive genital 
area must be removed as well. This hair removal is necessary because of the nature of 
gender reassignment surgery, which often entails hair-bearing genital skin in inacces-
sible and inconvenient areas (e.g. inside the vagina) . The use of the IPLS device (used 
in this study) saves time because it can treat surfaces of 2.8 to 5.6 cm2 per pulse. This 
cuts costs and saves time. With a choice of using individual parameters for each type 
of hair and skin, hair can be removed in an easier manner in the near future. We 
conclude that the IPLS system is effective in hair removal in transsexual patients 
because it saves time, cast, and inflicts less pain. 
The authors thank Dr Raulin and Dr Greve, (Karlsruhe, Germany) and Dr ThOrlimann 
(ZOrich, Switzerland), who assisted in collecting data, and Marieke Duis (Maastricht 
University, the Netherlands), who performed the data entry. 
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Abstract 
Background. Long-term hair removal in hirsute women remains a challenging issue. 
Various laser and laser-like devices are currently in use for hair removal , but little is 
known about the permanence of their results. This study deals with the permanence of 
hair removal using the Intense Pulsed Light Source (IPLS). 
Objectives. To test the effectiveness in long- term hair reduction. 
Methods. Seventy female hirsute patients were selected in the department of Laser 
Therapy at the Medical Centre, Maastricht, the Netherlands. The average age of the 
mostly dark haired patients of various skin types (Fitzpatrick I to V) was 41 years. They 
were subjected to a mean of 8.0 treatments (range of 2 to 23) followed for a mean pe-
riod of 27.3 months. 
Results. Using the IPLS, 87% hair removal was achieved, whereby the number of 
treatments correlated with the amount of hair lost. No correlation was found between 
hair removal and patient- related or technical data. Minimal side effects occurred in 
1 0% of the patients. 
Conclusion. The IPLS system with its broad range of technical variables is effective in 
achieving long-term hair removal. 
The management of hirsutism remains a challenge to dermatologists and cosmetic 
surgeons. Women with unwanted hair in the face, neck, or any part of the body have 
physical and social problems. There are four distinct groups with this problem: a 
group of hirsute patients that show a male pattern of hair growth caused by increased 
influence of androgens on hair follicles, patients with hypertrichosis with a general in-
crease in density of hair growth, male-to-female transsexual patients, and patients 
presenting for cosmetic reasons. Previous studies raised the question as to which 
method of hair removal was preferable for hirsute patients. ' A distinction was made 
between temporary and permanent/long-term methods of hair removal. Temporary 
methods include shaving! plucking , mechanical and chemical dermabrasion.J.S 
Long-term methods include needle, surgical, and laser epilation as well as more re-
cently epilation using an incoherent, intense-pulsed light source (IPLS). Each method 
has a distinct set of advantages and disadvantages. The question raised is about the 
method that will give enduring satisfactory results with a minimum of side effects. 
Electrolysis consists of a direct current being passed between two electrodes to form 
hydrogen gas and hydroxide ions that chemically destroy the hair bulb and the pa-
pilla." Thermolysis was first used by Bordier, a French physician in 1924.7 This tech-
nique uses high frequency electro-coagulation and destroys the hair bulb by the heat 
generated. It is much faster than electrolysis (galvanic) but is more likely to produce 
pain and scarring ." Surgical epilation was introduced by Bouwman in 1978. He per-
formed a submental incision; the subcutaneous fat was trimmed until the follicles were 
visible, and the hair roots were then cut with serrated scissors. 9 
Laser assisted epilation uses the principle of selective photothermolysis. 10 The laser 
energy is selectively absorbed by a target chromophore. In the case of hair removal, 
this chromophore is melanin, which is concentrated around the hair bulb. Performed 
by experienced hands, the use of laser leaves no damage to the surrounding tissues. 
Different lasers are used for removing hair. The concept of using laser light for hair re-
moval was first described by Kuriloff et al., in 1988 for pharyngo-oesophageal hair 
growth. The Argon laser was used for photo-epilation in the treatment of tracho-
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matous trichiasis'2'13 and the Neodynium:YAG laser for epilation of hair- bearing ure-
thral grafts." Dover et al. 15 was one of the first groups who succeeded in showing that 
the Ruby laser caused selective injury to pigmented hair follicles. Grossman et al. '6 
performed another study in which she showed that the normal -mode Ruby laser 
pulses damage the hair follicles. Zaias17 proposed the concept of a pulsed laser for 
hair removal in 1991. 
It is necessary that the laser beam penetrates deep into the dermis in order to reach 
the hair follicles and be selectively absorbed by melanin . This is important if there is to 
be selective destruction of the hair follicle. 
Our study is concerned with the permanence of the results obtained after application 
of an incoherent IPLS for epilation in hirsute patients. This device has also been called 
Flashlamp,S Epilight, 18 and PhotoDermavL. '9 Just like lasers, it uses the principle of se-
lective photothermolysis. The IPLS was mainly developed as a means to treat vascu-
lar lesions located deeper in the skin and it has been used for the treatment of port-
wine stains! 0'21 leg telangectasias,22•24 essential telangiectasias! 5'26 venous malforma-
tions!7 and pigmented lesions! 8'29 Various studies have reported on the efficacy of the 
IPLS system in removing hair.1'18'19'30 The IPLS is also known to be effective in long-term 
hair removal. 
Recently, second-generation IPLS devices have been marketed."0 These are also ef-
fective in hair removal, and the side- effect profiles are documented in one study relat-
ing particularly to pain development after treatment."0 
The IPLS has several distinct advantages over lasers, mainly arising from its flexibility 
in allowing a wide range of settings relating to individual patient characteristics. For 
the same reasons, it is an effective tool in the hands of an experienced specialist. This 
research aims to study the permanence of hair removal using IPLS system. 
Method 
Patients 
Seventy female patients, aged 18-67 years (mean of 41.7 years), were chosen at ran-
dom in the Medical Centre Maastricht, Maastricht, the Netherlands. 
A detailed history of abnormal hair growth was taken from each patient, and when 
necessary, the patients were sent to see an endocrinologist or gynaecologist for fur-
ther investigation. 
Patients were scored according to their skin types (Fitzpatrick). Three patients (4.3%) 
had skin type I. Thirty-nine patients (55.7%) had skin type II. Twenty-one patients 
(30%) had skin type Ill. Four patients (5.7%) had skin type IV, and three patients 
(4.3%) had skin type V. Patients were asked to shave 1-2 days before the treatment 
(advised to shave instead of plucking and waxing) and to use a sun blocker during the 
time of treatment. 
Treatment protocol 
Test spots were first performed on each patient and reviewed 10 minutes later to ob-
serve hair breakage and perifollicular oedema. After this evaluation and after ensuring 
that there were no adverse reactions, the treatment was continued. Settings were 
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made taking patient characteristics into account (discussed later here). The treated 
area was cooled with an ice pack afterwards, and when necessary, flammazine (silver 
sulphadiazine from Solvay Pharma) cream was applied. 
Follow-up 
Follow-up was performed 4-6 weeks after the first treatment. Thereafter, it was per-
formed regularly at intervals based on the individual hair-growth characteristics of 
each patient. 
IPLS 
The IPLS uses incoherent light of a broadband spectrum in the range of 500-1200nm. 
By applying different cut-off filters (515, 550, 570, 590, 615, 695, and 755 nm}, a spe-
cific part of the shorter wavelengths (below the indicated filter) can be filtered. The tis-
sue penetration depths of visible light depends on its wavelength; longer wavelengths 
penetrate deeper into the skin. Alteration of the spectral range used during IPLS treat-
ment (which is done by selecting different cut-off filters) allows modifying the penetra-
tion depth of the light to match the specific target structure, i.e. , vessels of different 
sizes and depths and hair follicles. The use of different cut-off filters also allows ad-
justing the treatment parameters to the patient's skin type; using longer filters to con-
trol the spectrum of higher wavelengths results in reduced overlap with a higher 
absorption coefficient of melanin, the concentration of which depends on the skin 
type. 
The pulse duration can be varied, ranging between 2 and 25 ms, and should be lower 
than the thermal relaxation time of the target tissue in order to avoid cooling of the le-
sion during the application of light energy. To improve the selectivity of the light to the 
target tissue only, the IPLS system provides, besides a single pulse, trains of two and 
three pulses with controlled intervals between the pulses in the range of 1 0-500 ms. 
This delay allows the cooling of the epidermis. Furthermore, a cooling gel is used on 
the skin during the IPLS treatment, which permits good optical coupling of the light to 
the patient's skin and also results in better heat transfer from the epidermis to the cold 
gel. 
Fluence applied by the IPLS system ranges between 3 and 90 J/cm2• The size of the 
IPLS treatment head (8x35 mm) plays an important role in improving light penetration 
into the tissue because the large spot size diminishes the scattering. 
Statistical analysis 
The statistical analysis of the data consists of frequency tables for all categorical vari-
ables and a standard description (by mean, SO, and range) for all quantitative parame-
ters. Results are presented for all treatment-related variables as well as for all 
patient-specific data. Treatment parameters were averaged for each patient in order 
to analyse the effect of treatment- specific variables on the outcome for the patient. 
The association between the outcome (reduction) and quantitative variables was ana-
lysed using correlation and linear regression analysis. The possible effect of categori-
cal variables on the outcome was tested with a Kruskai-Wallis test or a Wilcoxon 
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rank-sum test (for binary variables), respectively. Because of the observational nature 
of the study, all p values are to be interpreted in an exploratory sense. 
Resu lts 
In this study, a mean of 87% (range of 50% to 1 00%), hair reduction was achieved af-
ter a mean of 8.0 (range of 2 to 23) treatments. This was maintained after a mean of 
27.4 months (range of 9 to 74 months) of follow-up. Hirsutism in these patients had 
been present for an average of 18 years (range of 2 to 60 years) before treatment with 
the IPLS. 
Of the 70 patients enrolled in the study only 3 had not used other methods for hair re-
moval before presenting to our department. Of the remaining 67 patients, 19 (27%) 
had shaved, 53 (76%) had plucked and 26 (36%) had used needle epilation to remove 
hair. Furthermore 19 (27%) patients were on hormonal medication (including the use 
of the oral contraceptive pill). All patients expressed dissatisfaction with the previ-
ously used methods. 
The most common skin types encountered were type II (39 patients- 56%) and type Ill 
(21 patients- 30%). The majority of patients had black or dark hair (55-78%). In 34 pa-
tients (49%) there was a positive family history of hirsutism (Table 1). Fifty-one pa-
tients (73%) had normal menstrual cycles. Six patients (9%) reported irregular cycles. 
In 4 patients polycystic ovaries (Stein-Leventhal syndrome) had been diagnosed by 
the gynaecologist (Table 2). 
The most common body sites treated were the chin (50 patients) and the upper lip (32 
patients) (Table 3). 
A correlation was found between hair removal and the number of treatments received 
(p = 0.0042). No correlations were found between hair removal and any of the clinical 
(patient-related) variables including age (p = 0.8864), skin type (p = 0.8583), hair col-
our (p = 0.1613), family history of hirsutism (p = 0.3580) and previous treatments used 
(Table 1). Furthermore hair removal did not correlate with any of the technical vari-
Table 1: Clinical data of the patients 
Variable N Mean St Dev p 
Skin type 3 93.3 5.7 0.8583 
II 39 86.4 11 .6 
Ill 21 84.5 13.3 
IV 4 91.7 2.9 
v 3 91.7 2.9 
Hair colour black or dark 55 87.5 11.3 0.1613 
blond/fair/mixed 15 83.7 12.5 
Family history positive 34 88.0 10.7 0.3580 
negative 36 85.4 12.3 
Pill (OC) yes 20 86.1 13.0 0.9829 
no 50 86.8 11 .1 
Needle epilation yes 26 86.2 10.2 0.4636 
no 44 87.0 12.4 
Shaving yes 19 86.6 13.6 0.5770 
no 51 86.6 10.8 
Plucking yes 53 88.0 9.9 0.1806 
yo 17 82.2 15.3 
Yes- used treatment; No- did not use treatment; Missing frequency= 0 
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Table 2: Gynaecological status 
Number of patients Percentage 
Increased androgens 4 5.7% 
Polycystic ovaries 4 5.7% 
Menopause 8 7.7% 
Hysterectomy 4 5.7% 
Surgical Sterilization 4 5.7% 
In-vitro Fertilization 3 4.3% 
Other* 7 10% 
No significant gynaecological history 36 51.4% 
TOTAL 70 100% 
Frequency missing = 0; • includes menstrual abnormalities, diabetes gravidarum, endometriosis and history 
of operative delivery 







Frequency missing = 0 






Table 4: Hair removal in relation to clinical and technical data 
Variable 

















abies including the wavelength (p = 0.6370), the pulse time (p = 0.6688) and the energy 
(p= 0.7162) (Table 4). 
Discussion 
The IPLS is being studied as a method of long-term hair removal. In our study, after a 
mean of 8 (range of 2 to 23) treatments, an average of 87% hair reduction was 
achieved . To our knowledge, no study with IPLS with such a high percentage of hair 
reduction has been published so far. 16"30"31 
It was observed that hair reduction depended on the hair color, skin type, and the 
number of treatment sessions given (i.e., the more treatment sessions, the greater the 
hair reduction). It was also found that blond- and grey- haired patients required a 
larger number of treatments then dark- haired patients. Blond hair contains less mela-
nin compared with darker hair. Consequently, the light source can target less 
chromophore, and hence, the response is less reliable. It was easier to treat fine hair 
compared with coarse hair because coarse hair often has a thick layer of keratin and 
requires a higher energy level for removal. We did not use higher energy levels, as they 
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would have resulted in more side-effects, such as scar formation, hyoppigmentation, 
etc. In some patients, we observed paradoxical growth of hair. This was particularly 
seen in patients whose treatment intervals were more than 8 weeks apart. Our hypoth-
esis is that light helps to stimulate the hair follicles to enter the anagen growth phase 
more readily (has yet to be scientifically proved). Therefore, we suggest that the inter-
val between two treatments should be between 4 and 6 weeks in order to avoid any 
paradoxical growth of hair. 
At first we used short pulse times, such as a pulse of 5 ms; the optimal parameters of 
the new light source were not confirmed. Time taken for the hair follicles to be de-
stroyed was longer, and subsequently, hair reduction was less. Thus, more sessions 
were necessary to satisfy the patients. The conclusion based on our histological study 
later was that pulse times longer than 12 ms were more effective (data not published 
yet). Consequently, longer pulse times were used in this study, which gave better re-
sults, ensuring hair reduction with fewer treatment sessions to satisfy the patients. 
Previously, quite a few studies have been done using first- generation flashlamps for 
hair removal. In one such study, 37 subjects received a single treatment using one of 
four cut-off filters consisting of two to five pulses with energies of 34 to 55 J/cm2 • ' 8 Ap-
proximately 60% hair removal was noted at 12 weeks. Long-term epilation of 75% 
hair removal was found in this group of patients after one year with a single trea!'-
ment." Weiss et al.32 enrolled 23 patients with Fitzpatrick types I-III for a single- treat-
ment IPLS and 48 patients with Fitzpatrick skin types 1-V randomly for two treatments. 
Their results showed that for the double- treatment protocol, hair clearance of 64% 
was achieved immediately after the second treatment. By week 8, reduction of hair 
counts was 42%, whereas at 6 months, hair counts were reduced by 33%. 
Intense pulsed light has been shown to be more effective when multiple treatments 
are given. 30 '33 Some studies showed that 3 treatments were optimal , beyond which no 
significantly better result could be obtained. 30'34 Sadick et al. 34 demonstrated 
long-term results of photo epilation with Epilight (IPLS} in 34 hirsute patients. The 
mean hair removal efficiency achieved was 76% after a mean of 3.7 treatments in pa-
tients followed up for a mean of 21.1 months. The parameters used in this study were 
wavelength spectrum of 615 to 695 nm, pulse duration of 2.6 to 3.3 ms, fluence of 34 
to 42 J/cm2 , and a 1 Ox45-mm exposure field. In our study, we treated each of the 70 
patients with individual parameters and with lower mean energy. Moreover our mean 
follow-up period was longer, i.e., 27.3 months. These could be some of the reasons 
why more treatment sessions were required for hair removal in our study. 
Bjerring et al.29 compared the effectiveness of a second generation IPL (Ellipse) with a 
normal mode Ruby laser for hair removal in 31 patients. Another study with a second-
generation IPLS was conducted by Troilius and Troilius.33 They observed a hair reduc-
tion of 7 4.7% ± 18.3% (mean± SO) 4 months after the treatments and 80.2% ± 20.3% 
8 months after the last treatment. 
Because our study was conducted using the first- generation flashlamps and the 
mean follow-up period was more than 2 years (i.e., longer than the follicles' complete 
growth cycle), we had to carry out an average of 8 sessions to be able to demonstrate 
permanence rather than long-term reduction in hair. Future studies using the new 
generation of flash lamps will reveal whether a lesser number of treatments will be suf-
ficient for a substantial number of hair reduction. 
It was emphasised that both the hair follicle and the bulge area were important in hair 
regrowth. 35 ' 36 At first it was assumed that only the hair follicle was involved in this func-
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tion. This is now known to be inaccurate. Animal experiments showed that hair could 
be regenerated from totally follicle- free skin.37 The bulge area of the pilosebaceous 
unit in the mouse skin model is capable of such a function .36 Liew et al. 35 demonstrated 
that the mere destruction of the bulge area, however, resulted in only temporary hair 
reduction. In conclusion, from these studies, it can be said that both the hair bulb and 
the bulge area have to be destroyed before long-term hair removal is achieved. This 
could be an explanation for the need for multiple treatments in order to destroy both 
structures in the hair follicles. Theoretically, this should be possible in one treatment. 
However, complete selective destruction depends on how much energy can be deliv-
ered to the hair follicle without causing side effects. Furthermore, it is known that hair 
follicles are most sensitive to laser light in the mid- to late anagen phase.38 This plus 
the fact that human hair follows a mosaic pattern of growth means that only a certain 
proportion of important structures in hair follicles can be destroyed in one treatment. 
As pointed out by some authors, the term "permanent hair removal" means different 
things to different people. Dierickx et al. 39 defined permanent hair loss as a significant 
reduction in the number of terminal hairs after a given treatment stable enough for a 
period longer than the complete growth cycle of the hair follicle at the given body site. 
Patients, on the other hand, understand "permanent" to mean lifelong. The clinician is 
then responsible for explaining to the patient the capabilities of the method, as already 
elucidated by scientific methods. 
No correlations were found between hair removal and any of the technical variables. 
These variables include pulse time, interval, wavelengths used, and pulse mode used. 
For each patient, a different combination of technical settings is required . The aim is to 
apply selectively as high an amount of energy to the hair follicles while avoiding any 
side effects. Given the many different combinations of possible settings, a very large 
number of patients would be required to find any correlations with technical variables. 
As seen , the amount of energy is important in having an impact on hair removal. It was 
found in a study carried out by Sadick et al. 40 that hair removal by the IPLS is a direct 
result of the amount of energy delivered to the follicle. The possibility that the treat-
ment with the IPLS interfered with the hair growth cycle in any way was excluded. Side 
effects were encountered in the study. These were mostly limited to a burning sensa-
tion experienced by many patients after the treatment. In our study, only 4 out of the 
70 patients experienced pain and erythema after the treatment. This was followed 
days later by postinflammatory pigmental changes such as hyperpigmentation ap-
pearing in the form of a "footprint" . The small amount of side effects could be ex-
plained by the tailoring of various technical settings to the requirements of each 
patient. 
We conclude that the IPLS offers an effective method of long-term hair reduction free 
of side effects when applied by an experienced and trained clinician. Multiple treat-
ments are necessary for long-term hair removal. Because of the many different tech-
nical settings, studies with larger numbers of patients are required to understand 
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Abstract 
Background. Up to now, vascular diseases were treated with various lasers, such as 
Argon, Pulsed Dye, and Copper Vapour lasers, which can lead to side-effects like 
hypopigmentations, hyperpigmentations, and scarring. We treated patients with vas-
cular lesions with an incoherent intense light source the PhotoDerm~L- flashlamp. 
Objective. The aim of the study was to test the effectiveness and safety of the 
PhotoDerm~L for vascular skin lesions. 
Methods. One hundred and twenty patients with facial or leg telangiectasias, spider 
nevi, erythrosis interfollicularis and senile angiomas were treated with the 
PhotoDerm~L. 
Results. In 73.6% of patients there was an immediate clearing, and in 84.3% of the 
patients a clearing after 1 month was found of leg telangiectasias up to 1 mm in 
diameter. Facial telangiectasias and erythrosis interfollicularis calli showed clearance 
up to 90% . Spider nevi and senile angiomas often only needed to be treated once. 
Conclusion. From our experience we conclude that the PhotoDerm~L is an excellent 
device to treat vascular lesions as there were hardly any side-effects seen, however, 
the user needs a sufficient experience to get good results. 
Keywords: Erythrosis interfollicularis, facial- and leg-telangiectasias, PhotoDerm~L. 
spider nevi, senile angiomas 
Vascular skin lesions such as facial- and leg telangiectasias, spider nevi, erythrosis 
interfollicularis, and senile angiomas are very common. Most patients with those kinds 
of skin lesions will visit their dermatologist for cosmetic reasons. For most of the con-
cerned patients telangiectasias in the face are a big cosmetic problem, which they try 
to hide with a thick layer of make-up. Telangiectasias are superficial vessels, which 
may represent expanded venules, capillaries and arterioles and may have a diameter 
of 0.1-3.0 mm. They are classified as: linear, aborizing, spiders, and punctiform. Spi-
ders have a central vessel of arteriolar origin, compared to linear and aborizing 
telangiectasias which are of venular origin. Up to now, a good, safe, and easy treat-
ment did not always provide an effective solution for their problem. Reasons for devel-
oping facial telangiectasias are excessive sun radiation, topical steroids, and 
hormonal replacement therapy. Fine wire diathermy was used for a long time. This a 
non-selective process that is painful and destroys excessive normal tissue surround-
ing the vessels. Electric stinging bears the risk of hypopigmented, depressed scar for-
mation, and mostly turns out to be inefficient. ' The Argon laser was one of the first 
lasers being used for port-wine stains and telangiectasias of the face. The green light 
of the Argon 514 nm was used for treatment but the penetration was not deep 
enough ! '3 The light of Argon lasers absorb melanin and oxyhemaglobin because of 
their wavelength, and due to this they destroy epidermis and vessels .<·s Pulse lasers 
for yellow light followed the Argon. Lasers such as Pulsed Dye (POL) and Copper 
Vapour (CVL) lasers absorb oxyhemoglobin around 577-585 nm. Glasberg et al dem-
onstrated a direct destructive effect upon endothelial cell structures with the 577nm 
pulsed dye laser.7 The penetration is only up to 0.5 mm in depth from the epider-
mal-dermal junction.8 Tan showed that by increasing the wavelength from 577 to 585 
nm the depths of penetration for destroying microvessels (50-1 00 J.lm in diameter) 
could be increased from 0.5 to 1.2 mm. 9 Unfortunately, this cannot be achieved with 
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larger vessels. To damage specific vessels, laser energy delivery time has to be 
shorter than the delivery time required for the cooling of the veins. In superficial , very 
small (less than 1 00 1-1m) cutaneous blood vessels, the thermal relaxation time ranges 
from 2 to 10 msec. Several studies were performed with different pulse-widths start-
ing from 1 to 450 nsec with intravascular damage and destruction of endothelial 
cells. 10'11 The POL is used for treating port-wine stains with good results. One of its 
side-effects is an intra-cutaneous hemorrhagia.5·' 2-14 
The CVL is supposed to produce less edema and pain. With the emission peek of 578 
nm the CVL corresponds well to the absorption peek of oxyhemoglobin. The absorp-
tion of melanin is less, at 488-515 nm. Histological studies have shown that the ther-
mal damage of the CVL is more selective than that of the Argon. 15-18 
A combined therapy of pulsed dye and sclerotherapy was proposed, e.g. for 
telangiectasias on the nasolabial folds, where telangiectasias were difficult to remove. 
As for these facial vessels higher energy is necessary, which again can lead to scar-
ring. Generally sclerotherapy of vessels in the face is not performed because of deep 
anastamoses with cerebral vessels. 5 
In the last decade laser therapy has also been used for treating leg telangiectasias. At 
first this treatment unfortunately turned out to be less promising. The carbon dioxide 
(C02) laser obliterates telangiectasias, but the overlying skin is destroyed with 
hypopigmented scars. 19-21 Due to its non-selective action this type of laser cannot be 
used as a treatment for telangiectasias. With Neodymium (Nd): YAG laser (1 060 nm) 
telangiectasias can be coagulated, but like the C02 laser the treatment is non-specific, 
resulting in scar formation. Apfel berg et al. reported linear depressed hypopigmented 
scars after Nd:YAG treatment!0 The Argon laser is commonly used for vascular skin 
lesions, but only in 16% of skin lesions were excellent or good results obtained! 2 
Recently, the PhotoDerm~L was introduced as an intense light source, which is, in 
use, comparable with lasers, for the treatment of telangiectasias! 3'24 In this article we 
will describe the possibilities and limitations of the PhotoDerm 110VL flashlamp for the 
treatment of vascular skin lesions. 
Patients and methods 
Patients 
In total, 120 patients with vascular skin diseases were randomly chosen from the de-
partment of dermatology: 30 patients (5 male and 25 female) with facial 
telangiectasias; 40 patients (40 female) with leg telangiectasias; 15 patients (15 fe-
male) with spider nevi with a diameter of 0.5-2 .0 mm; 15 patients (15 female) with 
erythrosis interfollicularis; and 20 patients (12 male and 8 female) with senile 
angiomas. There was no history of coagulopathy or use of anti-coagulants. 
In all 40 female patients with leg telangiectasias, venous hypertension was ruled out 
using photoplethysmography and Doppler Ultrasound as described before! 5 Varicose 
veins were first treated with selective surgery if necessary and/or sclerotherapy. Pa-
tients were evaluated for immediate response and followed-up after 1 week, 2 weeks, 
4 weeks, and 3 months. Patients were divided into three groups, according to the di-
ameter of the vessel treated: group 1, < 0.2 mm, group 2, 0.2-0.5 mm; and group 3, 
0.5 -1.0 mm. 
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PhotoDerm'VL 
The principle of operation of the PhotoDerm®VL (ESC Medical Systems Ltd. Yokneam, 
Israel) is based on the principle of selective photothermolysis, where the light, ab-
sorbed by the specific lesion, leads to its heating to a temperature high enough to 
cause thermal damage (T>80°C), sparing the epidermis and the surrounding healthy 
dermis. In contrast to laser systems, the PhotoDerm®VL uses non-coherent light of a 
broad band spectrum in the range of 500-1200 nm. By applying different cut-off filters 
(515, 550, 570, 590 nm), a specific part of the shorter wavelengths (below the indi-
cated filter) can be filtered off. 
The tissue penetration depths of visible light depends on the wavelength, with longer 
wavelengths being less absorbed by the skin. Alteration of the spectral range used 
during PhotoDerm~L treatment (which is done by selecting different cut-off filters) al-
lows modification of the penetration depth of the light to match the specific target 
structure, i.e., vessels of different sizes and depths, hair follicles, etc. The use of differ-
ent cut-off filters also allows adjustment of the treatment parameters to the patient's 
skin type; using longer filters, which control the spectrum to higher wavelengths, re-
sults in less overlap with the higher absorption coefficient of melanin, the concentra-
tion of which depends on the skin type. 
The pulse duration can be varied ranging between 2 and 25 msec, and should be 
lower than the thermal relaxation time of the target tissue, in order to avoid cooling of 
the lesion during application of light energy. In order to improve the selectivity of the 
light to target tissue only, the PhotoDerm®VL provides, besides a single pulse, also 
trains of two and three pulses, with controlled intervals between the pulses in the 
range of 1 0-500 msec. This delay allows the epidermis and the microvessels to cool 
(typical thermal relaxation time 1 0 msec) between consecutive pulses without signifi-
cant cooling of the bigger, deeper localised vessels. This is in accordance with the 
thermal relaxation time of different objects, which is proportional to their size (T oc r''), 
where r is the radius of a cylindrical object such as a blood vessel. Fluences applied by 
the PhotoDerm®VL range between 3 and 90 J/cm2 • The size of the PhotoDerm~L 
treatment head (8 x 35 mm) plays an important role in improving light penetration into 
the tissue since the large spot size diminishes the scattering. The large spot size is ad-
vantageous also in terms of the ability to treat a relatively large area with a single 
pulse, which speeds up the treatment time and causes less pain to the patients. 
A cooling gel is used over the skin during PhotoDerm®VL treatment, which allows 
good optical coupling of the light to the patient's skin and also allows better heat 
transfer from the epidermis to the cold gel. 
By changing the different parameters of the PhotoDerm®VL, namely wavelength, num-
ber of pulses, pulse duration, and delay between pulses, one can achieve efficient 
treatment for a variety of lesions with a high degree of selectivity and safety. 
Results 
The settings of the different parameters of the PhotoDerm®VL and the percentage of 
clearance of the different types of leg telangiectasias are given in table I. Clearance is 
based on the estimations of two physicians. 
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Blue facial telangiectasias on the nose were treated most of the time with a cut-off fil-
ter of 590 nm and triple pulses, with pulse times of 3.8, 3.1, and 2.6 msec, using en-
ergy rates of 38 and 50 J/cm2 • Seven nasal blue vessels, which hardly reacted to laser 
therapy, showed good response to the PhotoDerm®VL. Clearing was seen in up to 
90%. Red telangiectasias were treated with 550 nm, 30-34 J/cm2 , 4-5 msec, and sin-
gle pulse. Clearing was found in up to 95% (Figure 1). 
Spider nevi, if they had not been treated before with electro- coagulation, showed a 
good result, with parameters of 550 and 570 nm, with pulse times of 4-5 msec and en-
ergy rates of 32-36 J/cm2 using a single pulse, and triple pulses with 550 and 570 nm 
with pulse times of 3.8, 3.1, and 2.6 msec, with a pulse delay of 1 0 msec for skin type 1 
and 2, and a pulse delay of 20 msec for sun- tanned skin, using 38 and 50 J/cm2 • For 
senile angiomas the same parameters were used as for spider nevi. Almost all spider 
nevi and senile hemangiomas cleared (95%). 
Erythrosis interfollicularis calli, which has 2 components, a vascular and a pigmental 
one, was treated with cut-off filters of 515 and 550 nm, depending on the color of the 
skin and of the skin lesions and pulse times of 2.5 and 3 msec, and energy rates of 
22-26 J/cm2 • This skin lesion showed 90% clearance in the vascular part. 
Patients with leg telangiectasias were divided into 3 groups, according to the diame-
ter of vessel treated: group 1, < 0.2 mm; group 2, 0.2-0.5 mm; and group 3, 0.5-1 mm. 
Only leg telangiectasias above the knee were treated. In the group of up to 0.2 mm 
vessel diameter, we observed an immediate clearing in 82.0% of this patient group, 
with a clearing of 92.1% after 4 weeks. In the second group of patients, with a vessel 
diameter of 0.2-0.5 mm, 78.9% of those treated had an immediate clearing , and 
80.0% of patients after 1 month. In the group of patients with a vessel diameter from 
0.5-1 mm, 42.3% showed an immediate clearing and 81.0% after 1 month. 
In general we saw hardly any side- effects in our expanded study. In 2 patients with 
facial telangiectasias, who were pre-treated with cortisone cream due to psoriasis, 
small bullae were found, which did not leave any scarring. We did not see any 
hyperpigmentation, but temporary hypopigmentations were seen five times, and im-
proved after a few weeks. Spider nevi and senile angiomas only showed in dark skin 
types from sealing of the horny layer of the epidermis, which also improved. 
Table 1. Parameters used in the Maastricht experiment for vascular lesions 
Vascular lesions W.L.nm E/Jcm2 P.M.msec P.T.msec PD.msec Cl.(%) 
Blue facial telangiectasias 590 38 T.P. 3.8/3.1/2.6 10.20 90 
590 50 T.P. 3.8/3.1/2.6 10.20 
Red facial telangiectasias 550 30-34 S.P. 4-5 0 95 
Spider nevi 550 28-34 S.P. 4-5 0 95 
570 30-35 D.P. 3/2 10.20 
Erythrosis interfollicularis 515 22-26 S.P. 2.5-3 0 90 
550 22-28 S.P. 2.5-3 0 
Senile angiomas 550 30-36 S.P. 4-5 0 95 
Leg tel. <0.2mm 550 22-28 S.P. 3-4 0 92 
Leg tel. 0.2-0.5mm 570 24-30 D.P. 2.4/2.4 10.20 80 
Leg tel. 0.5-1mm 570 38-40 T.P. 3.8/3.1/2.6 10.20 81 
590 50 T.P. 3.8/3.1 /2.6 20.30 
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Figure 1a. Blue and red teleangiectasias an the back and an Figure 1b. Ten weeks after the first treatment. 
the ala of the nase before treatment. 
Figure 1c. Immediately after the second treatment with triple 
pulses, 590 nm, and different energies. 
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Concerning side effects in leg veins, in 20 patients hyperpigmentation was seen, 9 pa-
tients showed erythema with hyperpigmentation, 2 patients showed hyper-
pigmentation and a blister, and in 3 patients erythema was visible followed by 
hypopigmentation. One patient experienced only hypopigmentation and 5 patients 
only erythema. 
Discussion 
In this study we showed that there· is a good clearance of leg telangiectasias up to 1 
mm (84.3%), a good clearing of facial telangiectasias ( 95%), erythrosis interfollicularis 
colli ( 80%), and spider nevi and senile angiomas in general cleared in one treatment. 
Age did not play a role concerning our reported results. Single treatments gave con-
tent results; repeated treatments after 10-12 weeks diminished residual telangiectatic 
lesions. 
Telangiectasias develop out of dilatations within arterioles, venoles, or capillaries. 
Telangiectasias in the face are seen as punctures of branched lesions or as spider 
nevi.' One of the main important factors for developing facial telangiectasias is 
chronic exposure to the sun. The Argon Laser was another alternative, as it gave suffi-
cient results and cheaper treatments! 6 Side-effects of the Argon Laser were risk of 
scars and permanent pigmentation problems.'·' 2 '14 The penetration depths of the POL 
and Argon laser (1 and 1.2 mm, respectively), limit their indications, as vessels that are 
localised deeper in the skin cannot be treated. 5 For years the POL was one of the main 
laser sources for treating vascular lesions, using the principle of selective photo 
-thermolysis, where the energy works on special targets, in this case, the effecting 
erythrocytes and avoiding scars in the surrounding tissue.'·'··27 '26 One of the main 
side-effects of POL is haemorrhage, which remains for up to 2 weeks. These haemor-
rhages are difficult to cover with cosmetics! 6 '29 
The PhotoOerm"VL as a light source, shows, compared with older laser types, several 
advantages. First, with one application of the PhotoOerm"VL, a surface of 2.8 cm2 can 
be treated , while with the POL this is considerably less (for a diameter of 5 mm a sur-
face of 19.6 mm2 and for a diameter of 10 mm a surface of 78 mm2) , and with the Argon 
Laser this is only 3 mm2 • Less haemorrhage is seen when treating patients with the 
PhotoOerm® VL, and even if it appears, it only remains for up to 2 - 5 days. With the 
PhotoOerm®VL we hardly ever saw hypo- or hyperpigmentations treating facial 
telangiectasias and erythrosis interfollicularis. Furthermore the PhotoOerm"VL even 
offers new treatment possibilities, e.g. , erythrosis interfollicularis, as these vessels 
have a very small diameter and are very superficially localised. 
Bullae formation was seen in two cases of facial telangiectasias. These patients were 
pre-treated with topical cortison creams due to psoriasis. 
As a conclusion the PhotoOerm®VL has several advantages compared with previously 
used lasers such as the POL and the Argon laser.30'31 Even though we are able to show 
good results with the PhotoOerm"VL, in different vascular skin lesions, we have to limit 
our enthusiasm. The PhotoOerm"VL turns out to be very difficult to handle. Too little 
energy will not occlude the vessels, too much energy develops too much heat, leading 
to bullae and finally to scar formation and depigmentation. Also, the pigmentation rate 
of the skin will influence the final result. More pigmentation will increase the risk of ab-
sorption of light, and thus damage the skin. The difficulties in handling this machine 
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are at the same time also the key for good results in this treatment. Since not all pa-
rameters of the skin lesions can be put in a mathematical formula, the operator has to 
be extremely experienced. For setting the parameters of the device, one has to re-
member all the different alternatives. 
First are the several treatment modalities, which means different energy types, pulse 
modes, and pulse time, which can be chosen according to the disease of the patient. 
The larger surface of 2.8 cm2 using the PhotoDerm"'VL offers a more time-efficient 
treatment, and the side-effects you generally see with other laser types can be ne-
glected, which means that patients have less pain, there is less edema formation and 
there are fewer haemorrhages. The very large spot size enables much deeper light 
penetration into the skin. For years it has been known that port-wine stains are treated 
much better with a pulse duration from 1 to 1 0 msec, although there was no possibility 
to implement this fact practically in therapy until the PhotoDerm®VL was developed. 
By splitting the energy into 2 or 3 pulses with different pulse delays, the skin can be 
cooled in between. This results in fewer side effects in the surrounding tissue. Using 
these pulse sequences purpura, which is common with the POL, does not appear 
even when high frequencies are used. The intense pulsed light source has the follow-
ing other advantages. The wavelength can be produced with cut-off filters ranging 
from 515 to 590 nm. In general vessels require different wavelengths for optimal treat-
ment. Deeper penetration into the skin can be performed with longer wavelengths. 
The pulse duration can be varied between 0.5 and 25 msec so that the energy can be 
applied to the vessel with a controlled power. The advantage of the PhotoDerm"'VL is 
found in its flexibility. This makes an individual treatment for every patient possible. 
We can conclude out of our experience with the PhotoDerm"'VL up to now that the 
user needs a lot of experience with this device to become familiar with all the possible 
settings. These depend on the individual requirements of the patient's condition. It 
seems the relative low energy settings will avoid extravazation of erythrocytes. This 
lack of purpura, which increases acceptance for the patients, is one of the important 
reasons that hypopigmentation can be avoided, what is seen in other therapeutical 
modalities. In conclusion, the PhotoDerm VL- flashlamp is an excellent device for 
treating vascular lesions in the hands of experienced users. 
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Commentary 
The development of the pulsed dye laser in the mid 1980s revolutionized the treatment 
of cutaneous vascular lesions. Based on the theory of selective photo thermolysis, spa-
tial confinement of thermal injury in blood vessels was achieved by selective absorp-
tion by hemoglobin of 577-585 nm light with pulse durations in the millisecond domain. 
While effective in the treatment of a variety of vascular lesions and a revolutionary de-
velopment in the treatment of port-wine stains, the pulsed dye laser has limitations. 
Treatments are not without pain, mutiple treatments are required for port-wine stain 
lightening, treatment of dark-skinned patients is limited by increased pain, there is a 
high risk of side effects including pigmentary changes, and purpura develops after all 
treatments, lasting from 5 to 14 days. 
In the past few years a broad band pulsed light source (PhotoDerm) has been devel-
oped in an effort to optimize results in the treatment of vascular lesions without some 
of the limitations of the pulsed dye laser. The PhotoDerm is a flash/amp-pumped broad 
band light source with wavelength ranging from 515 to 1200 nm, and pulse durations 
varying from 1 to 10 msec. While not a laser, this pulsed broad band light source has 
the ability to achieve selective vascular injury, a tissue effect that we associate with 
pulsed lasers. The ability to choose wavelength from the visible to the near infrared 
range, to adjust the pulse duration between 1 and 10 msec (the thermal relaxation time 
of vessels most commonly found in port-wine stains and telangiectasia), and the ability 
to produce from one to three successive pulses per treatment sites lends the 
PhotoDerm substantial versatility. It facilitates treatment without purpura, treatment of 
darker skin types, and the ability to target nonvascular sites such as pigment and hair. 
Early results with the PhotoDerm have been encouraging. Schroeter and Neumann 
demonstrate the versatility of the PhotoDerm with effective clearing of a wider range of 
vascular lesions. While the ability to alter wavelength, pulse duration, fluence, and the 
number of pulses offers users tremendous choice, this choice is a/so one of the 
PhotoDerm 's limitations. Unlike pulsed lasers used in cutaneous surgery where only 
the spot size and fluence can be varied, the PhotoDerm offers users a wide array of 
choices and, as a result, ideal treatment parameters have been slow to be established. 
The tremendous variation in parameters used by these experienced authors is shown 
in Table 1. Six different types of vascular lesions were treated with four different wave-
lengths, 12 different f/uences, single, double, or triple pulses, with different pulse dura-
tions and different pulse delays. These numbers reflect the wide choice available to 
PhotoDerm users and explain, at /east in part, the difficulty in maximizing the 
PhotoDerm 's capability. 
Drs. Schroeter and Neumann's long experience with the PhotoDerm is evidenced by 
the excellent results they have reported in 120 patients treated with a variety of vascu-
lar anomalies. As our experience grows with the PhotoDerm, ideal parameters will be-
come known and the device will, no doubt, find its niche as a tool in our therapeutic 
armamentarium, not only for the treatment of vascular lesions but also for pigmented 
lesions and hair removal. 
JeffreyS. Dover, MD, FRCPC 
Associate Chairman, Department of Dermatology, Beth Israel Deaconess Medical Center 
Associate Professor of Clinical Dermatology, Harvard Medical School 
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CHAPTER 7 
Effective treatment of rosacea using 
Intense Pulsed light Systems 
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Abstract 
Background: To date, a variety of lasers have been used for treating vascular skin le-
sions. Intense pulsed light source (IPLS) is a new and promising technology for vascu-
lar lesion management such as rosacea. 
Objectives: The aim of this study was to test the effectiveness of IPLS in treating vas-
cular facial lesions in rosacea patients. 
Methods: Sixty patients presenting with telangiectasia due to facial rosacea were se-
lected randomly from the patient population in the Department of Laser Therapy at the 
Medical Centre Maastricht, The Netherlands. Patients of various skin types 
(Fitzpatrick I to IV) were selected with an average age was 44.2 years. A total of 508 
sites were treated with a mean of 4.1 site and an IPLS spectrum ranging from 515 to 
1200 nm with different pulse durations between 4.3 to 6.5 ms. The energy density var-
ied from 25 to 35 J/cm2 • 
Results: Patients were assessed clinically and photographically. A mean clearance of 
77.8% was achieved and was maintained for a follow-up period averaging 51.6 
months (range: 12 to 99 months). No correlation was found between the clearance of 
rosacea and patient-related or technical data. For approximately three years 
post-treatment, lesion recurrence was noted at 4 out of the 508 treated facial sites. 
Discussion: This study demonstrated that IPLS treatment of facial rosacea is effec-
tive in obtaining clearance of 77.8% , with minimal side effects and that treatment ef-
fects are maintained. 
Conclusion: The IPLS system with its broad range of technical variables is an effec-
tive tool in achieving meaningful and lasting rosacea clearance. 
Key words: facial telangiectasia, incoherent light, IPLS, erythema, rosacea. 
Introduction 
Rosacea is a common but often overlooked skin condition that can lead to significant 
facial disfigurement and ocular complications. The progression of rosacea includes 
typical stages: facial flushing , erythema and/or oedema as well as ocular symptoms, 
papules and pustules, and rhinophyma. , The exact etiology of rosacea is unclear but it 
is likely due to a combination of factors. Exposure to certain climatic conditions and/or 
radiation resulting in vessel wall abnormalities may play a role in the developing of the 
disease.2"3 The Demodex folliculorum mite could also be involved.'·5 Other causes of 
facial telangiectasias are thought to be excessive exposure to sun, topical steroids, 
and hormonal replacement therapy. The acne rosacea syndrome can cause 
telangiectasia on the nose. Although the papulo-pustular elements respond well to 
medium or long-term antibiotic therapy, the vascular elements are frequently persis-
tent. Usually the patients try to hide the blemishes with a thick layer of cosmetic foun-
dation. Many treatment modalities have been attempted to eradicate these lesions 
including excision, razor blades,6 electro surgery 7 and laser therapy. 
Telangiectasias develop out of dilatations within arterioles, venules or capillaries. The 
superficial lesions of the telangiectasia are a suitable aim for photocoagulation using 
yellow light lasers. Yellow light of the wavelength 575 to 585 nm is absorbed well by 
oxyhaemoglobin with only minimal damage to the overlying skin." 
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Selective laser treatment of vascular skin lesions is based on the principle that laser 
light of certain wave lengths can be preferentially absorbed by hemoglobin, and this 
generates thermal energy which diffuses in the immediate perivascular tissue, damag-
ing the vessel wall. Thermal diffusion , not confined to the epidermis can produce un-
wanted epidermal and dermal damage. Clinically this can result in pigment and 
textural changes, hypertrophic scarring, depending on the site and the degree of 
non-vascular damage. In addition to wave length, laser-skin interactions depend on 
other laser variables such as energy density, duration of exposure and laser beam di-
ameter, as well as lesion-variables such as the vascular structure and the epidermal 
melanin content. 
Lasers used for the treatment of micro vascular lesions include among others: Argon, 
Pulsed Dye, Neodymium YAG, Carbon Dioxide and Krypton lasers.9.14 Frequent 
hypopigmentation, scar, blister formation and pain was reported using these la-
sers.9'10'15 In particular, laser studies16.20 for rosacea and facial telangiectasias propose 
clearance of the vascular elements of rosacea but they are uncontrolled and lack 
actual measures of improvement. 
An effective technology in the treatment of telangiectasia is intense pulsed light 
source (IPLS). PhotoDerm~L and Vasculight® are IPLS systems developed to treat a 
variety of vascular lesions of the skin, including deeper ones. These devices use a 
wide band of an incoherent intense pulsed light source, which emits a continuously 
adjustable spectrum in the range of 515 to 1200 nm. 
One of the earlier studies using Photoderm~L for different skin lesions including vas-
cular lesions was carried out by Hellwig et al!' A number of studies have reported the 
successful use of the IPLS for the treatment of port wine stains, 22 '23 leg telangiec-
tasias ,"4'25 essential telangiectasias ,"6'27 venous malformations28 and poikiloderma of 
Civatte! 9'3° Findings from one of our earlier studies described a clearance of up to 
90% of facial telangiectasias and erythrosis interfollicularis colli. 31 Spider naevi and 
senile angiomas cleared following one treatment session only. 31 Using appropriate pa-
rameters 70 to 1 00% clearance could be achieved in venous malformations smaller 
than 100 cm2! 8 In one study 75 to 100% clearance was achieved in 174/188 patients 
with facial veins (primarily telangiectasia), facial hemangiomas, rosacea and port wine 
stains. 32 Another study reported more than 50% reduction in the number of vessels in 
79.2% and a 75%-100% reduction in 37.5% patients of facial telangiectasia. 33 Taub 
AF reported that after treatment 83% of the patients had reduced redness, 75% re-
duced flushing and improved skin texture, and 64% noted fewer acneiform break-
outs.34 
The aim of the current study was to demonstrate the treatment of erythema and the 
vascular components associated with rosacea using the IPL source, and to compare 
the results with those of the existing lasers. 
Patients 
Sixty patients (55 women and 5 men), with skin types I - IV and a mean age of 44.2 
years (range: 32 to 67 years) diagnosed to have telangiectasia associated with 
rosacea were chosen at random in the Medical Centre Maastricht, the Netherlands. 
Thirty-eight of the 60 patients had not received any previous treatment before pre-
senting at Maastricht Medical Centre. Nine had been on an antibiotic therapy, 7 had 
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been treated with laser, 2 with coagulation therapy, and the rest had received other 
medication (Table 1). 
The telangiectasias were located on the forehead, nose, cheeks and chin (Table II). 
The most commonly used filter was 550nm accounting for 93% of the treatments. In 
436/508 treatments a pulse of equal to 5 ms or less was used and in the rest (72/508) a 
pulse greater than 5ms. The mean pulse duration used was 4.8 ms. Fluence applied 
by the PhotoDerm~L ranged between 25 and 35 J/ cm2 • In our study a mean fluence 
of 30.4 J/cm2 was used. In 87.5% patients treatment was with a single pulse. 
A detailed personal history of each patient was taken. Photographs were taken before 
and after each session. Some of the patients were also treated topically with a 
metronidazole cream. Patients were evaluated for an immediate response and fol-
lowed by controls after 1 week, 2 weeks, 4 weeks and 3 months. The patients were fol-
lowed for an average of 51.6 months (range: 2 to 99 months) until June 2004. 













Table II. Correlation between the sites treated and the clearance obtained 
Site/localizat ion Number of sites Mean number of 
treatments 
Forehead 17 3.12 
Left cheek 191 4.19 
Right cheek 190 3.87 
Nose 77 5.11 
Chin 31 2.97 
Cheekbone 2 4.00 
Total 508 








In this study the IPL system, PhotoDerm~L (ESC Medical Systems Ltd., Yokneam, Is-
rael) and the Vasculight® (Lumenis, Yokneam, Israel) were used. Their effectiveness is 
based on the principle of selective photothermolysis. The PhotoDerm~L uses inco-
herent light of a broadband spectrum in the range of 500 - 1200 nm by applying differ-
ent cut-off filters (515, 550, 570 and 590 nm). An alteration of the spectral range during 
the PhotoDerm~L treatment, allows to modify the penetration depth of the light to 
match the specific target structure, i.e. vessels of different sizes and depths, etc. 
Fluence applied by the PhotoDerm~L ranges between 15 and 90 J/ cm2 • 
The size of the PhotoDerm~L treatment head (8 x 35 mm) plays an important role in 
improving light penetration into the tissue since the large spot size diminishes the 
scattering . A cooling gel was applied to the skin during the treatment, which allows 
good optical coupling of the light to the patient's skin and also better heat transfer. 
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Statistical analysis 
The statistical analysis of the data consists of frequency tables (absolute and relative) 
for all categorical variables. For all continuous variables, mean, standard deviation, 
median, minimum, maximum, and lower and upper quartiles are calculated . 
The Kruskai-Wallis-test, and if appropriate, the Mann-Whitney-U-test are used to 
compare continuous variables between categories. 
The correlations between continuous variables are measured by the Pearson correla-
tion coefficient. All tests are strictly exploratory. The type I error for all tests is set top= 
0.05. 
Results 
In this study, 60 patients (55 women and 5 men) with a mean age of 44.2 years (range: 
32 to 67 years) were treated for rosacea for a mean duration of 1.93 years. During this 
time 508 sites were treated with an average of 4.1 treatments per site. The mean suc-
cess rate in clearance was 77.8% (figure 1 a, 1 b, 2a). Patients were followed up for an 
average of 51.64 months (range: 12-99 months). 
The majority of the rosacea lesions were present in the left (191/508) and the right 
(190/508) cheeks of the patients. In other cases they were located on the chin 
(31/508), forehead (17/508), nose (77/508), and cheekbone (2/508). It was observed 
that the lesions on the forehead showed the best clearance, that of 87% (Table II). 
During the treatment, the mean energy that each patient was exposed to was 30.52 
J/cm2 (Table Ill) . Two hundred and twenty five treatments out of 508 were carried out 
using fluence greater than 30 J/cm2 and 283/508 with lesser or equal to 30 J/cm2• 
Table IV shows the immediate reaction after treatment. One hundred and nine out of 
508 treatments showed erythema, 67/508 purpura, and 5/508 complained of pain. 
Three patients showed oedema, one had blisters, five showed footprints, and one 
transient hyperpigmentation. After 3 years in 4/508, there was a recurrence of the le-
sion. There was no reaction observed in 315/508 treatments (62%). 
No correlation was found between any of the clinical (patient-related) variables includ-
ing, lesion duration (p = 0.0515), previous treatments (p = 0.341 0) and age (p = 0.7192) 
when the lesions cleared. The clearance also did not correlate with any of the techni-
cal variables including the pulse time (p = 0.1179), the number of treatments (p = 
0.2486), the wavelength (p = 0.871 0), or the fluence (p = 0.9636) (Table V). 
Table Ill. Mean values of clinical and technical data 
Variable 
Duration of treatment (years) 
Number of treatments 
Filter used (nm) 
Energy used (J/cm2) 
Pulse duration (msec) 









Figure 1a, Patient with rosacea both cheeks and Figure 1b. Left Cheek. 
chin prior to treatment. 
Figure 2. After 4 treatments with IPLS one year 
later. 
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Table IV. Immediate and late reactions after treatment 











Table V. Clearance in relation to clinical and technical data 
Variable 
Number of treatments 
Localization 
















We observed a 77.8% clearance of facial telangiectasias associated with rosacea af-
ter an average of four treatments. Age did not play a role in the reported results, al-
though the location of the lesion influenced the degree of their clearance. It was 
observed that the lesions on the forehead showed the best clearance (87%). Of the 
different sites treated the nose needed the maximum number of treatments (5) for the 
lesions to vanish. Furthermore there was no correlation found between the clearance 
of rosacea lesions and clinical or technical data of the patients. 
The IPLS we used has several advantages in treating facial telangiectasia compared 
to other lasers. Firstly, the Pulsed Dye, Copper Vapor, Argon and C02 lasers are co-
herent and monochromatic lights in contrast to the IPLS, which is an incoherent, wide 
band light source with a spectrum in the range of 515 to 1000 nm. Deeper penetration 
into the skin can be achieved using longer wavelengths. Shorter pulse-time of micro 
seconds obtained with the Pulsed Dye laser is not enough to close the vessels so the 
deeper penetration depth and longer pulse time is indicated. Furthermore the different 
filter settings of IPLS enable a higher selection of a broad range of vessel colour of the 
vascular system. Second, with one shot of the IPLS a surface of 2.8 cm2 can be 
treated, while with the POL this is considerably less (for a diameter of 5 mm a surface 
of 19.6 mm2 and for a diameter of 1 0 mm a surface of 78 mm2) and with the Argon La-
ser this is only 3 mm2 • The large surface of 2.8 cm2 offers a more time-efficient treat-
ment and less patient discomfort. The large spot size enables much deeper light 
penetration into the skin. Third, by splitting the energy into 2 or 3 pulses with different 
pulse delays, the skin can be cooled between pulses. This results in fewer and 
negligible side effects. 
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Since treatment is relatively painless, it was carried out without anesthesia. No serious 
local or systemic adverse effects occurred in any of the patients treated . The immedi-
ate response was a slight erythema and purpura, which disappeared within 24 to 96 
hours. 
Although treating different vascular skin lesions with Photoderm®VL, yields positive 
results , there are some difficulties. The Photoderm~L must be used by highly trained 
individuals. Too little energy will not occlude the vessels; too much energy develops 
too much heat, leading to bulla, scar formation and depigmentation. Also, the pigmen-
tation rate of the skin will influence the final result. More pigmentation increases the 
risk of light absorption and thus increases the risk of skin damage. The specificity in 
using this technology also contributes to the treatment success. Not all parameters of 
the skin lesions can be translated into a mathematical formula. Successful parameter 
selection includes all of the following: pulse type, pulse duration, pulse delays, colour 
and depth of the vessels and the type of skin. It should be noted that due to sample 
size and a large variation in the technical parameters, there was no correlation found 
between the technical data and lesion character. Future studies using a larger sample 
size need to be carried out in order to compare the results of flashlamps with those of 
other existing lasers. 
In conclusion the results from this study suggest that the Photoderm~L is an excel-
lent device for treating vascular skin lesions associated with rosacea, when used by 
an experienced physician. 
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Clinical significance of an Intense Pulsed 
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Abstract 
Telangiectasias on the legs are difficult to treat in contrast to those on the face. 
Sclerotherapy is widely used but often results in hyperpigmentation. Procedures such 
as argon, pulsed dye and copper vapour laser treatment may lead to scarring. 
Forty female patients with blue and red telangiectasias on the legs were treated with a 
new, intense light source, the PhotoDerm"'vL, developed by Energy Systems Corpo-
ration Inc (ESC), Boston, U.S.A. The diameter of the vessels was between 0.2 mm and 
1 mm. The average age of the patients was 41.7 years, the youngest was 24 years and 
the oldest 72 years. Patients were treated within the spectrum of 515 nm to 590 nm 
with varying pulse duration. Energy varied from 20 to 70 J/cm' . Reticular and feeding 
veins were treated first. 
Immediate clearing was achieved in 73.6% of the patients and in 84.3% of the pa-
tients after four weeks. Concerning the immediate response, 82.0% clearing was seen 
in the group with veins of up to 0.2 mm diameter, 78.9% was seen in the group from 
0.2 up to 0.5 mm and 59.7% was seen in the group, from 0.5 to 1 mm. After one 
month, clearing was seen in 92.1% in the first group, 80.0% in the second group and 
81.0% in the third group of patients. 
Cosmetic results were excellent, neither telangiectatic matting nor scarring was seen. 
There was no recurrence in the follow-up period of 1 year. Our results show that treat-
ment of telangiectatic veins of the leg with the PhotoDerm®VL is an effective treatment 
with minimal damage to the skin. 
Keywords: intense light source, laser, leg telangiectasias, PhotoDerm"'vL. 
Introduction 
Leg telangiectasias are very common, but have been difficult to treat. The term 
telangiectasias refers to superficial, cutaneous vessels which can be seen macro-
scopically,' although this term provides no information about their origin. 
Telangiectasias can be dilated arterioles, venules or capillaries. In general, the small 
red ones are regarded as being arteriolar and venular vessels are those which turn 
blue or purple as a result of venous backflow and increased pressure.' Although a 
wide variety of cases of cutaneous telangiectasias is known, the majority of leg 
telangiectasias are related to chronic venous insufficiency. The incidence of leg 
telangiectasias is high: 29 to 41% for women and 6-15% for men.3 Although up to 
53% of the patients have symptoms of telangiectasias on the leg, the majority of pa-
tients consult the dermatologist for cosmetic reasons. The ideal treatment has not yet 
been developed; sclerocompression therapy is the most common. However, 
post-treatment hyperpigmentation occurs in up to 30% of patients with or without 
telangiectatic matting .' In the last decade, laser therapy has also been used for the 
treatment of leg telangiectasias. Unfortunately, this treatment has turned out to be 
somewhat disappointing. The carbon dioxide laser obliterates telangiectasias, but the 
overlying skin is destroyed with hypopigmented scarring. '·7 Because of its non-selec-
tive action, this type of laser cannot be used as a treatment for leg telangiectasias. 
With the neodymium: YAG laser (1 ,060 nm) , leg telangiectasias can be coagulated, 
but as with the CO, laser, the treatment is non-specific, resulting in scar formation. 
Apfelberg reported depressed, linear, hypopigmented scars after neodymium: YAG 
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treatment. 6 The argon laser is commonly used for vascular skin lesions, but only in 
16% of skin lesions were excellent or good results obtained ! Glassberg et al ," demon-
strated a direct destructive effect upon endothelial cell structures with the 577 nm 
pulsed dye laser; penetration is only up to 0.5 mm depth from the dermal-epidermal 
junction. ' 0 Tan et al 11 showed that by increasing the wavelength from 577 nm to 585 
nm the depth of penetration for destroying microvessels (50 up to 1 00 microns in di-
ameter) could be increased from 0.5 mm to 1.2 mm. Unfortunately, this cannot be 
achieved with larger vessels. In very small (less than 100 microns), superficial cutane-
ous blood vessels the thermal relaxation time ranges from 2 ms to 1 0 ms. Several 
studies have been performed with different pulse widths starting from 1 ns to 450 ns 
with intravascular damage and destruction of endothelial cells. 12"13 Until now, the best 
results have been seen with the 585 nm flash lamp pulsed dye laser (PDL). '3 The 
PhotoDerm®VL was developed to treat a variety of vascular lesions of the skin includ-
ing deeper skin lesions. 14 This device is a high intensity, pulsed light source with a 
spectrum that can be selected for optimal treatment of a variety of vascular lesions us-
ing incoherent light. The PhotoDerm®VL can be used for the treatment of veins under 
the skin up to a depth and a diameter of 5 mm. With this device it is possible to use, not 
only a broad spectrum of energy and a wide range of pulse duration, but also different 
wavelength ranges. The device turned out to be very effective for the treatment of leg 
telangiectasias. In this study we report our first results for leg telangiectasias up to 1 
mm in diameter. 
Materials and methods 
Patients 
Patients were randomly selected and treated in 4 centres for dermatological laser 
therapy. Two centres are located in Germany (Oberndorf and Karlsruhe) , one in Swit-
zerland (Zurich) and one in the Netherlands (Maastricht) . 
Forty women with leg telangiectasias, aged 24 to 72 years, with an average age of 
41.7 years were selected for treatment. A personal medical history was taken, as well 
standard clinical investigations. The patients were examined before treatment with 
Doppler-ultrasound and photoplethysmography (LRR) to exclude functional reflux in 
the venous system of the legs. 14 Photographs and measurements were taken before 
treatment. Patients were evaluated for immediate response and followed-up after 1 
week, 2 weeks, 4 weeks and 3 months. Major sources of venous problems such as 
saphenofemoral or popliteal junctions and/or incompetent perforators or feeder veins 
were dealt with first. Patients were divided into three groups according to the diameter 
of vessel treated: group 1 < 0.2 mm, group 2 between 0.2 and 0.5 mm and group 3 be-
tween 0.5 and 1 mm. The vessel diameter was recorded with a transparent ruler. Only 
leg telangiectasias above the knee were treated. It was safer to treat them first, as at 
the beginning of our study we had had very little experience with the PhotoDerm~L 
and leg telangiectasias below knee are more difficult to treat. Three to up to 12 




The PhotoDerm«'VL is an intense, pulsed light source with a continuous light spectrum 
with most of its energy at wavelengths between 515 and 1,000 mm. 15 The pulse dura-
tion of the PhotoDerm«'VL range varies between 2 ms and 25 ms per pulse. The energy 
fluence varies between 3 J/cm2 to 90 J/cm2 in one pulse sequence. Operating modes 
are single, double or triple pulses in each pulse sequence. In contrast to lasers, the in-
tense pulsed light source produces incoherent light, The spot size is larger than that of 
other lasers with an illuminated area of 8 mm x 35 mm. The optical energy is directly 
coupled through a light guide. All settings are computer controlled. Treatments with 
the PhotoDerm«'VL were performed within energy ranges of 20 to 70 J/cm2 , lower 
cut-off filters of 515, 550, 570 and 590 nm, pulse duration between 3 and 6 ms and sin-
gle or double pulses. The treatment parameters were chosen according to the diame-
ter of the vessels, the colour of the vessels and the skin type. For vessels up to 0.2 mm 
in diameter, a single pulse of 3 ms and energy of 22 J/cm2 was used. For veins with a 
diameter greater than 0.5 mm, a double pulse mode was used with pulse duration of 
2.4 ms each, a pulse delay of 20 ms and 35 J/cm2 for the larger ones between 0.5 mm, 
and up to 1 mm a triple pulse of 3.5 ms, 3.1 ms and 2.6 ms was used with pulse delay 
of 20 ms and 50 J/cm2 • The choice of filter depended upon the colour of the skin and 
the vessel and the depth of the telangiectasia, ranging between 515 nm and 590 nm. 
Purpura and extravasions were avoided by careful adjustment of fluence, pulse dura-
tion and pulse mode. 
Statistical analysis 
For comparison of improvement of the immediate response and the response after 1 
month for all the patients and in each age group, the signed Rank Wilcoxon test was 
carried out. The two sample Wilcoxon test was performed to compare the groups of 
patients with different vessels diameters. 
The Kruskal Wallis test was carried out to compare in general, the immediate clearing 
and the clearing after one month for each group. 
Resu lts 
Clearing of the vessels was assessed by finding a vascular depression in the skin im-
mediately after treatment and a cordlike structure in the dermis after a month. Forty 
women with a median age of 41.7 years, the youngest patient being 24 and the oldest 
72 years old, were treated for leg telangiectasias. Four patients needed treatment for 
reflux before laser treatment. Out of these, 3 patients showed up with an insufficient 
sphenofemoral junction and one patient with a leak at the saphenopopliteal junction. 
Two patients initially received sclerotherapy, with 0.5% and 1% polidocanol depend-
ing on the type veins. In the group of up to 0.2 mm vessel diameter, we observed an 
immediate clearing in 82.0% of this patient group, with a clearing of 92.1% after four 
weeks. There was an improvement in clearing after 1 month in the first group, which 
was significant (p = 0.0003). This was shown with the signed rank Wilcoxon test. In the 
second group of patients, with a vessel diameter from 0.2 mm up to 0.5 mm, 78.9% of 
those treated had an immediate clearing and 80.0% of patients after 1 month. In the 
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Figure 1. Before treatment, Right arrow-legs telangiectasias Figure 2. After treatment. Right arrow-leg telangiectasias 
0.2-0.5 mm diameter. Left arrow-leg telangiectasias 0.5-1 0.2-05 mm diameter. Left arrow-leg telangiectasias 0.5-1 mm 
mm diameter diameter. 0.5-1 mm diameter 
second group there was no difference (p = 0.63), as 17 patients already showed im-
mediate clearing in what remained in the follow-up time. Of those patients in the 0.5 
mm to 1 mm diameter group 42.3% experienced immediate clearing. After 1 month, 
81.0% of the treated vessels had cleared (Table I) (Figs. 1 and 2). This difference be-
tween 42.3% and 81 .0% was again statistically significant (p = 0.0001). The Kruskal 
Wallis test was used to compare the results of all three groups. This test showed that 
in the immediate response there were difference in clearing between the three groups 
(p = 0.0001 ). After one month, a difference in clearing was seen with the same test (p = 
0.039). The Wilcoxon two sample test was carried out to compare two groups of pa-
tients with different vessel diameters. Between the first group, up to 0.2 mm, and the 
second group, 0.2-0.5 mm, no difference in clearing has seen in the immediate re-
sponse (p = 0.636), compared to the difference in clearing after one month which was 
statistically significant (p = 0.0177). The difference in clearing between group 1 and 
group 3 was significant for the immediate reaction (p = 0.0003), there was almost no 
difference in clearing after one month between the first and the third group (p = 
0.0449). There was a difference seen in the immediate clearing between groups 2 and 
3, which was significant (p = 0.0003). After four weeks there was no difference be-
tween the two groups (p = 0.670). Within the age group 20-49 years, there was a drop 
in the immediate clearing and in the clearing after one month. In the age group 20-29 
years, there was an immediate clearing of 86% and 1 00% clearing after one month; in 
the age group 30-39 years, there was an immediate clearing of 80% and 90.5% clear-
ing after one month; in the age group 40-49 years, there was an immediate clearing of 
70.1% and 80% clearing after one month. In the older age groups there were not 
enough patients participating, so the result had to be discounted. The signed rank 
Wilcoxon test showed an improvement in the immediate clearing compared to the 
clearing after one month only in age group 30-39 years (p = 0.0005) and in the age 
group 40-49 years (p = 0.0002) (Table II) . Concerning the side-effects, in 20 patients, 
only hyperpigmentation was seen, 9 patients showed erythema combined with 
hyperpigmentation, 2 patients showed hyperpigmentation and a blister, and in 3 pa-
tients erythema was visible followed by hypopigmentation. One patient just experi-
enced hypopigmentation and 5 patients just erythema (Table Ill). There was none of 
the telangiectatic matting seen with sclerotherapy, which is a common problem. Dur-
ing the treatment period no thombophlebitis was seen. In the follow-up period, 
brown-red spots were seen in 12 patients with erythema. None of our patients devel-
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Table I. Differences in immediate and after one month clearing 
Group 1: size < 0.2 mm Group 2: size 0.2-0.5 mm Group 3: size 0.5-1 mm 
Patient Age lmm.(%) 4W (% ) Patient Age lmm. (%) 4W(%) Patient Age lmm. (%) 4W(%) 
1 47 100 80 1 47 80 60 1 47 70 40 
2 45 90 90 2 45 70 60 2 45 70 60 
3 54 80 60 3 54 50 30 3 54 40 20 
4 30 100 100 4 30 90 60 4 30 70 60 
5 48 80 80 5 48 60 50 5 48 50 60 
6 61 80 90 6 61 80 60 6 61 50 70 
7 40 70 80 7 40 60 50 7 40 60 60 
8 31 100 100 8 31 100 60 8 31 80 70 
9 49 100 80 9 49 90 40 9 49 60 60 
10 38 90 90 10 38 90 50 10 38 50 60 
11 39 70 90 11 39 70 90 11 39 40 80 
12 41 60 80 12 41 50 80 12 47 20 80 
13 44 70 80 13 44 50 80 13 57 20 70 
14 47 50 80 14 47 50 80 14 51 10 30 
15 40 80 100 15 32 70 80 15 32 60 90 
16 40 50 70 16 40 40 60 16 40 40 70 
17 43 70 100 17 43 70 80 17 43 40 60 
18 46 60 18 43 50 70 18 44 50 70 
19 33 40 80 19 33 30 60 19 44 60 100 
20 44 40 70 20 44 40 60 20 46 60 70 
21 44 100 100 21 44 100 100 21 48 60 100 
22 46 100 100 22 46 100 100 22 30 60 100 
23 30 100 100 23 30 100 100 23 30 100 100 
24 30 100 100 24 30 100 100 24 72 70 100 
25 72 100 100 25 72 100 100 25 49 70 100 
26 49 70 100 26 49 100 100 26 37 60 100 
27 37 70 100 27 37 100 100 27 28 60 100 
28 28 100 100 28 28 100 100 28 49 60 100 
29 49 100 100 29 46 100 100 29 46 60 100 
30 46 100 100 30 36 80 100 30 36 70 100 
31 36 100 100 31 55 80 100 31 55 60 100 
32 55 70 100 32 31 100 100 32 31 70 100 
33 31 70 100 33 24 80 100 33 24 100 100 
34 24 80 100 34 31 100 100 34 31 70 100 
35 31 80 100 35 33 100 100 35 33 70 100 
36 33 80 100 36 41 100 100 36 41 60 100 
37 41 100 100 37 39 100 100 37 39 70 100 
38 39 100 100 38 43 70 80 38 43 100 100 
39 43 100 100 
mean 82.0 92.1 mean 78.9 80.0 mean 59.7 81 .1 
standard deviation 18.5 11 .2 standard deviation 21.9 21.4 standard deviation 19.4 22.5 
lmm. - immediate clearing; 4W - clearing after 4 weeks. 
Table Ill. Side-effects 
No side effects Erythema Blister Total 
No side-effects 75 0 0 75 
Hypopigmentation 1 3 0 4 
Hyperpigmentation 20 9 2 31 
Erythema 5 0 0 5 
Total 101 12 2 115 
(87.33%) (10.43%) (1 .74%) (100.00%) 
oped scarring. In those patients who were dark in colour or sun-tanned, temporary 
depigmentation in the total probe area was seen. No compression therapy was given 
for the leg telangiectasias. The same lesions were treated on each occasion. Gener-
ally 2-3 treatment sessions were necessary. 
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Table II. Difference in response according to each age group 
20-29 years 30-39 years 40-49 years 50-59 years 60-69 years > 70 years 
n 6 40 55 8 3 3 
Mean age 26 33 44 54 61 72 
Immediate 86% 80% 70% 51 % 70% 90% 
response 
Four week 100% 90% 80% 63% 73% 100% 
response 
p-value 0.25 0.005 0.0002 0.26 1.0 1.0 
Discussion 
In our combined study at four international laser centres, we have shown that the 
PhotoDerm~L is an excellent device for treating leg telangiectasias. Other studies 
have shown that the POL is effective for treating leg telangiectasias up to 0.2 mm in di-
ameter.2 The PhotoDerm~L was successful for the treatment of leg telangiectasias 
up to 1 mm diameter. The treatment showed fewer complications such as telangiec-
tatic matting and hyperpigmentation, which are usually seen with sclerotherapy and 
other laser device. Red blood cells are the targets, which undergo morphologic 
changes during treatment with the PhotoDerm~L. Pulse duration and delay between 
pulses and double pulse sequences depend on the diameter of the vessels and the 
thermal relaxation time.'" The very large spot size enables much deeper light penetra-
tion into the skin. For years it has been known that port wine stains are much better 
treated with a pulse duration from 1 ms to 1 0 ms, although there had been no possibil-
ity of implementing this practically in therapy until the PhotoDerm~L was developed. 
By splitting the energy into 2 or 3 pulses with different pulse delays, the skin can cool 
in between. This results in fewer side effects in the surrounding tissue. Using these 
pulse sequences, purpura, which is common with the POL, does not appear even 
when high frequencies are used. The intense, pulsed light source has the following ad-
ditional advantages. 
The wavelength can be produced with cut-off-filters ranging from 515 to 590 nm. Ves-
sels require different wavelengths for optimal treatment. Deeper penetration into the 
skin can be performed with longer wavelengths. The pulse duration can be varied be-
tween 2 ms and 25 ms so that the energy can be applied to the vessel with a degree of 
control. Flexibility is the great advantage of the PhotoDerm~L. This makes an individ-
ual treatment for every patient possible. We can conclude from our experience with 
the PhotoDerm~L that the user needs a lot of experience with this device to become 
famil iar with all the possible settings. The choice of settings depends on the individual 
requirements of the patient's condition. Using the PhotoDerm~L. the pulse type, 
pulse durations, pulse delays and fluence depend on the diameter, the colour, the 
depth of the vessel and on the skin type. These parameters have to be investigated 
before treatment. It seems that particularly the relatively low energy settings will avoid 
extravasation of erythrocytes. The lack of purpura is one of the important reasons that 
hypopigmentation is avoided, a side- effect that is often seen with sclerotherapy and 
POL. 
Leg telangiectasias related to chronic venous insufficiency demand proper investiga-
t ion of reflux in the venous system. The combination of LRR and ultrasound-Doppler is 
very useful to exclude serious hemodynamic venous problems. Major reflux always 
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has to be treated first. Long-lasting results will only be obtained in patients if reflux and 
feeder veins are treated first" . 
As our own experience shows, patients with perforators need more treatments and 
also higher energy treatments to damage feeder veins effectively. Because of the 
wavelengths, some melanin will be absorbed in the epidermis, therefore sun-tanned 
patients should be informed about the possibility of temporary hypopigmentation. In 
our study, hypopigmentation in each of the 4 patients affected disappeared within 3 to 
6 months, Furthermore, we conclude that the PhotoDerm~L seems to be the treat-
ment modality of choice for leg telangiectasias up to 1 mm in diameter. Our own re-
search (unpublished result) shows that veins larger than 1 mm in diameter, typical of 
reticular and feeder veins, will be able to be treated in the not-to-distant future with the 
PhotoDerm~L. More research in needed to optimise the treatment parameters. 
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Abstract 
Introduction: The nevus of Ota is a pigmented lesion occurring normally along the 
distribution of the fifth cranial nerve. Earlier dermabrasion , freezing and laser irradia-
tion have been used for its treatment. There are no reports of its handling using the In-
tense Pulsed Light Source {IPLS). 
Patients and methods: Three case reports of patients with a diagnosis of nevus of 
Ota are presented. All of them had been treated with a-switched ruby laser prior to 
treatment with IPLS. Initially an evaluation of the skin reaction to IPLS was conducted, 
which was later followed by a complete treatment. 
Results: Treatment intervals tended to be longer than those with the a-switched ruby 
laser. Oedema occurred and lasted for up to 24 hours. No erythema was noted after 
treatments. There were no permanent pigmented changes. 
Discussion/Conclusion: Treatment of nevi of Ota using IPLS is effective, however, 
many treatment sessions are necessary; even after partial treatment with a-switched 
ruby laser. On the other hand there are no permanent side effects and the cosmetic re-
sult is better in comparison to the lasers. 
Keywords: IPLS, laser, nevus of Ota. 
Introduction 
The management of pigmented lesions by lasers is a relatively new field in dermatol-
ogy. However, within a short period of time, a wide range of applications for different 
types of lasers has been found. Nevus of Ota was first described by Ota and Tanino in 
1939.' Usually nevus is unilaterally located and found situated on the sclera as well as 
somewhere along the course or distribution of the trigeminal nerve, in the skin and tis-
sues innervated by the first or second branches! Studies done on ocular findings in 
Japanese women with nevus of Ota showed some changes in the optic disc. 3 This, 
however, did not interfere with visual acuity. 
Nevus of Ota is thought to occur mainly in the people of Asian descent but it also oc-
curs in people of African and European descent. The consequences of the lesion are 
mainly cosmetic although other more adverse effects may occur for instance chronic 
glaucoma. •.s 
More recently another classification has been offered based on therapeutic response 
of the nevus specifically to laser therapy." This classification can be used to predict 
clinical outcome unlike other classifications employed before. In designing this classi-
f ication the peri-orbital under-response was used (panda's sign), defined as the de-
gree of peri-orbital laser clearing significantly less than clearing in other areas. Ueda et 
a/ also noted variation in response to a-switched ruby laser therapy based on the col-
our of the lesion. The best results were obtained with brown lesions while blue-green 
lesions were the most difficult to treat. 7 Other researchers using the a-switched 
Alexandrite laser have found that the depth of the lesion was more important than the 
colour in determining outcome of the treatment, lesions < 1 mm in depth give good to 
excellent results. Blue-black nevi tended to show deeper infiltration of melanocytes 
into the dermis than the dark brown nevus. However, it was concluded that colour it-
self was not a reliable indicator for predicting therapeutic outcome. 8 
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Several modes of therapy have been used in the treatment of nevus of Ota including 
dermabrasion (nevus of Ota-like maculae),9 freezing ,>·'o and skin grafting. Patients may 
also use cosmetic foundation or obtain cosmetic tattoos. Different types of lasers 
have now been added to the choice of therapies for the nevus. 
Lasers have already been shown to be effective in the management of pigmented le-
sions. These include the a-switched Ruby,>·7·" Alexandrite, 12'13 and Nd:YAG14'15 lasers 
which have been successfully used. The quality-switched lasers produce very short 
pulses of very high energy. This increases the photo selectivity. The pulse duration is 
shorter than the tissue relaxation time of the target chromophore. 14 This means that 
high energies can be delivered with enough time for cooling so that surrounding tis-
sues are not adversely affected. Histological studies have shown that a-switched 
Alexandrite laser irradiation fragments the melanosomes present in dermal 
melanocytes leaving behind empty spaces in the form of vacuoles. This occurs sec-
ondary to a photo-acoustic event, the high energy delivered in a short pulse creates a 
high-energy gradient, which then acts as a mechanical wave causing shattering of the 
target. No damage is seen in surrounding tissues. 12 
Ono et al ranked therapeutic effectiveness of a-switched ruby laser in 14 patients: 6 
were judged excellent, 5 good, and 3 fair." Taylor et al reported treating nine nevi with 
65 treatments using a-switched ruby laser with significant cosmetic improvement.2 1n 
another study 151 patients were treated, depending upon the predominant colour of 
the lesion. 7 
Kunachak et al in a follow-up study of treatment of bilateral nevus of Ota-like maculae 
after irradiation with a a-switched Nd:YAG laser found that clearance of 100% after a 
mean of 2.8 treatments (range: 2-5) was maintained over a mean of 42 months of fol-
low-up in 68 patients. '5 
Up to now no published literature has reported on the use of the Intense Pulsed Light 
Source in the treatment of nevus of Ota. The Intense Pulsed Light Source has already 
been applied in the treatment of other benign pigmented lesions, based on the same 
principle of selective photothermolysis.' 6'17 1t is a versatile system capable of delivering 
high energies by trains of short pulses. It is therefore likely that this is an ideal system 
for the management of nevus of Ota lesions. Presented are case reports of patients 
with nevus of Ota, which did not improve after several a-switched ruby laser sessions 
and were successfully managed by IPLS. 
Patients and methods 
Three cases of nevus of Ota are presented here for discussion. All were initially treated 
using a a-switched ruby laser (694nm, 40ns) followed by treatment using the Intense 
Pulsed Light Source (IPLS). The first patient had 4 a-switched ruby laser sessions and 
141PLS, the second patient had 6 treatment sessions with a-switched ruby laser and 
12 with IPLS. And the third patient had 2 a-switched ruby laser sessions and 3 IPLS 
treatments, which are still continued. 
Intense Pulsed Light Source 
PhotoDerm~L was used. This IPLS uses incoherent light of a broad band spectrum in 
the range of 500-1200nm. By applying different cut-off filters (515, 550, 570, 590, 615, 
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Figure 1. After 5 times with ruby laser. Figure 2. After 8 times with IPL whole face . 
Figure 3. After 8 times treatment with I PL. 
695, 755 nm), a specific part of the shorter wavelengths (below the indicated filter) can 
be filtered off. The use of different cut-off filters allows adjusting the treatment param-
eters to the patient's skin type; using longer filters, which control the spectrum at 
higher wavelengths, results in reduced overlap with the higher absorption coefficient 
of melanin, the concentration of which depends on the skin type. 
For skin types IV-V, pulse times >4 ms and energy of 22J/cm2 and above were used. 
For skin type V double pulses with a delay of 30ms were used. For all the three pa-
tients the wavelength of 590 nm was used. 
A cooling gel is used on the skin during the IPLS treatment that allows good optical 
coupling of the light to the patient's skin and also better heat transfer from the epider-
mis to the cold gel. 
The intervals between different sessions varied from 3 to 6 months. 
The size of the IPLS treatment head (8x35 mm) plays an important role in improving 
light penetration into the tissue since the large spot size diminishes the scattering . 
Case Reports 
Case 1 
An 18-year old woman was referred to the department with a congenital lesion on her 
forehead and left cheek for which a diagnosis of nevus of Ota had been made by the 
dermatologist. There was no family history of a similar lesion. She had not been 
treated elsewhere for the same problem. Local examination of the frontal area showed 
a dark blue lesion 10 x 4 em in size on the left side. In the left buccal area a similarly 
coloured lesion of 5 x 6 em was seen which extended medially onto the nose. In the 
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department she was initially treated using a a-switched ruby laser. A test spot in the 
frontal area was first made using 8 J/cm2 • There were no side effects noted. She was 
treated a year later at irregular intervals using energies ranging between 8.5-20J. 
Based on dissatisfying results she was then treated with IPLS. She received 11 treat-
ments at intervals of 6 to 8 weeks. A cut-off filter of 590nm was used throughout the 
treatments. After these treatments the lesion on the cheek cleared about 95% and 
there was significant lightening of the frontal lesion. This was maintained over 6 
months of follow-up. Photographs were taken before and after the treatment. (Figures 
1,2,3) 
Case2 
A 25-year old man was referred by his General Practitioner with a history of a dark pig-
mented patch around the right eye extending into the temporal region on the same 
side. It had appeared when the patient was 7 years old . There was progressive wors-
ening of the lesion and at 13 years of age his dermatologist diagnosed it as nevus of 
Ota. There was no family history of a similar lesion. He denied that the lesion had 
caused him any psychological problems. He was initially treated with a a-switched 
ruby laser. He received 11 treatments over a period of 22 months at irregular intervals 
using energies ranging between 7-20 Joules. The inter-treatment interval was based 
on the extent of the lesion covered during the treatment and individual response to the 
treatment. The a-switched ruby laser did not give uniform results- spotting occurred 
within the lesion. He was then treated using the IPLS. After 7 treatments with the IPLS 
there was significant lightening of the lesion. A cut-off filter of 590nm was used for all 
treatments with a pulse of 5 ms and low energy. A clearance of about 90% was 
achieved. 
Case3 
A 26-year-old woman was referred to the Medical Centre with a dark coloured patch 
under her left eye, measuring 2X5X0.8 em, which had been present since birth. She 
had another hyperpigmented patch on the right shoulder and on the upper arm pres-
ent since puberty. A diagnosis of nevus of Ota was made by the dermatologist. The 
patient was initially treated using the a-switched ruby laser. But due to side effects 
leading to discoloration, she was switched over to IPLS. After three treatments she 
showed an improvement of about 80%. The patient is still being followed up to receive 
further treatment with IPLS as this paper is written (Figure 1, 2 and 3). 
Discussion 
The purpose of treating nevus of Ota lesion is by and large a cosmetic one. People 
with these lesions are known to be stigmatised by societies in which they live and this 
has adverse psychological consequences for each of them. Unlike concerning the 
treatment of congenital and dysplastic nevi, there is less controversy in the literature 
surrounding the treatment of nevi of Ota using lasers and other light sources. '8 This is 
because nevi of Ota are not associated with increased risk of malignant transforma-
tion. Therefore treating these lesions would not interfere with the monitoring of a pos-
sible malignant transformation. 
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We began treating the three patients with a Q-switched ruby laser initially. But there-
sults obtained were not uniform, there was a spotty appearance and the presence of 
discoloration and hyperpigmentation was seen; therefore we switched to IPLS. Al-
though the treatment using IPLS takes many sessions, the advantage is that an optical 
homogenous fading of the pigment was achieved . 
The possibility of occurrence of side effects such as pigmental changes is virtually 
eliminated because of the versatility of the IPLS in catering to individual patient char-
acteristics. A treatment session consists of an initial assessment of the skin reaction 
by a test spot. This reaction determines the parameters to be used in treating the le-
sion of the patient. In all three cases presented here significant improvement (lighten-
ing) of the lesions was demonstrated after treatment with IPLS. A distinct advantage 
of IPLS was the larger treatment head (2.8 cm2), which allowed the entire treatment 
area to be covered in a single session in comparison to the Q-switched ruby laser with 
a limited spot size of 5mm. In addition a more uniform result could be obtained for the 
same reason. With the ruby laser an entire area was covered over a number of days 
and this also created variation in the intervals between treatments. The intervals be-
tween treatment sessions became more definite with the IPLS. In the cases presented 
here the intervals tended to be longer than those between the ruby laser treatments. 
The intervals are important as the maximum effect of a single treatment becomes fully 
apparent in about three months. This has been shown histologically following treat-
ments using the Q-switched Alexandrite laser.' 2 This is the duration of time in which 
particles from destroyed melanosomes are phagocytosed and mobilised by 
macrophages in the dermal tissue. Kunachak et a/ used shorter intervals between 
treatments while treating nevus-of-Ota-like macules with a Q-switched ruby laser.' 5 
Their objective was to retreat lesions before epidermal repigmentation had occurred, 
thus eliminating the barrier effect to laser light of epidermal melanin. This approach re-
mains controversial and probably causes more permanent pigmental changes. 
The wavelength of 590nm was used in all the patients presented. This wavelength has 
been reported to be effective in the treatment of Nevus Spilus using the IPLS. ' 9 
During treatments using IPLS on our patients, oedema occurred and lasted for up to 
24 hours before resolving. There was no occurrence of erythema. Brown-grey crusts 
formed after the treatment, which fell off later. The odd case of hyperpigmentation 
was transient and was dependent on the dose of energy used. This may occur as a 
post-inflammatory phenomenon, but has also been thought to be a reactive process 
occurring in (deeper localized) partially damaged melanocytes.'0 
We conclude that the IPLS offers a new possibility for the treatment of nevus of Ota 
and it can also be used to improve the skin structure after previous treatment with 
other lasers for pigmented lesions. Summing up it can be noted that using IPLS to 
treat nevi of Ota takes more sessions than using lasers, but there are no permanent 
side effects and the cosmetic results are better. 
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This thesis is the result of several studies in which flash lamps, also known as Intense 
Pulsed Light Sources (IPLS) are used to treat various dermatological conditions. 
Seven major questions were raised as summarised in Chapter 1, and each was an-
swered in the cumulative research project. 
Before the introduction of IPLS, lasers were a widely used device for major 
dermatological indications. The major progressions of laser are summarized in Table 
1. 1. 13 Lasers are a perfect complement to IPLS, and for certain aesthetic challenges, 
IPLS technology provides a refining touch to laser procedures. IPLS technology em-
ploys full spectrum, non-coherent light and low-range infrared radiations that are fil-
tered to allow a specified range of wavelengths. This filtered light is delivered from a 
hand piece into the skin, where it targets different chromophores such as melanin in 
the hair sheath and haemoglobin in the capillaries. Thermal and/or mechanical dam-
age to the hair follicle results while sparing surrounding tissues in a process known as 
selective photo-thermolysis. The filters can be adjusted to match the patient's skin 
type and the target lesion. As the light energy is target specific, adjacent tissue is 
spared, and the possibility of scar formation is decreased. Due to the nature of the 
treatment, intense pulsed light (IPLS) energy can be applied to the surface skin layers 
for gentle and gradual results with reduced side effects and patient downtime. 
Flashlamps started to be used for medical purposes in the 1960's with published data 
on treating eye and skin disorders emerging in the latter half of the decade.14·15 By the 
mid-1990's, researchers were exploring the use of flashlamps for treating vascular le-
sions, and in the year 1995, the FDA cleared the first flashlamp for the treatment of 
vascular lesions. 16 
Little information is available about the mechanisms of flash lamp action into the skin, 
and one of our questions was to elucidate the post-treatment effects of IPLS. To solve 
this question we started an experimental study on 2 pigs with a given protocol. We in-
vestigated the histology of the epidermis, dermis and subcutaneous fat immediately 
after treatment, one and two day's post-treatment and , after 1 week, 2 weeks, 1 
month, and 3 months post-treatment. Our study showed that IPLS targets several 
components including pigment, vessels and hair. 
Another histological study aiming to understand the effects of IPLS on transforming 
growth factor beta (TGF-b), and extracellular matrix proteins in the skin was also car-
ried out in our clinic. This showed that TGF-b in the epidermis increases to the outer-
most layers one week post IPLS treatment while tenascin expression increase begins 
one day after treatment at the epidermal/dermal layer and remains for about two 
weeks. These findings support the hypothesis of growth factor stimulation following 
IPLS treatment. Additional investigations regarding this point are currently ongoing in 
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our clinic (data unpublished). These findings also suggest that due to targeted heat in 
the skin post treatment, vessel dilatation occurs and this increased blood flow trans-
ports growth factors and/or their receptors to the wound healing area. These stimulate 
collagen and elastin production leading to a better skin texture. 
Skin rejuvenation and skin improvement are in demand by patients worldwide. Today 
the flash-lamp is increasingly used to permanently remove or greatly reduce the ap-
pearance of blemishes and for skin rejuvenation. All aspects of photo-damage includ-
ing wrinkling, skin coarseness, irregular pigmentation, pore size, and telangiectasias 
showed visible improvement."·" The results for superficial skin problems such as skin 
pores, acne scars, and superficial wrinkles are encouraging; however, there is much 
more going on in the skin compared to what we macroscopically see. In one study by 
Negishi et al., forty-eight full-face photo-rejuvenations for Asian patients was carried 
out in Japan! 2 After the fifth treatment, a combined rating of greater than 60% im-
provement was given to more than 80% of patients for pigmentation improvement, 
telangiectasia reduction or removal , smoother skin texture, and overall improvement. 
Histological evaluations showed strong staining of Type I and Type Ill collagen in the 
upper dermis indicating new formation of collagen. There is an increasing demand for 
a safe, effective, and long-term hair removal method. One study noted hair loss as a 
side effect of treatment with IPLS.'3This side effect promoted research into the area of 
hair removal. An ever-increasing number of published studies have confirmed the 
long-term efficacy of flash lamp treatment in removing hair. Some of our studies sup-
port this claim including a study with 40 hirsute women completed in 1999 that 
showed effective hair removal in these 40 patients with a 76% of clearance! 3 
Perhaps Tse gives the best overview regarding the clinical data in hair removal, 24 how-
ever, most of the studies published on hair removal have a follow-up of a few months, 
therefore no conclusion is possible on long lasting hair removal. 25.34 According to the 
FDA, a one-year follow-up is sufficient to claim permanent hair removal. From our ex-
perience we conclude that long-lasting hair removal can be demonstrated after a 
two-year hair free period in the treated area. One of our studies published in 2004 in 
the J Derm Surg showed a clearance of 87% after 27.3 months in 70 hirsute women, 
which confirms our findings on long lasting hair removal with IPLS.35 
The possibility of permanent hair removal is important for transsexual patients as well. 
In another study by our group, we have shown "satisfactory" results of 90% clearance 
of hair removal in a group of 25 transsexual patients.36 This study proved that hair re-
moval with IPLS is cheaper, shorter in duration, has less side-effect and is more suit-
able for the patients than hair removal with needle epilation. 
The challenge still remains to eliminate light-coloured hair as well as the capability to 
safely treat individuals with darker skin. The rapid movement of technological ad-
vancement as well as continued studies of hair follicle biology promise to improve this 
field over the years to come. Recent observations are made that IPLS offers the option 
for hair removal of blonde hair when double treatment in one session is carried out 
(own observation). A very recent new development - the combination of light (IPLS) 
and radio frequency (RF) - provides good results and gives an added benefit of fewer 
required treatment sessions in comparison to any devices used previously. Whether 
this device is superior to the former systems has to be proven in further studies. 
Since IPLS is approved to clear vessels, our next question was to determine whether 
IPLS can be effectively used for vascular lesions. Indeed, the wide range of treatment 
parameters, have been used in the treatment of cavernous hemangiomas, venous 
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Table 1: Laser and flashlamp treatment studies 
First author Machine used No. of Treatment Result Follow-up Skin 
pat. type 
Laser treatment studies 
Brunnberg' Alexandrite laser 20 Leg vein In 15/20 a clearance 3 months I-III 
telangiectasia of 26-75% 
Omura' Nd:YAG laser 20 Reticular veins 213" of (1-3mm diameter) vessels- 3 months 
>75% clearance 
Spendel' KTP laser 70 Spider leg veins Variable clearance 7,5 months 
Kaudewitz' diode laser 20 Leg vein 50-75% clearance 12 months 
telangiectasia 
Sarradet' Nd:YAG laser 15 facial telangiectasia Moderate to significant improvement 3 months 
Clark' KTP laser 204 Facial 90-98% improvement 24 months I-III 
telangiectasia, 
spider angioma 
Kel ly' Pulsed dye laser 20 Port wine stains Variable from <25 to >75% blanching 
Westerhof' Ruby laser 12 Melanocytic nevi 100% removal of all flat lesions, 12 months 
others partial response 
Levy' Nd:YAG laser 29 Unwanted facial 46% hair reduction 9 months 
hair 
Sadick" Diode laser 24 Unwanted hair 79% hair removal 6 months II-IV 
Keller" KTP laser 62 Glabellar frown Effective skin rejuvenation 18 months 
lines and forehead 
creases 
Lee" KTP and Nd :YAG 150 Mild rhytides and Mild to moderate degree of 18 months 1-V 
lasers skin toning improvements 
Hellwig" Ruby laser, pulsed 100 Vascular Excellent results 
dye laser and malformations and 
Photoderm"VL benign pigmented 
lesions 
Flashlamp treatment studies 
Bitter" IPLS 49 Photo rejuvenation Visible improvement 
Goldberg" IPLS 30 Rhytides Some improvement 6 months I-ll 
Hernandez-Perez" IPLS 15 Striae distensae Clinical improvement 
Weiss" IPLS 80 Photoaged skin Long lasting improvement 48 months I-IV 
Ho21 IPLS 19 postburn 50-75% clearance 32 months 
hyperpigmentation 
Negishi22 IPLS 73 Full face 60% improvement Asian 
photorejuvenation pat. 
Schroeter" IPLS 40 Unwanted hair 76.7% hair reduction 
Gold" Epilight 37 Unwanted hair 60% hair removal 3 months 
Gold" IPLS 24 Unwanted hair 75% hair reduction 12 months 
Weiss" IPL 23 Unwanted hair 33% hair reduction 6 months I-III 




Schroeter" IPLS 70 Unwanted hair 87% hair removal 27.3 months 1-V 
Schroeter" IPLS 25 Unwanted hair in 90% hair reduction 44 months 
transsexuals 
Schroeter" Photoderm"VL 120 Vascular skin 90% clearance 
lesions 
Angermeier" Photoderm"VL 200 Facial vascular 75-1 00% clearance 2 months 
lesions 
Raulin" IPLS 37 Port wine stains 70-1 00% clearance 
Weiss" IPLS 135 Poikiloderma of 75% clearance 
Civatte 
Goldman" IPLS 66 Poikiloderma of 50-75% clearance 
Civatte 
Goldman" IPLS 159 Leg veins 50-1 00% clearance 
Schroeter" IPLS 40 Leg veins 7 4-92% clearance 12 months 1-111 
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malformations, facial telangiectasias, spider nevi, the vascular part of poikiloderma of 
Civatte, and leg telangiectasias with great success. Facial veins were found to clear 
up to 100%.37-39 The fading of port wine stains depends on the thickness, colour, local-
ization of the lesion, age of the patient and the pre-treatment conditions 40 .. 1 and excel-
lent results have been achieved worldwide using IPLS for port wine stains (PWS) and 
facial telangiectasias. Poikiloderma of Civatte on the face and neck are a challenge to 
treat with flashlamps.'2 .. 3 lf both a pigmented and vascular component are present, the 
pigment has to be treated first due to its localization in the skin. If only a vascular com-
ponent is present, a clearance can be gained of up to 90% (personal observation). 
Leg telangiectasias remain a difficult problem to treat due to different factors such as 
variations in anatomic microcirculation, thickness and pigmentation of the skin. A light 
source such as IPLS that produces a non-coherent light as a continuous spectrum 
longer than 550 nm has certainly more advantages over a single wavelength laser sys-
tem. First, both oxygenated and deoxygenated haemoglobin will absorb at a combi-
nation of wavelengths. Second, blood vessels located deeper in the dermis will be 
affected. Third, thermal absorption by the exposed blood vessels occurs with less 
overlying epidermal absorption since the longer wavelengths penetrate deeper and 
are absorbed less by the epidermis. Leg vein results range between 50 -1 00% clear-
ance are a potential new indication for flash lamps if the user is experienced with the 
technology, 44 '45 Table I. ,_45 
Following the excellent results we obtained in treating facial lesions, we pioneered the 
treatment of rosacea with IPLS in 1998 which was not previously treated with lasers or 
such similar devices. Rosacea patients are traditionally treated with local systemic 
and antibiotics for a few months. Rosacea is a good example of an indication that can 
be successfully treated (even when treatment resistant) using a combination of IPLS 
with locally applied medicines. 
The final question we addressed was whether IPLS is also a new treatment possibility 
for pigmented lesions, and indeed it is when treatment is given by a highly trained indi-
vidual. Nevi respond better to lasers than flash lamps. In the author's opinion, 
Becker's nevi do not respond well to treatment with either lasers or flash lamps. 
Lentigines, ephilides etc. do however respond well. Melasma, if epidermal, requires a 
lot of care to treat effectively and avoid unwanted treatment-related side effects. Pig-
mented lesions should be treated with long intervals of up to 3-4 months. Nevus of Ota 
is a potential new indication for IPLS treatment, but it might require more treatments 
using flashlamps compared to lasers; however, the lesion will be much more equal 
and less spotty after the IPLS treatment. In erythrosis interfollicularis colli one should 




IPLS is currently used to treat a variety of skin indications as well as for hair removal, 
and has several distinct advantages over lasers arising from its flexibility in allowing a 
wide range of settings relating to individual patient characteristics. Modification of 
various parameters that include (but are not limited to) wavelength, fluence, pulse du-
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ration, pulse delay, pulse sequence and temperature control of the skin, gives a lot of 
flexibility. The use of the IPLS device saves time and costs because it can treat sur-
faces of 2.8 cm2 to 5.6 cm2 per pulse. Another cost benefit of IPLS over lasers is the 
fact that one IPLS device can treat a multitude of indications where as several different 
laser devices would be required to treat the same set of indications. 
Another desirable property of flash lamp technology is the possibility to split an indi-
vidual pulse into a maximum of 5 partial pulses. Each pulse can be adjusted to its own 
fluence level and the 2 to 4 in-between delays can be of varying duration. Multiple 
pulses can be effectively used in darker skin types as the epidermis can be cooled 
down during the delays. Despite this cooling, there is still enough available heat in the 
target area so that the next pulse delivered has an additive effect in increasing the heat 
more rapidly and extending the heat from the absorber, such as haemoglobin, to the 
target which is the vessel wall. 
The initial cost of the devices and of the procedures is cheaper to that of comparable 
lasers. 
How to use a flash-lamp 
Flash lamps offer extensive treatment flexibility but care must be taken to select the 
proper wavelength which is determined by the colour and depth of the target. For ex-
ample, if a red oxygenated facial vessel , 0.5 mm diameter is to be treated, a "cut-off" 
filter of 550 nm is used, due to the colour absorption of HB02 at 540 nm. Furthermore, 
pulse durations of 5 ms and greater are applied. If the target vessel is a thick blue ves-
sel on the wings of the nose, multiple pulses are used in combination with a "cut-off" 
filter of 590 nm and pulse durations of 5 ms depending on the size of the vessels. Thus, 
various vessels can be effectively treated with the same flash-lamp due to the flexible 
parameter settings. 
Multiple pulses are also useful in the treatment for deeper located leg telangiectasia. 
Triple pulses can be applied, referring to the diameter and the depth of the vessel, and 
pulse delays of 20-50 ms between the pulses can be defined according to the skin 
type bypassing the epidermis (due to the delay the epidermis is cooled down). Using 
multiple pulses, less fluence is needed for a partial pulse time to damage the endothe-
lium of the target vessel wall. Biochemical and coagulation mechanisms then follow. 
In smaller leg veins with a diameter of 0.5 mm, oedema around the vessel is found im-
mediately after treatment, which helps to occlude the vessel (personal observation). 
After a few weeks the treated vein is replaced by fibrous tissue which is a palpable 
cord-like structure. 
The question remains as to whether all the various settings are necessary for effective 
treatment by any such flashlamp device. From a therapeutic and scientific point the 
answer is yes. Due to their great flexibility, multiple medical indications can be treated 
with a single flash-lamp device, which is a clear benefit over lasers, which must be 
matched with a specific indication to be effective. It is important that the physician 
makes the correct decision on the parameters such as wavelength, fluence, pulse 
type and duration including spot size for each patient treatment session (Table II) . It is 
necessary to select specific parameters every time before treatment of an individual 
patient, independent on the previously applied parameters. Such is not the case with 
the use of lasers due to their limited flexibility. 
Using the combination of all the flash-lamp settings results in: 
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a) Flexibility in a broad range of treatment possibilities 
b) Faster results and a higher success rate in the clearance of the targets 
Indeed IPLS is a revolutionary new mini-procedure, which is able to diminish or fully 
rid one of age/liver spots, fine wrinkles (rhytides), facial flushing, redness, broken cap-
illaries, telangiectasias, hemangiomas, freckles, minor sun damage, port wine stains, 
tattoos, varicose veins, spider veins, flat birth marks, hyper-pigmentation and even 
hair removal. When combined with the relatively low cost of flash-lamps in compari-
son to lasers, the ease of maintenance, and the flexibility of treatment parameters, this 
makes IPLS an ideal tool for dermatological therapy. 
Table II: Parameters used for skin lesions treated by flash lamps 
Indication Skin type Wavelength Pulse time Difference Ener~y 
(nm) (s) (J/m) 
Vascular Lesions 
Facial telangiectasia 1-111 550/570 4-5 26-32 
Rosacea 1-11 550 5 20 28-36 
PWS: light 1-11 590 =6 35 
Dark I-ll 590 =6 
Papula 1-11 550/570 4 30-36 
Spider veins 1-11 550 > 8 30-40 
Leg veins: red 1-11 590 4 20 30-40 
Blue 1-11 550 4 20 30-40 
Pigmented Lesions 
Lentigines Ill 570 4 20 30-40 
Hair removal: 1-11 655 7-7 60 26-36 
Ill 655 7-7 80 26-36 
IV 655 7-7 80-100 26-36 
v 750 7-7 100-120 26-36 
VI 750 7-7 > 150 26-36 
The standardized evaluation of IPLS treatment results 
Currently, there is no objective system or scale that is validated for the evaluation of 
laser or flash-lamps treatment results. Both patient- satisfaction and the judgement of 
a physician are used in evaluation of therapies, but an objective scoring of the results 
following treatment with flash-lamps or lasers is urgently needed. In our studies, stan-
dard photographs were taken in patients with vascular lesions, using a Minolta cam-
era outfitted with a 200mm objective, before the treatment as an overview of the face, 
joined by the sides of the skin lesion after the 3rd, 5th and last treatment. These photo-
graphs are scored by 2 independent physicians and the patient as well. 
Leg veins were assessed before treatment with Doppler-Ultrasound and photo-
plethysmography to exclude functional reflux. Photographs and measurements were 
taken before treatment, and the diameter of the vessel was determined with a 
transparent ruler. 
For hair removal, photographs were taken before treatment, after the 3rd, and last 
treatment. The photographs were evaluated by two independent physicians. Addi-
tionally, hair counts were performed as an objective scoring system for successful 
epilation. Since the cosmetic satisfaction of a patient is an important aspect in most 
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laser and flash-lamp treatments, the patients' satisfaction of the treatment is also 
evaluated. 
Limitations 
Additional limitations that remain to be addressed in the effective use of flash-lamps 
include: 
- Manufacturing companies should be aware to sell machines only to qualified and 
trained medical staff 
- Depending on the variability of the treatment settings, limitations and protocols of 
the applied parameters are necessary and should be carefully defined 
Laser and flash-lamp systems users do need a high standard of qualification 
Technical data including wear of "cut-off" filters, head filters, fibres should be 
known 
Long learning curve is necessary 
Taken together these facts dictate the involvement of a treating physician who is 
highly qualified including a training of at least one year, involving basic physics, histol-
ogy, research and clinical application in the academic field. The Photoderm~L is a 
commercially available flash-lamp device which offers all the aspects described 
above and can be effectively used by the trained physician. 
Future aspects 
An area of future research includes: 
- The development of a device which analyses the clinical parameters of the pa-
tient's skin before and after each treatment. This data can be used to provide tech-
nical control and settings for flash lamp systems 
End filters 
- The development of the combination of a low and high cut off filter 
- The development of longer pulse times 
Better cooling systems 
Double or Triple pulse over layer treatments 
PDT 
Equal energy delivery by the condensator of the IPLS to obtain a full equal pulse in 
the wavelength spectrum and in energy 
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This article deals with Lasers and laser-like devices such as flashlamps. 
The word laser is an acronym for "Light Amplification by Stimulated Emission of Radi-
ation". A laser is a source of light in the visible or infrared region of the light spectrum 
that emits rays with a high spectral density on a very small area. Various lasers have 
been used for a wide range of medical purposes. For example: CO, lasers are useful 
for treating disorders of skin surface texture and topography (wrinkles, scars, sun 
damage, benign skin appendages and rhinophyma). Vascular lasers such as the 
flash lamp pumped dye laser are effective for treating port w ine stains, hemangiomas, 
telangiectasia, rosacea and spider naevi. a-switched lasers, which allow ultra short 
high intensity pulses, are effective for removing tattoos and some benign pigmented 
lesions. 
There are 3 essential components to a laser system. First is a Lasing medium, which 
may be a gas, crystal , liquid or a semiconductor. Second is a Source of Excitation for 
the lasing medium, for example, flashlamps or continuous light, radio frequency, high 
voltage discharge, diodes and in some cases another laser. Finally, Mirrors are 
needed to reflect the excited photons back into the resonant cavity containing the 
lasing medium. 
As the lasing medium is excited , molecules are "pumped" to a higher energy level. 
Some of the excited molecules spontaneously decay back to the original lower en-
ergy, or ground state, releasing a photon, and if the photon is emitted in the right di-
rection, it will hit one of the mirrors at the ends of the resonant cavity and be reflected 
back into the excited lasing medium. This excited photon can "stimulate" another ex-
cited molecule to decay back to the ground state, releasing another photon that trav-
els in the same direction, which in turn is reflected back into the resonant cavity 
stimulating emission of even more photons. If most of the molecules in the lasing me-
dium are in the excited state, termed as "population inversion", there is a net amplifi-
cation of light energy. 
The a-switched laser is a laser in which the state of the device introducing important 
losses in the resonant cavity and preventing lasing operation is suddenly switched to a 
state where the device introduces very low losses. This increases the quality factor of 
the cavity rapidly, allowing the build-up of a short and very intense laser pulse. Typical 
pulse durations are in the nano second (ns) range. 
Unlike ordinary light, laser light is coherent, coll imated, and monochromatic. Coherent 
refers to the synchronized phase of the light waves, collimated refers to the parallel 
nature of the laser beam (laser light is emitted in a very thin beam with all the light rays 
parallel} and monochromatic refers to the single (wavelength} color of the laser beam. 
Joule (J) is the total energy in a laser pulse or system, fluence is the dose stated in 
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J/cm2 , energy intensity is laser power per unit area, measured in W/cm2 , the wave-
length is related to stimulated energy transition, the shorter the wavelength, the higher 
the energy of the photon, focal spot size determines the maximum energy density that 
can be achieved when the laser beam power is set, the depth of focus is the distance 
over which the focused beam has about the same intensity. Laser light is monochro-
matic, therefore it has a selective effect on biologic tissue, either being transmitted, 
scattered , reflected or absorbed. Light absorption must take place for there to be any 
biologic effect, and a given wavelength of light may be strongly absorbed by one type 
of tissue, and be transmitted or scattered by another. The components of the tissue 
are responsible for its specific absorption characteristics. The main absorbing com-
ponents, or chromophores, of tissue are: hemoglobin in blood . melanin in skin, hair, 
moles, etc. , water (present in all biologic tissues). 
When light is absorbed, it delivers energy to t issue. An intense, but short pulse of laser 
light will usually cause an explosive expansion of tissue, or photomechanical reaction. 
A less intense, longer pulse will cause a rapid heating, or photo thermal effect. Selec-
tive photothermolysis is the process in which transfer of laser energy is restricted to a 
particular site because of the selective absorption of a chromophore. 
One of the first lasers to be used clinically is the Argon laser whose light is strongly ab-
sorbed by hemoglobin and melanin but it shows significant non-selective heating in 
surrounding tissues, thus increasing the chance of scar formation. 
VAG lasers use a Yttrium-Aluminum-Garnet crystal rod as the lasing medium. The 
Q-Switched Nd:YAG is effective in removing black tattoo ink. The Ruby laser emits red 
light with a wavelength of 694 nm. The lasing medium is a synthetic ruby crystal of alu-
minum oxide and chromium atoms, which is excited by flashlamps. Ruby laser light is 
strongly absorbed by blue and black pigments, and by melanin in skin and hair. 
The pulsed dye laser (POL) uses a lasing medium of Rhodamine dye which is excited 
by flash lamp. The Pulsed Dye Laser is useful to treat vascular lesions such as: cuta-
neous hemangiomas, port wine stains, cutaneous lupus erythematosus, oral granula-
tion tissue and some vascular birthmarks. 
A flash lamp is an arc lamp that operates in the pulsed mode and is capable of convert-
ing stored electrical energy into intense bursts of radiant energy covering the ultravio-
let, visible and infrared regions of the spectrum. Xenon is used in most flashlamps, 
since it is the most efficient of the inert gases at converting electrical energy to opt ical 
energy. 
There are two types - linear, or wall-stabilized; and bulb, or probe-stabilized . 
One such well-known type is the linear xenon flashlamp. It consists of a quartz tube 
with two sealed electrodes - cathode and anode, made from tungsten or from special 
low-sputtering materials. A flashlamp is usually filled with the xenon gas at ca. 200 to 
400 Torr pressure. 
A typical energy load on a flashlamp is from a few Joules to hundreds of Joules. A 
flashlamp is, due to its dense spectra, somewhat similar to the sun spectra. 
A flashlamp bombards a media with UV photons at extreme densities, thousands 
times as much as a continuous wave lamp does, it wipes out toxic chemical sub-
stances, bacteria etc. that are present in (or on) a treated media. 
Flashlamp also known as intense pulsed light source (IPLS) is the perfect complement 
to lasers. Employing a broad spectrum of light energy in a range of wavelengths, IPLS 
supplies high levels of light power in millisecond bursts. IPLS devices also offer so-
phisticated, computer-driven precision and tremendous versatility. Due to the nature 
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of treatment, Intense Pulsed Light energy can be applied to the sub-surface skin lay-
ers for gentle and gradual results with reduced side effects and patient recovering 
time. 
As mentioned earlier, flashlamps do not use one wavelength of light the way a laser 
does. Flashlamps emit every wavelength of light in the visible spectrum, and a little 
into the band of infrared radiation (up to about 1200 nm). Practitioners select a cut-off 
filter to block out lower wavelengths. Most flash lamps emit a beam that covers more 
area than a laser. 
Flashlamp are currently used for the same field of indications in dermatology as la-
sers. These devices are capable of effectively treating pigmented skin lesions, birth-
marks, facial spider veins, and leg veins, as well as for hair removal applications. 
Transforming growth factor-beta and extracellular matrix stimulation using 
intense pulsed light systems: an experimental study 
The skin 's normal reaction to tissue damage is inflammation. Macrophages and neu-
trophils enter the wounded area and start to clean up foreign material and dead cells . 
Afters this, proliferation of fibroblasts begins, which also stimulates the synthesis of 
extracellular matrix (ECM) proteins. Several growth factors play an important role in 
this reconstruction process, including Transforming Growth Factor (TGF). One of the 
functions of TGF is the stimulation of the production of ECM proteins. Among the pro-
teins TGF effects is the tenascin (TN) family of glycoproteins. These proteins are ex-
pressed in the adult during processes such as wound healing, vascular disease and 
tumour genesis. 
Tenascin and TGF also play a role in the protection against various diseases such as 
cancer. 
The aim of our study was to investigate the stimulation of TGF and the release of ECM 
proteins such as tenascin after radiation with intense pulsed light sources. 
We treated two pigs on the back with the Vasculight® and the Quantum® light sources 
five times each according to the protocols .. At various intervals after each treatment 
punch biopsies were performed on the radiated back of the pig. A total of 240 biopsies 
were taken. The biopsies were examined microscopically and by immunohisto-
chemistry. 
Variations in the TGF levels corresponded to the time after treatment. Notably, one 
week and 60 days after treatment high levels of TGF-beta were observed . 
Variations in the level of tenascin were also observed, two weeks post-treatment. A 
rise of the tenascin level in the epidermis and dermis and a fall of the tenascin level in 
the plama cells was found. 
Thus it seems that radiation with a high-intensity flashlight provides Please double 
check if you mean flashlamp an exogenous stimulus to produce an artificial wound , 
which causes latent TGF-~ and tenascin activation. 
Hair removal in 40 hirsute women using an intense laser-like source 
In this study the effective removal of hair was achieved without significant side-effects 
using an ILPS flashlamp emmitting non-laser incoherent light. The study involving 5 
centres in Germany, The Netherlands and Switzerland was carried out on 40 women 
with a median age of 38.6 years with hirsute hair growth of different hair colours on the 
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upper lip and chin. In general the unwanted hair was removed within 6 treatments and 
a success rate of 76.7% was achieved. There were virtually no side effects and hardly 
any pain was reported. 
The absence of side-effects and the high clearance rate led us to the conclusion, that 
the ILS is ideal for removing unwanted hair but that further research is needed in order 
to demonstrate that the hair loss is long term. 
Ninety percent permanent hair removal in transsexual patients 
Transsexualism is classified as a gender identity disorder and promotes the need to 
remove unwanted body hair in order to accomplish some degree of feminization. An 
effective, permanent method of hair removal is desired by transsexuals as part of the 
supportive management in gender reassignment. Several methods including the dif-
ferent types of electrolysis and laser epilation are used with varying effectiveness. The 
following study describes patients who received treatments with Intense Pulsed Light 
Source (IPLS) and achieved effective hair removal. 
Twenty-five transsexual patients between the age of 22 and 67 were treated with IPLS 
at three centres in The Netherlands, Germany and Switzerland. The PhotoDerm®yL 
system was used. A mean hair clearance rate of 90% was achieved in an average of 9 
treatments, and patients were followed up for an average of 44 months. 
We found that IPLS is not only effective in permanently removing hair without painful 
side effects in transsexual patients, but it also saves time and operation costs. 
Long-term hair reduction achieved in 87%of hirsute women treated with IPLS 
The management of hirsutism remains a challenge to dermatologists and cosmetic 
surgeons. Women with unwanted hair on the face, neck or any part of the body have 
psychological and social problems. Various laser and laser- like devices are currently 
in use for hair removal, but little is known about the permanence of their results. 
Our study examined the long-lasting of hair removal using IPLS on seventy female pa-
tients, aged 18-67 years who were treated in the Medical Centre Maastricht, the Neth-
erlands for unwanted hair on the chin and upper lip. The average age of the mostly 
dark haired patients of various skin types was 41 years. They were subjected to a 
mean of 8.0 treatments followed up for a mean period of 27.4 months. This period of 
time was selected to demonstrate the permanence of the treatment since it is longer 
than the follicles' complete growth cycle. Long-term hair removal was achieved after 
several sessions. 
Using the IPLS 87% hair removal was attained with virtually no side effects 
Because of the high success rate we conclude that the IPLS offers an effective and 
safe method of long-term hair removal. 
The PhotoDerm"VL flashlamp as a new treatment possibility for vascular skin 
lesions 
This study examined the IPLS treatment of vascular skin abnormalities such as facial 
and leg telangiectasias, spider nevi , erythrosis interfollicularis and senile angiomas. 
The reason for treating these expanded linear, aborizing, spiders and punctiform ven-
ules, capillaries and arterioles is mostly a cosmetic one, and several lasers have been 
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used for skin lesions with differing results. In this study the treatment of vascular skin 
lesions and the limitations of such treatments with the PhotoDerm~L flashlamp was 
examined. 
A total of 120 patients were chosen randomly at the Department of Laser Therapy at 
the Medical Centre, Maastricht, the Netherlands and treated with the PhotoDerm®VL. 
A clearance rate of 84.3% was achieved for leg telangiectasis up to 1 mm. Addition-
ally, 95% of facial telangiectasias and 80% of erythrosis interfollicularis colli were 
cleared. Spider nevi and senile angiomals cleared after a single treatment. While pre-
vious studies on treatment with other lasers showed side effects such as scars, per-
manent pigmentation, hemorrhage, hypo- or hyperpigmentation, the treatment with 
the PhotoDerm~L produced only minimal side effects which resolved in a brief period 
of time. 
The choice of setting variables is an important factor and makes a knowledgeable 
technician an asset. The range of settings determines the clearing rate. The chal-
lenges of operating the machine are at the same time also the key for good results. In 
conclusion, the PhotoDerm~L flashlamp is an excellent device for treating vascular 
lesions if in the hands of an experienced operator. 
Treatment of rosacea using PhotoDerm~L 
Rosacea is a common, but often overlooked skin condition that can lead to significant 
facial disfigurement, ocular complications and severe emotional distress. The pro-
gression of rosacea includes typical stages: facial flushing, erythema and/or oedema 
as well as ocular symptoms, papules and pustules, and rhinophyma. It is an idio-
pathic, widespread, chronic skin disorder commonly observed between the ages of 
40 and 50. The exact reasons for developing of rosacea are unclear but it is likely to be 
due to a combination of factors. 
Different lasers have been used for treating vascular skin lesions. Lasers used for the 
treatment of microvascular lesions are among others the Argon, Pulsed Dye lasers 
(POL) , Neodymium YAG, and Carbon Dioxide lasers. Frequent hypopigmentation, 
scar and blister formation have been reported using C02 , Nd:YAG and Argon laser, 
which paved the way to use the POL, which was also painful and caused bruises and 
hyperpigmentation. For years the POL was one of the main laser sources for treating 
vascular lesions, using the principle of selective photothermolysis, whereby the en-
ergy works on special targets, {haemoglobine). The surrounding tissue is left free of 
scarring. 
In this study we used the intense pulse light source and compared the results with 
those of lasers from literature review used to treat rosacea. We demonstrated a virtu-
ally side-effect free and successful treatment of the vascular abnormalities associated 
with rosacea using the intense pulse light source. In our department of Laser Therapy 
at the Medical Centre, Maastricht, the Netherlands sixty patients and a total of 508 
sites of telangiectasia due to rosacea in the face {chin, nose, forehead) were treated 
with a mean of 4.1 treatments per location with a spectrum ranging from 515-590 nm 
with different pulse durations between 4.3- 6.5 ms. The energy varied from 24 to 32 
J/cm2 • About half of the patients had no previous treatment before presenting at 
Maastricht Medical Centre. Some had been on an antibiotic therapy or other medica-
tion and/or had been treated with laser or coagulation therapy. 
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A mean clearance of 72 percent was achieved and maintained for a follow up period of 
about 4 years. Only in four treated sites, a recurrence of lesions was observed. Imme-
diate side-effects such as erythema, purpura and pain were observed in 62% of the 
patients. But they were slight and disappeared 24-96 hours after the treatment. 
In conclusion we infer that the PhotoDerm~L is an excellent device for treating vascu-
lar skin lesions if applied by experienced technicians. 
Clinical significance of an Intense Pulsed Light Source on leg telangiectasias of 
up to 1 mm diameter 
Leg telangiectasias are common, but difficult to treat. They can be dilated arterioles, 
venules or capillaries, usually related to chronic, venous insufficiency, and are much 
more common in women than in men. Cosmetic reasons are usually the motivation for 
seeing a dermatologist. With time the classical sclerocompression therapy was re-
placed by laser therapy for treating telangiectasias. Although some of the lasers 
showed good result, the side effects turned out to be severe enough to attempt treat-
ment with yet another device, relatively new at the time of the publication or this pa-
per, the intense light source (ILS), provided by way of the PhotoDerm®VL. The 
PhotoDerm®VL was used on 40 women of an average age of 41.7 years with 
telangiectasias of up to 1 mm on the upper leg. Since neither scarring, nor 
telangiectatic matting was seen nor did other side effects worth mentioning occur, the 
treatment with this flashlamp turned out to be very successful. The younger patients 
(under 30 years of age) and those above 70 showed the best results after this treat-
ment. In general three sessions were sufficient for a clearance of up to 1 00% in those 
above mentioned age groups, being around 75% for the age groups in between 30 
and 70. There were no recurrences seen during the follow up of one year. 
The outstanding results in the four research centres in the Netherlands, Germany and 
Switzerland in combination with the absence of side-effect lead us to the conclusion 
that the PhotoDerm~L is an excellent tool for leg telangiectasias up to 1 mm, but pos-
sibly also larger. 
Effective treatment of nevus of Ota with Intense Pulsed Light Source after 
incomplete clearance with q-switched Ruby laser 
Nevus of Ota, a pigmented lesion occurring normally along the distribution of the fifth 
cranial nerve has been treated more or less successfully in the past with 
dermabrasion, freezing and laser irradiation. The treatment of nevi of Ota using IPLS is 
relatively new, but so is the treatment attempt for pigmented lesions by lasers in gen-
eral. It proves to be effective with no permanent side effects and gives excellent cos-
metic result. Nevus of Ota is thought to occur mainly in the people of Asian descent 
but not exclusively. These lesions can be brown or blue-green, which are harder to 
treat. 
Lasers that are effective in the management of pigmented lesions include: the 
Q-switched ruby, Alexandrite, and Nd:YAG lasers. 
The purpose of treating nevus of Ota lesion is primarily a cosmetic one because it is 
not associated with increased risk of malignant transformation. We began treating the 
3 patients with a Q-switched ruby laser initially, but the results obtained were not uni-
form, there was a spotty appearance and the presence of discoloration and 
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hyperpigmentation was seen . We therefore switched to IPLS. Altogether success was 
recorded between 3 and 9 treatment sessions in intervals of 3 to 6 months. Although 
the treatment with IPLS takes a few more sessions than using a laser, the advantage 
of an optical homogenous fading of the pigment outweighs the time needed for 
treatment. 
The possibility of occurrence of side effects such as pigmental changes is virtually 
eliminated because of the versatility of the IPLS in catering to individual patient 
characteristics. 
We conclude that IPLS offers a new possibility for the treatment of Nevus of Ota and it 
can also be used to improve the skin structure after previous treatment with other la-
sers for pigmented lesions has left its traces. There are no permanent side effects and 
the cosmetic results are superior to those attempted with other lasers, although more 
treatment sessions are needed. 
Discussion 
For a long time now, light energy has been successfully used in medicine, especially in 
surgery and dermatology. New devices are continuously being developed which have 
extended and improved treatment possibilities for many cutaneous and congenital 
defects, (including vasular, pigmented lesions) and for hair removal. Improvements in 
laser and flash lamp technology and methods have provided more therapeutic options 
and better clinical results. The devices have become non-selective, non-ablative from 
having been selective, ablative, and longer pulse times instead of a short pulses has 
been developed. 
Originally it was speculated that melanin selectively absorbed laser light. Later is was 
established that the Q-Switched Ruby Laser (QSRL) targeted individual 
melanosomes, as well as the Alexandrite and Nd:YAG lasers with short pulses are ef-
fective in the management of pigmented lesions. The QSRL was reported to be very 
succesfull in completely removing flat acquired junctional melanocytic naevi. With 
IPLS longer pulse times were used and a clearance of 76-100% was obtained for su-
perficial lesions such as ephelides, epidermal melasma, and cafe au lait macule. Fur-
ther research led to the development of the pulsed dye laser, which was the first laser, 
where the principles of selective photothermolysis were applied to eliminate marks 
without damaging surrounding skin. Lasers were used in the treatment of vascular 
birthmarks (port-wine stains and hemangiomas) as well as for rosacea and facial 
telangiectasias. The treatment of vascular lesions is efficiently carried out with the 
IPLS where longer pulses are used in contrast to lasers and a good and complete 
clearance in 70% of the portwine stains was obtained. 
In the treatment of leg veins mixed results of success were obtained using lasers and 
IPLS with 75-100% clearance using the IPLS. 
In some instances, hair loss was observed that occurred accidentally in the treated ar-
eas, which led to experiments in epilation on animal models and later humans. 39 
Since then, there have been several studies on hair-removal using different lasers and 
flash lamps with long-lasting hair reduction of 80% achieved after 8 months with a sec-
ond-generation IPLS. 
Today lasers and flashlamps are extensively being used in skin rejuvenaton and in the 
permanent removal or reduction of blemishes. However, the side effects associated 
113 
with lasers, such as exudation and crusting followed by long-lasting erythema and a 
downtime of at least two weeks and redness in the treated areas that can occur up to 
a few months, makes IPLS the better choice in treatment. 
IPLS devices offer sophisticated, computer-driven precision and tremendous versatil-
ity. Due to the nature of the treatment, IPLS energy can be applied to the subsurface 
skin layers for gentle and gradual results with recuded side effects and patient down-
time. For certain aesthetic prodecures, IPLS technology provides a refining touch over 
lasers. All aspects of photo-damage including wrinkling, skin coarseness, irregular 
pigmentation, pore size, and telangiectasias showed visible improvement in more 
than 90% of subjects. The IPLS has several distinct advantages over lasers mainly 
arising from its flexibility in allowing a wide range of settings relating to individual pa-
tient characteristics, such as the modification of various parameters that include 
wavelength, fluence, pulse duration, pulse delay, pulse sequence, and temperature 
control of the skin. It saves time as surfaces of 2.8 cm2 to 5.6 cm2 per pulse can be 
treated, which also reduces operational cost. 
Conclusion 
We can conclude from our experiences that flashlamps give excellent results in per-
manent hair removal and vascular skin lesions. Compared to lasers a lesser number of 
treatments is needed tot get a clearance of up to 95%. 
Skin rejuvenation and skin improvement are issues of great interest these days. This 
gives us the major impetus for continuing investigation in this field. 
Indeed the IPLS is an outstanding , revolutionary new mini-procedure, which is effec-
tive in the treament of aging skin or liver spots, fine wrinkles, facial flushing , redness, 
broken capillaries, telangiectasia, hemangiomas, freckles, minor sun damage, port 
wine stains, tattoos, varicose veins, spider veins, flat birth marks, hypo-pigmentation 




Dit artikel bespreekt lasers en laser-achtige apparaten, zoals flitslampen. 
Het woord ' laser' is een acroniem voor 'Light Amplification by Stimulated Emission of 
Radiation' . De laser produceert Iicht uit het zichtbare en infrarode spectrum in een 
lichtbundel met een hoge spectral density op een zeer klein oppervlak. Er zijn diverse 
soorten lasers gebruikt voor vele medische doeleinden. Zo worden bijvoorbeeld 
C02-lasers succesvol gebruikt bij de behandeling van afwijkingen aan het huidopper-
vlak, zoals rimpels, littekens, schade t.g.v. zonlicht, benigne huidafwijkingen en rhino-
pyeem. Oak vaatafwijkingen, zoals wijnvlekken, heamangiomen, teleangiectasieen, 
rosacea en spider naevi, worden succesvol behandeld met flash lamp pumped dye la-
sers. a-switched lasers produceren ultra korte pulsen met een hoge intensiteit en zijn 
effectief voor het verwijderen van tatoeages en enkele benigne gepigmenteerde 
leasies. 
Een lasersysteem is opgebouwd uit drie essentiele componenten . Ten eerste is er het 
Lasing medium: een gas, kristal, vloeistof of semiconductor. Ten tweede is er de 
Source of excitation voor het lasing medium, bijvoorbeeld flitslampen of continu Iicht, 
diodes, high voltage discharge, radiogolven en in sommige gevallen een andere laser. 
Het laatste component bestaat uit de spiegels, die de geexciteerde fotonen reflec-
teren naar de resonant cavity waar het lasing medium zich in bevindt. 
Als het lasing medium wordt geexciteerd worden de moleculen aangeslagen. Enkele 
van deze geexciteerde moleculen vallen spontaan terug in hun oude energieniveau 
(ground state), waardoor er een foton vrij komt. Als dit foton in de juiste richting wordt 
uitgestraald , zal het een van de spiegels aan het uiteinde van de resonant cavity raken, 
waardoor deze weer terug gestuurd wordt. Dit geexciteerde foton kan andere 
geexciteerde moleculen door middel van een botsing er toe aanzetten oak een foton 
uit te zenden door terug te vallen naar de ground state. Het vrijgekomen foton 
beweegt in dezelfde richting als de eerste en zo wordt er een cascade op gang 
gebracht. Er is sprake van een netto amplificatie van lichtenergie als het gros van de 
moleculen in het lasing medium zich in de aangeslagen toestand bevindt (population 
inversion). 
De a-switched laser is een laser waarbij de stand van het apparaat, dat de grate 
losses in de resonant cavity veroorzaakt en de lasing operation voorkomt, plotseling 
omgeschakeld kan worden naar een stand waarbij het apparaat slechts kleine losses 
introduceert. Hierdoor neemt de quality factor in de lasing cavity snel toe, waardoor er 
een build-up ontstaat van een korte en zeer sterke laser pulse. De duur van zo een 
pulse is niet Ianger dan enkele nanoseconden (ns). 
In tegenstelling tot gewoon Iicht is laserlicht coherent, monochroom met een parallelle 
eigenschap. Coherent betekent dat de lichtgolven zijn gesynchroniseerd, van de 
laserstraal en monochroom betekent dat de laserstraal bestaat uit een enkele 
golflengte/kleur Iicht. De eenheid die men gebruikt om de totale energie van de 
laserpulse of -systeem uit te drukken is Joule (J). Fluence is de dosis ,stated' in J/cm2 • 
De energy intensity van de laser per oppervlak wordt gemeten in W/cm2 • De golflengte 
(?) is gerelateerd aan stimulated energy transition: hoe korter de golflengte, hoe hager 
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de energie van het foton. De oppervlakte van de focal spot bepaalt de maxi male en-
ergy density die bereikt kan worden als de kracht van de laserstraal wordt ingesteld. 
De diepte van de focus is de afstand waarover de gefocuste straal ongeveer dezelfde 
intensiteit behoudt. Zoals gezegd is laserlicht monochroom en hierdoor heeft het een 
niet selectief effect op biologisch weefsel als het wordt (door)geleid, verspreid , 
gereflecteerd of geabsorbeerd. Het Iicht moet geabsorbeerd worden om enig 
biologisch effect te veroorzaken en een bepaalde golflengte kan sterk worden 
geabsorbeerd door een bepaald type weefsel, terwijl het door een ander type juist 
wordt doorgelaten. De componenten van het weefsel zijn bepalend voor deze 
eigenschappen. De belangrijkste absorberende componenten (chromophores) van 
het lichaam zijn: hemoglobine in bloed, melanine in de huid, haar, 'moles' en water 
(deze laatste is aanwezig in aile biologische weefsels) 
Als het laserlicht wordt geabsorbeerd, Ievert deze energie aan het weefsel. Een in-
tense, maar korte puis laserlicht veroorzaakt meestal een explosieve uitzetting van 
weefsel (fotomechanische reactie). Een minder intense, langere puis veroorzaakt een 
snelle verhitting (fotothermale reactie). Selectieve fotothermolyse is het proces 
waarbij het vrijkomen van laserenergie wordt beperkt tot een bepaalde plek door de 
selectieve absorptie van een chromophore. 
Intense Pulsed Light Source (IPLS), ook wei de flitslamp genoemd, wordt 
tegenwoordig gebruikt voor de behandeling van dermatologische aandoeningen in 
hetzelfde spectrum als de laser. De IPLS is een apparaat dat non-coherent Iicht en 
low-range infrarode straling filtert, waardoor er specifieke golflengtes geselecteerd 
kunnen worden. Deze kunnen succesvol worden gebruikt bij de behandeling van 
gepigmenteerde laesies, zoals moedervlekken, spider naevi in het gezicht, varices, 
maar ook voor de verwijdering van ongewenste haargroei. De aanschafkosten van de 
apparatuur en kosten per behandeling zijn gelijk aan die van vergelijkbare lasers. 
Een flitslamp is een booglamp die, in de pulse mode, in staat is om opgeslagen 
elektrische energie om te zetten in sterke uitbarstingen van radiant energy 
opgebouwd uit Iicht van het ultraviolette, zichtbare en infrarode lichtspectrum. Xenon 
wordt het meest gebruikt in flitslampen, aangezien het het meest efficiente edelgas is 
in het omzetten van elektrische energie in optische energie. 
Een bekend type Xenon-flitslamp in de lineaire Xenon-flitslamp. Het is opgebouwd uit 
een buis van quartz met twee gesealde electrodes: de kathode en anode. Deze zijn 
gemaakt van tungsten of van speciale low-sputtering materialen. Gebruikelijk is een 
flitslamp gevuld met Xenon-gas onder een druk van 200 tot 400 Torr. De energy load 
van een flitslamp is over het algemeen tussen een paar tot enkele honderden Joules. 
Het lichtspectrum van een flitslamp is ongeveer gelijk aan dat van de zon. 
Flitslampen, ofwel IPLS, zijn een perfecte aanvulling op de laser lichtbronnen. Ze 
hebben een breed spectrum van lichtenergie in vele golflengtes. IPLS voorziet veel 
lichtenergie in pulsen van slechts enkele milliseconden. IPLS-apparaten zijn zeer 
nauwkeurig en hebben een grote versatiliteit. De IPLS kan worden gebruikt voor de 
sub-surface lagen van de huid, met graduele resultaten, minder bijwerkingen en een 
kortere herstelperiode voor de patient door de aard van de behandeling. 
Zoals eerder genoemd, gebruiken flitslampen niet een golflengte zoals men dat bij de 
laser ziet. Flitslampen stralen iedere golflengte van het zichtbare lichtspectrum uit en 
een kleine band van het infrarode lichtspectrum (tot en met 1200 nm). Artsen kunnen 
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een cut-off filter selecteren om lagere golflengtes weg te filteren. De meeste 
fl itslampen kunnen ook met hun straal een groter oppervlak behandelen dan de laser. 
Transforming growth factor-beta en extracellulaire matrix stimulatie door 
Intense Pulsed Licht Sources: een experimentele studie 
De normale reactie op weefselbeschadiging is inflammatie. Macrofagen en neutrofie-
len komen naar het gewonde gebied en beginnen met het opruimen van vreemd mate-
riaal en dode cell en. Hi ern a begint de proliferatie van fibroblasten , die de synthese van 
extracellulaire matrix (ECM) stimuleren . Verschillende groeifactoren spelen een be-
langrijke rol in dit reconstructieproces. Transforming growth factor (TGF) is een van 
deze belangrijke eiwitten. Een van zijn functies is de stimulatie van de productie van 
ECM. Onder de eiwitten waarTGF effect op heeft is de tenascine familie van glycopro-
te"lnen (TN). Zij komen tot uiting in volwassen bij processen zoals wondheling , 
vasculaire pathologie en tumorgenese. 
Tenascine en TGF lijken een belangrijke rol te hebben bij de bescherming voor 
verschillende ziektes zoals kanker en tussenwervelschijf degeneratie. 
Het doel van onze studie was het onderzoeken van de stimulatie van TGF en het vrij-
komen van ECM prote"lnen zoals tenascine na bestraling met intense pulserende Iicht 
bronnen. 
We behandelen twee varkens met de Vasculight"' en de Quantum"' Iicht bronnen vijf 
keer. Op verschillende momenten na elke behandeling werden er biopten afgenomen. 
Een totaal aantal van 240 biopten werd verzameld . De biopten werden microscopisch 
onderzocht met immunohistochemie. 
We zagen variaties in het niveau van de TGF concentraties die afhankelijk waren van 
de tijd na de behandeling . Vooral na een week en na 60 dagen werden er hoge 
concentraties van TGF-beta geobserveerd. 
We zag en ook variaties in de concentratie van tenascine. Vooral na twee weken zagen 
we een stijging van de tenascine concentratie in de epidermis en dermis en een daling 
van de tenascine concentratie in de plasmacellen. 
Dus het lijkt erop dat radiatie met een intense pulserende flitslamp een exogene stim-
ulus is om een kunstmatige wond te veroorzaken, die weer zorgt voor een activatie 
van latent TGF-beta en tenascine. 
Haarverwijdering bij 40 overbehaarde vrouwen met een Intense Pulsed l ight 
Source 
In deze studie wordt haarverwijdering beschreven met een IPLS flitslamp waarbij 
geen bijwerkingen optreden zoals littekens of kleine wondjes. In deze studie zijn 5 
centra betrokken in Duitsland, Nederland en Zwitserland . De studie had betrekking op 
40 vrouwen met een gemiddelde leeftijd van 38.6 jaar met overbeharing op de boven-
lip en kin ; de haarkleur was verschillend . Over het algemeen was het ongewenste haar 
verdwenen binnen 6 behandelingen met een succes ratio van 76.7%. Er waren vrijwel 
geen bijwerkingen en er werd bijna geen pijn ervaren. 
De PhotoDerm"'VL is een flexibeler instrument dan een laser doordat het een breder 
gamma aan settings aanbiedt, deze kunnen aangepast worden aan de individuele 
karakteristieken van de patient door een ervaren technicus. Net als lasers is de 
werking gebaseerd op het principe van selectieve thermolyse. 
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De afwezigheid van bijwerkingen en de hoge clearance rate laat ons concluderen dat 
de IPLS een ideale manier is voor de verwijdering van ongewenst haar. Maar er is 
verder onderzoek nodig om aan teton en dat de haarverwijdering ook op lange termijn 
een succes blijft. 
Negentig procent permanente haarverwijdering bij transseksuele patienten 
Transseksualiteit, een syndroom dat geclassificeerd is als een geslachtsidentiteits-
stoornis met de wil om ongewenst haar op het lichaam te verwijderen om er vrouwelij-
ker uit te zien. Deze studie gaat over patienten die zijn behandeld met een Intense Pul-
sed Light Source (IPLS) daar dit een ideale methode is voor haarverwijdering. 
Een effectieve, permanente haarverwijderingsmethode is ideaal voor transseksuelen 
als onderdeel van hun aanpak bij geslachtsverandering. Verscheidene methodes 
zoals verschillende types elektrolyse en laser epilatie worden gebruikt met uiteen-
lopende effectiviteit. Deze studie betreft vijfentwintig transseksuele patienten bij wie 
een permanente methode van haarverwijdering van psychologisch belang is tijdens 
hun proces. De patienten zijn tussen 22 en 67 jaar en zijn behandeld in drie centra in 
Nederland, Duitsland en Zwitserland. Een Intense Pulsed Light Source, 
PhotoDerm~L werd gebruikt. Gemiddeld verdween 90% van de haren bij een 
gemiddelde van 9 behandelingen, met een gemiddelde follow-up van 44 maanden. 
Wij concluderen dat het Intense Pulsed Light System een effectieve methode is voor 
permanente haarverwijdering bij transseksuele patienten daar het tijd en geld spaart 
en pijnloos is. 
Haar reductie door gebruik van een Intense Pulsed Light Source 
De aanpak van hirsutisme blijft een uitdaging voor dermatologen en plastisch chirur-
gen. Verschillende lasers en laserachtige apparaten worden tegenwoordig gebruikt 
om haar te verwijderen maar er is maar weinig bekend over de resultaten op lange ter-
mijn. Vrouwen met ongewenst haar in het gezicht, hals of een ander deel van het 
lichaam hebben fysische en sociale problemen. 
Aile laserbehandelingen hebben gemeen dat de laserstraal diep in de dermis 
penetreert met als doel de haarfollikels te raken en selectief geabsorbeerd te worden 
door het melanine. Oak de intense pulserende lichtbronnen, PhotoDerm~L en 
Epilight werken volgens dit principe. Het is flexibeler dan lasers omdat het door een 
ervaren specialist aangepast kan worden aan de eigenschappen van de individuele 
patient. 
Deze studie gaat over de permanentie van haarverwijdering met behulp van de IPLS 
bij 70 vrouwelijke patienten tussen 18-67 jaar die behandeld werden in het Medisch 
Centrum Maastricht, Nederland voor ongewenst haar op kin en bovenlip. De 
gemiddelde leeftijd van de meestal donkerharige patienten met verschil lende 
huidtypes was 41 jaar. Zij werden gemiddeld 8 keer behandeld en gemiddeld 
opgevolgd gedurende 27,4 maanden. Dit is Ianger dan de complete groeicyclus van 
de follikels en toont zo de permanentie aan. Bij het gebruik van de IPLS bereikte men 
een haarvermindering van 87% zonder bijwerkingen. We concluderen dat IPLS ons 
een effectieve methode biedt voor lange termijn haarverwijdering zonder 
bijwerkingen. 
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De PhotoDerm"'VI flitslamp als een nieuwe behandelingsmogelijkheid voor 
vasculaire huidlaesies 
Dit artikel gaat over de behandeling van vasculaire huidafwijkingen zoals teleangiecta-
sien in het gezicht of op het been, spider naevi, erythrosis interfollicularis en seniele 
angiomas. De reden om deze uitgebreide lineaire, aborizing, spiders en punctiforme 
venules, capillairen en arteriolen te behandelen is meestal een cosmetische. Met wis-
selend resultaat worden er vershcillende lasers gebruikt bij de behandeling van deze 
afwijkingen . In dit artikel wordt de behandeling van vasculaire laesies besproken met 
de PhotoDerm"VL flitslamp. De mogelijkheden en de beperkingen van dit apparaat 
worden besproken. 
Op de afdeling lasertherapie van het Medisch Centrum Maastricht werden in totaal 
120 patienten at random gekozen en behandeld met de PhotoDerm"VL. De clearance 
rate van 84,3% werd behaald bij telangiectasien op het been met een grootte tot 
1 mm. 95% van de faciale telangiectasien en 80% van de erythrosis interfollicularis 
verdween. Spider naevi en seniele angioma's verdwenen na een enkele behandeling. 
Terwijl vorige studies over de behandeling met andere lasers bijwerkingen toonden, 
zoals: littekens, permanente pigmentatie, hemorrhage, hypo- of hyperpigmentatie, 
toont de behandeling met de PhotoDerm"VL bijna geen van deze bijwerkingen. 
Wanneer deze wei optraden dan verdwenen ze weer snel. 
Een belangrijke factor is de keuze van setting variabelen en dit maakt een deskundige 
technicus een must. De range van settings bepaalt de clearance rate. Te weinig 
energie zal de vaten niet occluderen; te veel energie daarentegen veroorzaakt te veel 
warmte, hetgeen leidt tot blaar- en littekenvorming en depigmentatie. 
De nadelen van het apparaat zijn op hetzelfde moment de sleutel naar een goede 
behandeling. Concluderend is de PhotoDerm"VL flitslamp een excellente methode bij 
de behandeling van vasculaire laesies indien toegepast door een ervaren arts. 
Behandeling van rosacea met de PhotoDerm"'VL 
Rosacea is een veelvoorkomende maar oak vaak over het hoofd geziene huidaandoe-
ning die kan leiden tot significante gezichtsmisvormingen, oogcomplicaties en ernsti-
ge emotionele ellende. Het ziektebeloop van rosacea bestaat uit typische fases: blo-
zend gezicht, erytheem en/of oedeem als oak oculaire symptomen, papels en pustels, 
en rhinophyma. Het is een idiopatische, wijdverspreide chronische huidaandoening 
die meestal zichtbaar wordt tussen 40 en 50 jaar. De exacte oorzaken van rosacea zijn 
onbekend maar het blijkt een combinatie van factoren te zijn. 
Verschillende lasers worden gebruikt om vasculaire huidlaesies te behandelen. Er 
waren vaak bijwerkingen als hypopigmentatie, littekens, blaarvorming en pijn. Bij de 
behandeling met een intense pulserende lichtbron wordt gebruik gemaakt van het 
principe van selectieve fototthermolyse. Hierbij werkt de energie in op een specifiek 
doel (hier erythrocyten) waardoor men de vorming van littekens van het omliggende 
weefsel tegengaat. 
Het doel van deze studie is de behandeling te tonen van vasculaire aandoeningen 
geassocieerd met rosacea gebruik makend van de Intense Pulse Light bran en de 
resultaten te vergelijken met die van de reeds Ianger bestaande lasers. Binnen onze 
afdeling Lasertherapie van het Medisch Centrum Maastricht, Nederland werden 60 
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patienten {508 locaties) met teleangiectasien te wijten aan rosacea in het gezicht 
gemiddeld aantal van 4,1 keer behandeld per locatie. 
Gemiddeld verdween 72% van de laesies en dit resultaat werd behouden gedurende 
een follow-up van ongeveer 4 jaar. In slechts 4 behandelde gebieden werd er een 
terugkomst van de laesie gezien. 
Wij concluderen dat de PhotoDermOVL een uitstekend middel is voor de behandeling 
van vasculaire huidlaesies indien toegepast door een ervaren deskundige. 
Klinische significantie van een Intense Pulsed light Source op teleangiectasien 
tot 1 mm diameter op het been . 
Been teleangiectasien komen veel voor maar zijn moeilijk te behandelen. Ze kunnen 
bestaan uit gedilateerde arteriolen, venulen of capillairen , meestal zijn ze gerelateerd 
aan chronische veneuze insufficientie, wat veel meer bij vrouwen dan bij mannen 
voorkomt. Cosmetische redenen zijn meestal de aanleiding om naar een dermatoloog 
te gaan. Gedurende de tijd is de klassieke sclerocompressie therapie vervangen door 
lasertherapie om teleangiectasien te behandelen. Ook allieten sommige lasers goede 
resultaten zien, de bijwerkingen bleken echter ook ernstig genoeg om een andere be-
handelingsmethode te proberen, relatief nieuw ten tijde van de publicatie van dit arti-
kel , is de intense Iicht bron in de vorm van de PhotoDermOVL. Net als andere lasers ge-
bruikt de PhotoDermOVL het principe van selectieve fotothermolyse. Het is echter 
meer flexibel dan andere lasers omdat het een grote variatie aanbiedt in instellingen 
die aangepast kunnen worden door een ervaren specialist aan de karakteristieken van 
de individuele patient. 
Als behandelingsmethode werd bij 40 vrouwen met teleangiectasien tot 1 mm op het 
bovenbeen met een gemiddelde leeftijd van 41,7 jaar de PhotoDermOVL gebruikt. Er 
waren geen verschijnselen van bijwerkingen zoals littekens of matvorming dus de 
behandeling met de flitslamp bleek erg succesvol. De jongere patienten (onder de 30 
jaar) en degenen boven de 70 jaar lieten de beste resultaten zien na deze behandeling . 
Over het algemeen waren drie behandelingen voldoende om een clearance te 
bereiken tot 100% in de hierboven genoemde groepen, in de groep tussen de 30 en 
de 70 jaar werd een clearance tot 75% bereikt. Er werden geen recidieven gezien 
gedurende een follow-up periode van een jaar. 
De uitstekende resultaten die werden behaald in de vier onderzoekscentra in 
Nederland, Duitsland en Zwitserland in combinatie met het gebrek aan bijwerkingen 
leidde tot de conclusie dat de PhotoDermOVL een excellente methode is voor de 
behandeling van been teleangiectasien tot 1 mm, maar mogelijk ook groter. 
Effectieve behandeling bij naevus van Ota met Intense Pulsed light Source na 
onvolledige verdwijning met q-switched Ruby laser. 
Een naevus van Ota is een gepigmenteerde laesie die normaal uittreedt rond de distri-
butie van de 5°" hoofdzenuw. Het komt vooral voor bij personen van Aziatische af-
komst maar niet uitsluitend. De laesies kunnen bruin of blauwgroen zijn, welke moeilij-
ker zijn om te behandelen. 
Het doel van de behandeling van de naevus van Ota is eerder cosmetisch want deze 
laesie is niet geassocieerd met een verhoogde kans op maligniteit. In het verleden 
werden de naevi behandeld met dermabrasion, bevriezen en laserbestraling. De 
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behandeling met laserbestraling geaf geen uniforme resultaten. De laesie werd 
vlekkerig en er werd verkleuring en hyperpigmentatie gezien. Daardoor zijn we 
overgeschakeld op de intense pulserende lichtbron (IPLS). 
De behandeling van naevi van Ota met behulp van een intense pulserende lichtbron 
bewijst effectief te zijn zonder permanente bijwerkingen en geeft een uitstekend 
cosmetisch resultaat. Ook al duurt deze methode enkele sessies Ianger, de voordelen 
van een optisch gelijkmatig webebbende vlek overtreffen de behandelingstijd . 
Drie patienten zijn behandeld met een verbetering na 3 tot 9 behandelingen met een 
interval van 3 tot 6 maanden. 
De kans op de bijwerkingen zoals pigment veranderingen is minimaal door de 
veelzijdigheid van de IPLS in catering to individual patient characteristics. 
Samengevat, kunnen we besluiten dat IPLS een nieuwe methode aanbiedt ter 
behandeling van de naevus van Ota. Er zijn geen permanente bijwerkingen en de 
cosmetische resultaten zijn beter dan bij andere behandelingen. 
Discussie 
Lichtenergie wordt al vele jaren succesvol gebruikt in de geneeskunde, met name bin-
nen de vakgebieden chirurgie en dermatologie. Nieuwe apparaten zijn voortdurend in 
ontwikkeling , waardoor de behandelingsmogelijkheden voor vele congenitale en 
huidafwijkingen (vasculaire malformaties, pigmentlaesies) en haarverwijdering ver-
ruimd worden. Verbeteringen in de laser- en flitslamptechnologie en -methodes zor-
gen voor betere klinische resultaten en meer behandelingsmogelijkheden. De appara-
ten zijn dus ontwikkeld van zeer selectief tot non-selectief, van ablatief tot non-ablatief 
en van een korte tot een langere pulse. 
Oorspronkelijk werd gedacht dat melanine het laserlicht specifiek absorbeert. Later 
werd vastgesteld dat de Q-switched ruby laser (QSRL) individuele melanosomen tar-
get en dat dit soort lasers, evenals de Alexandrite en Nd:YAG laser met korte pulse, 
effectief zijn in de behandeling van van pigmentlaesies. De QSRL bleek erg effectief in 
het verwijderen van flat aqcuired juctional melanocytic nevi. Dit was de eerste laser 
waarbij selectieve fotothermolyse werden toegepast, welke aandoeningen verwijdert, 
zonder de omliggende huid te beschadigen. Verder onderzoek leidde tot de 
ontwikkeling van de pulsed dye laser. Lasers werden gebruikt voor de behandeling 
van aangeboren vasculaire malformaties, zoals wijnvlekken en hemangiomen en ook 
voor de behandeling van rosacea en faciale telangiectasieen . De IPLS is een goede 
behandelingsmethode voor vasculaire laesies. Deze werkt met langere pulsen, dit in 
tegenstelling tot lasers, waardoor een goede en volledige clearance wordt bereikt bij 
70% van de laesies. Gemengd succes was er bij de behandeling van varices met la-
sers en IPLS. Met de IPLS werd een clearance van 75-100% bereikt. Een langere 
pulseduur kon worden gebruikt bij de IPLS en een clearance van 76-100% werd 
bereikt bij het behandelen van ephilides, epidermale melasma en cafe-au-lait vlekken . 
In enkele gevallen werd er haarverlies in de behandelde huidoppervlakken geconsta-
teerd. Dit leidde tot experimenten met laser en haarverwijdering, eerst op diermodellen, 
later op mensen. Sindsdien zijn er diverse studies gedaan naar haarverwijdering met 
verschillende types lase en flitslampen. Na 8 maanden werd er met een tweede 
generatie flitslamp een 80,2% langdurige reductie in haargroei bereikt. 
121 
Tegenwoordig worden lasers en flitslampen extensief gebruikt op het gebied van 
huidverjonging en permanente verwijdering of reductie van huidvlekken. De bij-
werkingen van lasers, zoals exudatie en korstvorming gevolgd door langdurig 
erytheem en een downtime van tenminste twee weken en roodheid in het behandeld 
oppervlak maakt echter de IPLS een betere behandelingsmogelijkheid. 
IPLS apparaten bieden een grote veelzijdigheid en enorme nauwkeurigheid. Door de 
aard van de behandeling kan IPLS-energie worden toegepast in de dermis met een 
geleidelijk resultaat en minder bijwerkingen en een kortere downtime. IPLS-
technologie voorziet in bepaalde esthetische behandelingen een 'refining touch' . Een 
zichtbare verbetering werd gezien in 90% van de gevallen bij de behandeling. Dit geldt 
voor aile aspecten van photo damage, zoals rimpeling, irregulaire pigmentatie, 
poriegrootte, telangectasieen en een grove huid. De IPLS heeft diverse significante 
voordelen in vergelijking met lasers, met name op het gebied van flexibiliteit: een wijde 
range van settings waardoor de behandeling kan worden afgesteld op de 
karakteristieken van de patient. De IPLS bespaart tijd en kosten door het grote 
behandelingsoppervlak per pulse van 2,8 to 5,6 cm2 • 
Conclusie 
Uit onze ervaringen kunnen we concluderen dat de flitslamp uitstekende resultaten 
laat zien in de permanente verwijdering van haar en de behandeling van vasculaire 
huidlaesies. In vergelijking met lasers zijn er minder behandelingen nodig om een cle-
arance van 95% te bereiken. Huidverjonging en huidverbetering zijn issues die steeds 
meer aandacht krijgen. Deze ontwikkeling is onze drijfveer om onderzoek op dit 
gebied voort te zetten. 
De IPLS is inderdaad een uitstekende, revolutionaire nieuwe mini-procedure in de 
behandeling van ouderdoms- of levervlekken, kleine rimpels, roodheid, gebarsten 
capillairen, telangiectasien, hemangiomen, freckles, kleine zonbeschadigingen, wijn-
vlekken, tatoeages, varices, spider veins, platte moedervlekken, hypopigmentatie en 
zelfs ongewenste haargroei. 
122 
Dankwoord 
Allereerst dank aan prof. Neumann, de inspirator van dit proefschrift. 
Beste Martino, ik wil je bed an ken voor de steun en het geduld om dit proefschrift af te 
ronden. Jouw enthousiasme voor het onderwijs, tesamen patienten behandelen en de 
conclusies hiervan zijn een deel van dit proefschrift geweest. 
Professor Neumann heeft ideeen tot studies gegeven en de artikelen voor publicatie 
steeds weer gecorrigeerd. 
Professor van Gernert, professor Oosterhuis, professor Hovius en dr Sterenborg voor 
het becommentarieren van dit manuscript. 
Professor Mario Castellucci die de gelegenheid gaf in zijn instituut in Ancona het 
wetenschappelijk onderzoek, uit te voeren. Vanuit zijn ervaring op extracellulaire ma-
trix prote·in is de studie ECM tot stand gekomen. Naar aanleiding van deze resultaten 
en de conclusies ervan ontstaan weer nieuwe ideeen die van belang zijn voor nieuwe 
technische ontwikkelingen. 
De afdeling pathologie van professor De Potter in Gent met wie ik de weten-
schappelijke basis heb gelegd voor het het mechanisme van haarverwijdering. 
Thorsten Reineke, statisticus uit Aken die al de jaren de statistiek van studies heeft 
verricht. 
Dr Moore voor het becommentarieren en corrigeren van de Engelse tekst van dit 
manuscript. 
Daniela Marzioni die als biologe het histologisch onderzoek heeft verricht op 
extracellulaire matrix prote·inen. 
Wasila Abu baker die sam en met mij op de OK van het CPV biopten heeft gena men en 
verzorgd. 
Afdeling CPW die het dierkundig gedeelte van de studies heeft uitgevoerd. 
Frau Hulse, die de engelse manuscripten en lay outs voor de publicaties heeft 
gecorrigeerd. 
Els Wachelder, Karola Watschke en Lydia Coerver, de secretaresses die het 
proefschrift hebben overgenomen en steeds de correcties hebben toegepast. 
Wil Lokkerbol als aanspreekpartner voor de Rotterdamse contacten. 
Onze studenten , Judith, Claire, Jan, Koert-Jan, Marijke, Petra, Marjanka, Jerome, 
Laurens, Claudia, lise, Muriel, en Gemma, Bas die data van patienten hebben 
verzameld en verwerkt. 
Datawyse voor de snelle en professionele verzorging van dit proefschrift. 




Afgestudeerd in januari 1984 aan de Universiteit Limburg, Maastricht in Nederland. 
Daarna 5 jaar algemene heelkunde gevolgd in Nederland en lerland, tussendoor een 
jaar in het Fatima College, Medical School , Lahore, Pakistan in de oncologische 
chirurgie gewerkt te zijner tijd ook onderzoek op borstkanker en placenta vooral op 
het C-erbB-2 oncogen en aanvullende publicaties gedaan. 
Een laserbasisopleiding gevolgd in Berlijn in het Laser Medizinisches Zentrum (LMZ) 
bij prof. Berlien, diverse stages in lasers gevolgd. 
Ze leidt sinds november 1994 de afdeling lasertherapie. 
Auteur en co-auteur van internationale publicaties over flitslampen en lasers. Sinds 
1998 op nationaal en internationaal niveau opleidingen in flitslampen en bijbehorende 
therapieen. 
In november 2003 de laser award van ILLAS (International Laser Light Association) 
Trier, Duitsland voor wetenschappelijk onderzoek in flitslampen en lasers ontvangen. 
Biography 
C. Schroeter graduated from the University of Limburg, Maastricht, the Netherlands in 
1984 with a degree in general medicine. From 1985 to 1992 she followed a training in 
general surgery in the Netherlands, followed by a one-year oncologic surgery at 
Fatima Hospital Medical School, Lahore Pakistan and joined by two years general sur-
gery residency in Ireland. In 1992 she completed a scientific year where she investi-
gated oncogenes such as C-erbB-2 in breast cancer and placenta morphogenesis 
resulting in several publications. A basic training in laser physics and laser therapy 
was performed at the Laser Medizinisches Zentrum (LMZ) of prof Berlien, Berlin, Ger-
many. From 1994 to the present, she serves as the Head of the Department of 
Lasertherapy in Maastricht, the Netherlands and is an active speaker and author in the 
area of Laser and flashlamp therapy. In November 2003 she was awarded the Interna-
tional Laserlight award (ILLAS) for her scientific research in Trier, Germany. 
125 
list of publications 
Schroeter CA, De Potter CR, Rathsmann K, Willighagen RGJ & Greep JC. C-erbB-2 
positive tumours behave more agressively in the first years after diagnosis. BR J Can-
cer 1992; 66:728-734. 
De Potter CR, Foschini MP, Schelfhout AM, Schroeter C.A & Eusebi V. 
Immunohistochemical study of neu protein overexpression in clinging in situ carcinoma 
of the breast. Virchows Archiv A Path Anat 1993; 422:375-380. 
Castellucci M, et al. Extravillous trophoblast: Immunohistochemical localization of 
extracellular matrix molecules. Frontiers in Gynaecologic and Obstetric Investigation 
1993: Edited by AR Genazzani, F Petraglia & AD Genazzani. 
De Potter CR, Schelfhout AM , Verbeeck P, Lakhani SR, Brunken R, Schroeter C.A, Van 
den Tweel JG, Schauer AJ & Sloane JP. Neu-overexpression correlates with extent of 
disease in large cell ductal carcinoma in situ of the breast. Human Pathol 1995; 26: 
Muhlhauser J, Crescimanno C, Kaufmann P, Hofler H, Zaccheo D & Castelucci M. Dif-
ferentiation and proliferation patterns in human trophoblast revealed by c-erbB-2 
oncogene product and EGFR. J Histochem and Cytochem 1993; 41 /2: 165-173. 
Schroeter C.A, Castellucci M. Expression of c-erbB-3 in the human placenta and 
trophoblast cell lines. 2004. Submitted to Lab Invest. 
Hellwig S, Raulin C, Schroeter. Behandlung essentieller Telangiectasien durch das 
PhotoDerm"VL. Z Hautkr. 1996;71 :44-4 7 
Schroeter C.A, Wilder D, Reineke Th, Thurlimann W, Raulin Ch, Neumann H.A.M. 
Clinical significance of an intense, pulsed light source on leg telangiectasias of up to 1 
mm diameter. Eur J Dermatol1997, 7: 38-42 
Raulin C, Schroeter C.A, Naushagen-Schnaas E. Einsatzgebiete einer hoch-
energetischen Blitzlampe (PhotoDerm"VL). Hautarzt 1997, 48:886-893 
S. Werner, C.A. Schroeter, M. Dresner, H. Tiel, Chr. Raulin. Neue Moglichkeiten der 
Epilation durch eine hochenergetische Blitzlampe. Eur J Dermatologie 1997, 1 : 3-7 
C.A.Schroeter, Neumann H.A.M. An intense light source. The PhotoDerm 
VL-Fiashlamp as a new treatment possibility for vascular skin lesions. American Soci-
ety for Dermatologic Surgery, Dermatol Surg 1998, 24: 7 43-7 48 
Raulin C, Schroeter CA, Maushagen-Schnaas. Vaskulare Hautveranderungen -
Behandlung mit einer hochernergetischen Blitzlampe. T&E Dermatologie 1998, 28: 
136-138. 
126 
C.A. Schroeter, Chr. Raulin , W. Thurlimann, T. Reineke,C. De Potter, H.A.M. Neumann. 
Hair loss in 40 hirsute women with an intense light source, the PhotoDerm~L. Eur J 
Dermatol 1999; 9: 37 4-379. 
Saskia Werner, C.A. Schroeter, Chr. Raulin , R.A. Weiss, M. Keiner. Treatment of 
Port-wine Stains with a Noncoherent Pulsed Light Source. Arch Dermatol. 1999; 
135:679-683 
Thissen MR, Schroeter CA, Neumann HA. Effective photodynamic therapy with 
5-aminolevulinic acid for nodular basal cell carcinomas using a preceding debulking 
technique. Br J Dermatol2000;142(2):338-9 
C.A. Schroeter, MD, J.S. Groenewegen, H.A.M. Neumann, M.D., Ph.D. Ninety percent 
permanent hair removal in transsexual patients. Annals of Plastic Surgery.2003;3:243-8 
C.A. Schroeter. Photorejuvenation using intense pulsed light: my technique. J Cosmet 
Laser Ther. 2003;5(3-4):206-7. 
C.A. Schroeter, MD, J.S. Groenewegen, T. Reineke, H.A.M. Neumann, MD, PhD. Hair 
Reduction Using Intense Pulsed Light Source. J Derm Surg 2004;30:168-173 
J.S. Groenewegen, C.A. Schroeter, MD, H.A.M. Neumann, MD, PhD. Treatment of ne-
vus of Ota using an intense pulsed light source: three case reports. JAAD Submitted 
2004 
C.A. Schroeter, J. Pleunis, C. van Nispen tot Pannerden, T. Reineke, H.A.M . Neumann. 
Photodynamic therapy: a new treatment for therapy resistant plantar warts. J Derm 
Surg accepted. 
C.A. Schroeter, S. Haaf-van Below, H.A.M. Neumann. Effective treatment of rosacea 
using intense pulsed light systems. J Derm Surg accepted. 
C.A. Schroeter, N. Mbon, T. Reineke, H.A.M. Neumann. Long term hair reduction 
achieved using a combination of optical energy and radio-frequency with ELOS. Eur J 
Derm submitted. 
C.A. Schroeter, N. Mbon, T. Reineke, H.A.M. Neumann. Blonde hair epilation using 
electro-optical synergy. J Cutan Laser Therapy. Submitted. 
Abstracts 
Schroeter CA, Marx D, Schauer A & Castellucci M. The expression of the c-erbB-1 , 
c-erbB-2 and c-erbB-3 oncogene in the human placenta. Eur Cell Biology 1994; Suppl 
40, 63:173. 
Schroeter CA, Wilder D, Keiner M, Raulin C & Neumann HAM. PhotoDerm~L treat-
ment of leg teleangiectasia. JEADV 1995; Suppl 1, 5:W76. 
127 
C.A. Schroeter, C.Raulin, W. Thurlimann, C. De Potter, H.A.M. Neumann. Hair removal 
with the intense light source in 34 dark-haired hirsute women. A multicenter study. Cos-
metology, Suppl. 1997 
C.A. Schroeter. Hair removal with the PhotoDerm~L as an intense light source: A 
histopathological study. ASLMS, 5 April 1998 San Diego, California 
C.A. Schroeter. Approaches to the management of vascular lesions with systems as 
supplement to lasers. JEADV 1999; C1-1 0 
C.A. Schroeter. Laser and IPL treatments of CALMS, Becker's Nevus and 
nevomelanocytic lesions. The future of laser and IPL. J Cosm and laser therapy June 
2002; Abstracts from Laserderm 31 Aug- 3 Sept 2002, Trieste, Italy. 
C.A. Schroeter, W. Abubaker. Treatment of inflammatory diseases with a flashlamp 
system combined with radio-frequency. Abstract from 7th congress of dermatology, 29 
Sept- 2 Oct 2004, Tehran, Iran. 
128 
